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“My advice is, never do tomorrow what you can do today. Procrastination is the 














“[W]e talk about the tyranny of words, but we like to tyrannise over them too; we 
are fond of having a large superfluous establishment of words to wait upon us on 
great occasions; we think it looks important, and sounds well. As we are not 
particular about the meaning of our liveries on state occasions, if they be but fine 
and numerous enough, so, the meaning or necessity of our words is a secondary 
consideration, if there be but a great parade of them. And as individuals get into 
trouble by making too great a show of liveries, or as slaves when they are too 
numerous rise against their masters, so I think I could mention a nation that has 
got into many great difficulties, and will get into many greater, from maintaining 
too large a retinue of words.” 
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The term dementia refers to a group of progressive neurodegenerative diseases 
in which patients experience a range of cognitive symptoms, with memory 
impairment the most common. These patients are also at risk of experiencing 
epileptic seizures. Transient Epileptic Amnesia (TEA) is a syndrome of temporal 
lobe epilepsy in which the principal manifestation of a seizure is a brief episode 
of amnesia during which other mental functions are predominantly or entirely 
preserved. Patients with TEA describe persistent memory impairments which are 
distinct from their seizures. In this thesis two studies are described which look in 
detail at each of these conditions separately. The demographic features, seizure 
presentations and cognitive profiles of these two groups are then compared in 
order to improve our understanding of these under-recognised conditions, and to 
assist clinicians tasked with their diagnosis. 
It has been known for over a century that patients with Alzheimer’s disease (AD) 
can experience epileptic seizures. However, the degree to which the risk of 
epilepsy is increased in these patients remains unclear. Seizures were long 
thought of as a feature of advanced disease in these patients, only occurring 
several years after the onset of symptoms. However, more recent evidence has 
suggested that seizures can occur at an early stage of the disease, maybe even 
prior to the onset of memory symptoms. This suggests that seizures in this 
population may be a cause of decline, rather than purely a marker of severe 
disease. The aim of the work reported in this thesis is to investigate a cohort of 
patients with dementia and Mild Cognitive Impairment (MCI), recruited from a 
regional memory clinic in order to determine the prevalence, clinical features and 
prognosis of epileptic seizures in patients with MCI and all forms of dementia. A 
UK-based, prospective study of this nature has not been conducted before 
144 patients with MCI and dementia were recruited from the Exeter memory 
clinic. Diagnoses were confirmed using established diagnostic criteria, together 
with a group of 80 age- and gender- matched healthy control subjects. 
Participants underwent a clinical interview and cognitive testing, in the company 
of a reliable informant, who also completed further questionnaires. Cognitive 




A prevalence of epilepsy of between 12.5 and 25.7% is identified in this 
population. Patients in whom a clinical suspicion of epilepsy was suspected were 
no different to those in whom there was no clinical evidence of epilepsy in terms 
of age of onset or cognitive performance at their initial study assessment. 
However epilepsy patients scored higher on the informant questionnaires, 
suggesting a greater impairment and increased care requirements. At the time of 
their 12-month assessment, the patients in whom epilepsy had been identified 
performed significantly worse on cognitive testing, suggesting that the presence 
of seizures was associated with a more rapid decline in this group. 
The concept of TEA has been established for over 25 years. These patients 
describe amnesic episodes which are brief and frequently occur upon waking. 
Seizures may be associated with olfactory hallucinations. Studies have shown 
that they respond well to anti-epileptic medications. An initial cohort of 50 patients 
with TEA was described in 2007. In this thesis a further cohort of 65 patients is 
described and combined with the original 50 patients in order to clarify and more 
fully describe the demographic, clinical and neuropsychological features of this 
condition. Through this largest ever cohort of TEA patients it is shown that the 
mean age of onset of TEA is 61.7 years, and that men are more commonly 
diagnosed than women. Seizures in TEA typically last from 15 to 30 minutes and 
frequently occur on a monthly basis. 93% of patients in this study reported 
cessation of seizures following the initiation of medication. Despite this, interictal 
memory concerns are common: including autobiographical amnesia, accelerated 
long-term forgetting and topographical amnesia.  
In comparing these two groups it is shown that patients who experience TEA are 
younger than those who experience epileptic seizures as a feature of MCI or 
dementia. They perform better on cognitive testing and neuroradiological 
investigations are more likely to be normal. In TEA, ictal amnesia is more likely 
to be the sole feature of a seizure, and olfactory hallucinations are more common. 
Patients with dementia are more likely to experience periods of 
unresponsiveness. Patients who develop epileptic seizures as a feature of MCI 
or dementia demonstrate significant cognitive decline over time, whereas 




CHAPTER ONE: GENERAL INTRODUCTION 
 
1.1  INTRODUCTION 
The work reported in this thesis investigates the prevalence and clinical features 
of epileptic seizures in dementia. Whilst the association between dementia and 
epilepsy has been well known for over a century, it remains incompletely 
understood, disputed and under-recognised. Previous studies have reported 
markedly discrepant rates of epilepsy in patients with dementia as well as 
inconsistent clinical features and long-term effects (Noebels, 2011, Vossel et al., 
2013, Horvath et al., 2016).  
One of the reasons why these questions remain unresolved is the blurred line 
between epilepsy in dementia and memory loss in epilepsy. Patients with 
epilepsy frequently report problems with memory that can sometimes resemble 
dementia (Giovagnoli et al., 2014, Leeman-Markowski and Schachter, 2016, 
Rayner and Tailby, 2017). This is especially true of epilepsy involving the 
temporal lobes (Tramoni Negre et al., 2017). Transient Epileptic Amnesia (TEA) 
- a form of epilepsy in which the principal manifestation of a seizure is transient, 
isolated impairment of memory is a specific example of this phenomenon and 
seizures in this condition have been shown to frequently originate from the 
temporal lobes  (Butler et al., 2013, Butler et al., 2007). Many patients with this 
condition are initially suspected of having dementia before a final diagnosis is 
made, often many years after seizures initially start (Zeman et al., 1998, Butler et 
al., 2007, Mosbah et al., 2014). It is clear that improvements in our understanding 
of both epilepsy in dementia and of TEA are required in order to expedite the 
diagnostic process and facilitate prompt treatment of these two conditions, 
related in their predilection for involvement of the temporal lobes.  
There are three principal questions under investigation in this thesis: what is the 
prevalence of epileptic seizures in patients with dementia? Is there a relationship 
between a clinical suspicion of epilepsy and the rate of cognitive decline in these 
patients? How do patients who develop epilepsy as a feature of their dementia 
compare with patients who experience memory impairment as a feature of their 




In this introductory chapter I review the history of the association between 
dementia and epilepsy and summarise the clinical, and pathophysiological 
features of the most common dementia subtypes. In section 1.5 I introduce the 
concept of TEA and outline many of the features of this epilepsy syndrome, 
before, in section 1.6, comparing epilepsy in dementia and TEA and the clinical 
questions posed by a patient with a presentation of transient amnesia.  
1.2 THE HISTORICAL BACKGROUND OF EPILEPSY IN ALZHEIMER’S 
DISEASE 
1.2.1 ALZHEIMER’S 1911 CASE REPORT 
In 1907 Alois Alzheimer reported the case of Auguste D; in it he describes many 
of the key features that would come to define the condition which would later bear 
his name (Alzheimer, 1907, Stelzmann et al., 1995).  
Her memory is seriously impaired. If objects are shown to 
her, she names them correctly, but almost immediately 
afterwards she has forgotten everything. When reading a 
test, she skips from line to line or reads by spelling the 
words individually, or by making them meaningless through 
her pronunciation. In writing, she repeats separate syllables 
many times, omits others, and quickly breaks down 
completely. In speaking, she uses gap-fills and a few 
paraphrased expressions (“milk-pourer’’ instead of cup); 
sometimes it is obvious that she cannot go on. Plainly, she 
does not understand certain questions. 
 
Whilst the details of this case have been repeated and discussed on many 
occasions over the following century, for the purposes of this thesis it is a later 
case, again reported by Alzheimer, which holds more interest. This case, reported 
4 years later, is that of Johann F (Alzheimer, 1911, Moller and Graeber, 1998).  
Quiet; since 1/2 year very forgetful, clumsy, could not find 
his way, was unable to perform simple tasks or carried 
these out with difficulty, stood around helplessly, did not 
provide himself with lunch, was content with everything, 
was not capable of buying anything by himself and did not 
wash himself. Very dull, slightly euphoric, slow in 
comprehension, unclear. Slowed speech, rare answers, 




Whilst this patient again describes many of the features of Alzheimer’s disease, 
it is what happens two years after that initial presentation which is of particular 
interest (Moller and Graeber, 1998). 
3 Feb. 1909. Epileptiform seizure lasting a few minutes. 
Twitching of his face. 
6 Feb. 1909. Right-sided facial palsy. 
9 Feb. 1909. No obvious facial weakness anymore. Repeat 
tests of blood and serum yield the same negative results as 
before. Very reluctant to cooperate. Always busy with his 
blanket or shirt. Does not speak anymore; does not obey 
any commands. 
31 May 1910. His body-weight falls slowly and steadily. Still 
fidgeting with his sheets in the same manner. 
28 July 1910. Epileptiform seizure of 2 minutes duration. 
1 Sept. l910. Temperature increased to 38.5 C. Rhonchi 
over his lung. 
3 Oct. 1910. Death with features of pneumonia. 
 
Johann F suffers from a series of epileptic seizures. It is possible that these may 
have contributed to his death from pneumonia in 1911. The description raises a 
number of further questions: does the right sided facial palsy represent a Todd’s 
paresis? Are the periods of reduced responsiveness also representative of further 
seizures, and what about the constant fiddling with the blanket? Is that a sign of 
ongoing seizures manifesting as a motor automatism? Regardless of the answers 
to these questions we know that Johann F died only 10 months after his first 
witnessed seizure is recorded, and just 3 years after his initial admission to 
hospital and assessment by Alzheimer. 
Clearly Johann F was not the first patient with dementia to experience epileptic 
seizures, any more than Auguste D was the first patient to suffer from dementia. 
Nonetheless, Alzheimer eloquently describes both cases, and many others, in a 
manner which establishes both the clinical features of Alzheimer’s disease and 
the concept that these patients are at risk of developing epilepsy. 
1.2.2 FURTHER REPORTS OF EPILEPSY IN AD 
Despite this, the association between dementia and epilepsy continues to be 
debated, in terms of the clinical features and prevalence of these seizures as well 
as the stage of the disease in which they are most likely to occur. A literature 
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review of epilepsy occurring in patients with dementia forms the next chapter of 
this thesis.  
1.2.3 EARLY ONSET AD AS A FAMILIAL EPILEPSY SYNDROME 
Whilst the prevalence of epilepsy in sporadic AD, the most common form of the 
disease, remains disputed, there is more clarity when it comes to the early-onset, 
familial forms of the disease. Mutations in Presenilin-1 (PSEN1), Presenilin-2 
(PSEN2) and Amyloid Precursor Protein (APP) are the three most common 
causes of familial AD. All three have been associated with an increased risk of 
epileptic seizures. In the case of disease caused by mutations of PSEN1, the risk 
of epilepsy is sufficiently high that it has been considered a ‘genetic epilepsy 
syndrome’ (Larner, 2011). Given that the pathophysiological mechanisms which 
underpin sporadic / late-onset AD overlap substantially with those responsible for 
the familial forms of the disease, it should not come as a surprise that this far 
larger group of patients are also at risk of epilepsy. 
1.3  DEFINING DEMENTIA 
Dementia is an umbrella term used to describe a number of different conditions, 
all of which lead to decline in a range of cognitive functions, usually including 
memory, to a degree that impairs someone’s ability to complete their day-to-day 
activities. The prevalence of dementia increases with age such that it affects 5% 
of people older than 65 years of age and 20% of people over 80 (Plassman et al., 
2007, Rizzi et al., 2014, Wu et al., 2017, Livingston et al., 2017). The diagnostic 
criteria for dementia (all sub-types) are outlined in the current diagnostic criteria 
for AD (McKhann et al., 2011): 
1. Interfere with the ability to function at work or at usual 
activities; and 
2. Represent a decline from previous levels of functioning 
and performing; and 
3. Are not explained by delirium or major psychiatric 
disorder; 
4. Cognitive impairment is detected and diagnosed 
through a combination of (1) history-taking from the patient 
and a knowledgeable informant and (2) an objective 
cognitive assessment, either a “bedside” mental status 
examination or neuropsychological testing. 
Neuropsychological testing should be performed when the 
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routine history and bedside mental status examination 
cannot provide a confident diagnosis. 
5. The cognitive or behavioral impairment involves a 
minimum of two of the following domains:  
a. Impaired ability to acquire and remember new 
information––symptoms include: repetitive questions or 
conversations, misplacing personal belongings, forgetting 
events or appointments, getting lost on a familiar route. 
b. Impaired reasoning and handling of complex tasks, poor 
judgment––symptoms include: poor understanding of 
safety risks, inability to manage finances, poor decision-
making ability, inability to plan complex or sequential 
activities. 
c. Impaired visuospatial abilities––symptoms include: 
inability to recognize faces or common objects or to find 
objects in direct view despite good acuity, inability to 
operate simple implements, or orient clothing to the body. 
d. Impaired language functions (speaking, reading, 
writing)––symptoms include: difficulty thinking of common 
words while speaking, hesitations; speech, spelling, and 
writing errors. 
e. Changes in personality, behavior, or comportment–– 
symptoms include: uncharacteristic mood fluctuations 
such as agitation, impaired motivation, initiative, apathy, 
loss of drive, social withdrawal, decreased interest in 
previous activities, loss of empathy, compulsive or 
obsessive behaviors, socially unacceptable behaviors. 
 
These criteria describe a range of different cognitive impairments which can be 
present in a patient with dementia. Whilst dementia is sometimes thought of as 
a single clinical entity, it is in fact a collection of conditions which are 
epidemiologically, clinically and pathologically heterogeneous.  
1.3.1 PATHOPHYSIOLOGY AND CLINICAL FEATURES OF DEMENTIA 
SUBTYPES 
1.3.2 ALZHEIMER’S DISEASE 
Epidemiology: 
Alzheimer’s disease is the most common form of dementia, making up around 
60% of all cases. AD typically presents in the 7th-9th decades, although early 
onset familial forms can present much earlier (Hodges, 2006, Ballard et al., 2011). 
Moreover, evidence has shown the accumulation of the pathological changes 
associated with AD begins up to 2 decades before clinical symptoms manifest 
(Jack et al., 2013, Braak and Del Tredici, 2015). AD is equally prevalent in both 
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genders (Masters et al., 2015). AD has an average duration of illness of 8 to 10 
years, although this varies depending on the presence of other genetic and 
environmental risk factors.  
Clinical features: 
Most commonly the onset of AD is insidious. The archetypal presentation is 
amnestic, with well-preserved language skills in the early stages of disease 
(McKhann et al., 2011, Caselli et al., 2014, Cummings, 2018). As the disease 
progresses other cognitive domains become affected (Perry and Hodges, 1999, 
Klein-Koerkamp et al., 2012, Godefroy et al., 2016). 
Whilst the diagnosis of AD is most commonly clinical, the most recent guidelines 
for the diagnosis of AD describe a range of biomarkers which can be used to 
support the diagnosis (McKhann et al., 2011, Frisoni et al., 2017).  
Pathology: 
The pathophysiological hallmarks of AD are amyloid plaques and intraneuronal 
tau fibrillary tangles. The distribution of these pathological changes and their 
evolution as the disease progresses is described as Braak staging (Braak and 
Braak, 1991, Braak and Braak, 1995). This system describes pathology initially 
in the transentorhinal cortex before extending into the entorhinal region. 
Subsequently disease involves the neocortex of the fusiform and lingual gyri 
before spreading more widely into neocortical association areas (Braak and Del 
Tredici, 2015). 
Alzheimer’s disease is not a homogeneous entity either clinically or 
pathologically. Posterior cortical atrophy is an uncommon form of AD in which the 
focus of pathology is located in the parietal-occipital region rather than in the 
temporal lobes. This change in the site of pathology is inevitably associated with 
a change in clinical signs and symptoms. Patients with PCA report disorders of 
higher visual function including features of Gerstmann’s syndrome (acalculia, 
agraphia, right/left disorientation and finger agnosia) as well as Balint's syndrome 
(optic ataxia, oculomotor apraxia, simultanagnosia, and environmental agnosia) 
(Crutch et al., 2012, Peng et al., 2016, Suarez-Gonzalez et al., 2016). PCA is 
regarded as a subtype of AD due to the pathological similarities that they share: 
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the deposition of amyloid-beta (Aβ) and tau proteins and the altered levels of 
these proteins when measured in CSF. 
More recently, neuroinflammation in AD has been an increasing field of study. 
These studies have identified a number of neuroinflammatory markers in patients 
with AD such as activated microglia surrounding Aβ plaques and the ensuing 
production of interleukins. Our increasing understanding of AD as, in part, a 
neuroinflammatory disease, raises new possibilities for the treatment and 
prevention of this condition (Heneka et al., 2015, Lenart et al., 2016, Sims et al., 
2017).  
1.3.3 VASCULAR DEMENTIA 
Epidemiology: 
Often considered the second most common form of dementia, the prevalence of 
vascular dementia is disputed (Roman, 2004, Rizzi et al., 2014, O'Brien and 
Thomas, 2015). It increases with age and is associated with other vascular 
diseases, such as stroke, ischaemic heart disease, hypertension, and atrial 
fibrillation (Manso-Calderon et al., 2014). These risk factors appear to be 
particularly potent when present in mid-life (O'Brien and Thomas, 2015). 
Phenotypically AD and vascular dementia can be very similar and are often 
difficult to distinguish (Roman, 2004, Smith, 2017). Many patients diagnosed with 
probable AD during life are found to also have evidence of vascular pathology at 
post-mortem (Larsson and Markus, 2018) and vice versa. 
Clinical Features: 
Clinically, the main difference between AD and vascular dementia is considered 
to be the way in which these diseases progress over time. Whilst AD has a 
gradual and steady decline, archetypal vascular dementia progresses in a 
stepwise pattern, with variable periods of relative stability followed by significant 
acute decline in cognitive function (O'Brien and Thomas, 2015). In addition, whilst 
the pattern of cognitive deterioration in AD follows a reliable pathway, because 
the pathology affects certain regions in a certain sequence, the patterns of 
impairment in vascular dementia are more variable as the areas affected by 
vascular pathology are themselves far more mutable (Sachdev et al., 2014).  
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As a result of the variable nature of the regions affected in vascular dementia, as 
well as the variable nature of the risk factors which have led to it, the progression 
of disease in these patients is harder to predict and much more heterogeneous 
than in AD. 
Pathology: 
Extensive variation is also seen in the nature of pathological changes in the brains 
of patients affected with vascular dementia. These changes include small vessel 
ischaemic lesions, cortical infarcts and cerebral haemorrhages of different sizes 
and with different aetiologies (Jellinger, 2008, Kalaria, 2016, Kalaria, 2018).  
In post-mortem studies AD and vascular dementia pathologies are often found to 
co-exist (Sadowski et al., 2004, Jellinger, 2008, Chui et al., 2012). Whilst pure 
vascular dementia itself is relatively rare, vascular changes are seen frequently 
in patients with all forms of dementia and are likely to contribute to the cognitive 
impairment seen in these patients (Kalaria, 2018, Larsson and Markus, 2018, 
Scott et al., 2018, Sweeney et al., 2018).    
1.3.4 DEMENTIA WITH LEWY BODIES 
Epidemiology: 
Dementia with Lewy Bodies (DLB) makes up from 0% to 23% of patients with 
dementia (Vann Jones and O'Brien, 2014). Studies have shown that it is more 
common in females (Walker et al., 2015). Despite making up a smaller fraction of 
cases of dementia overall, patients with DLB represent a disproportionately large 
number when it comes to hospitalised patients with dementia. This is likely due 
to the increased care burden and morbidity associated with this condition, leading 
to increased admission to secondary care, and prolonged duration of hospital 
stay (Vann Jones and O'Brien, 2014).  
Clinical Features: 
Patients with DLB present with a catalogue of cognitive symptoms which help to 
distinguish this type of dementia from other forms. These are reflected in the most 
recent DLB diagnostic guidelines (McKeith et al., 2017). The core clinical features 
are, ‘fluctuating cognition with pronounced variations in attention and alertness, 
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recurrent visual hallucinations that are typically well formed and detailed and 
REM sleep behaviour disorder’. In addition, patients typically experience one or 
more of the features which we would typically recognise as cardinal features of 
Parkinsonism: bradykinesia, rest tremor and rigidity (Walker et al., 2015, 
Gomperts, 2016). 
Pathology: 
Pathologically, as its name suggests, DLB is marked by the presence of Lewy 
bodies throughout the brain. Lewy bodies are aggregates of alpha-synuclein, a 
presynaptic neuronal protein which has been recognised in patients with DLB and 
Parkinson’s disease for many decades (Braak et al., 2003, Dugger et al., 2014, 
van der Zande et al., 2018b). The Braak pathological staging of Parkinson’s 
disease (with or without dementia) describes Lewy body pathology starting in the 
dorsal motor nucleus or the intermediate reticular zone and then advancing 
rostrally into the brainstem, onwards into the limbic system and finally to the 
neocortex (Braak et al., 2003). Whilst many patients with Parkinson’s disease will 
ultimately be diagnosed with dementia, usually because of this Lewy Body 
pathology, the age at which this occurs, and the duration of time from the onset 
of Parkinsonism to dementia is variable; the mechanisms behind this are not well 
understood. 
Once again it is worth noting that AD and DLB frequently coexist and in many 
patients determining in-life which is the dominant pathology is not possible. Post-
mortem studies have shown that up to 90% of DLB patients show concomitant 
evidence of AD pathology (Dugger et al., 2014, Howlett et al., 2015).  Where this 
AD pathology is also present the cognitive impairment is greater and the 
deterioration more rapid. As with AD, recent research has focussed on the role 
of neuroinflammation in the pathology of DLB, as both a cause of progression 
and also a potential target for future therapies (Surendranathan et al., 2015). 
1.3.5 FRONTOTEMPORAL DEMENTIA 
Epidemiology:  
After Alzheimer’s disease, Frontotemporal Dementia (FTD) is the second most 
common form of dementia in those under 65 years of age. It affects 3-26 per 
100,000 of the UK population and 70% of patients are diagnosed before the age 
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of 65 (Bang et al., 2015, Olney et al., 2017). Whilst it makes up a smaller 
proportion of dementia prevalence over that age, it still accounts for between 3% 
and 26% of all cases of dementia (Bang et al., 2015). There appears to be an 
equal risk for males and females (Rosso et al., 2003, Onyike and Diehl-Schmid, 
2013), although conflicting studies have separately shown both a higher 
prevalence in men (Mercy et al., 2008) and in women (Bernardi et al., 2012).  
Clinical Features: 
Clinically and pathologically the conditions which are considered under the 
umbrella term of fronto-temporal dementia are a heterogeneous group. 
Traditionally FTD is divided into three clinical subtypes. Behavioural-variant 
frontotemporal dementia (BV-FTD) is the most common form, and is associated 
with early behavioural and executive dysfunction. Patients with Non-fluent variant 
primary progressive aphasia (NFV-PPA) experience progressive dysfunction of 
speech, grammar and output.  Semantic-variant primary progressive aphasia 
(SV-PPA), is a progressive disorder of semantic knowledge and naming. More 
recent PPA classifications have divided aphasic forms of FTD into three 
categories - SV-PPA, non-fluent or agrammatic PPA (NFV-PPA) and logopaenic 
variant PPA (LV-PPA) further adding to the phenotypic heterogeneity of these 
patients.  
Of these types, BV-FTD is the most common accounting for 50-70% of all FTD 
cases (Bang et al., 2015, Finger, 2016). Clinically, patients with BV-FTD may 
present with apathy, disinhibition or behavioural change. Whilst memory and 
visuospatial skills are often relatively preserved, at least in earlier stages of the 
disease,  socially inappropriate behaviour with loss of empathy, changes in 
dietary intake (a ‘sweet-tooth’ and predilection for eating the same foods 
repeatedly) and behaviour which becomes repetitive, almost ritualistic, are more 
common. 
Slow, halting and effortful speech are the hallmarks of NFV-PPA. Whilst aphasia 
can be a feature of AD, FTD is more likely to be the cause when episodic memory 
is relatively preserved. Patients with NFV-PPA have difficulties in comprehending 
complex sentences and may also show difficulties with written language 
production (Grossman, 2012, Lanata and Miller, 2016). 
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In contrast to NFV-PPA, patients with SV-PPA retain the rate and fluency of 
speech, but early-on show anomia and loss of comprehension for individual 
words. Behavioural changes are common early in the disease, especially where 
the right temporal lobe is involved, and increase in severity as the orbitofrontal 
cortex is affected (Liu et al., 2013).  
The logopaenic variant of primary progressive aphasia (LV-PPA) is the most 
recently defined form of PPA and is an atypical presentation of AD. LV-PPA is 
characterised by difficulties in word retrieval and repetition of words and phrases 
as well as phonologic errors (Madhavan et al., 2013, Beber et al., 2014).   
Pathology 
Much like AD, FTD is a neurodegenerative disease in which the primary 
pathologic finding is the abnormal accumulation of protein(s). However, unlike 
AD, which is invariably due to the accumulation of beta-amyloid and tau, FTD is 
associated with a number of different pathological proteins: most commonly 
microtubulin-associated protein tau (MAPT), the TAR DNA-binding protein (TDP-
43) or fused-in-sarcoma protein (FUS) (Hsiung et al., 2012, Finger, 2016, Olney 
et al., 2017). Studies into the pathology of LV-PPA have shown these patients to 
have extensive Aβ pathology involving left temporoparietal regions, leading to its 
characterisation as an atypical form of AD (Madhavan et al., 2013). 
Recent decades have seen a great expansion in our understanding of the 
pathologies involved in FTD. This is particularly true of genetic risk factors for 
FTD where mutation in C9orf72, MAPT and GRN (progranulin) genes have been 
found to account for the majority of inherited cases of FTD (Olszewska et al., 
2016, Zhang et al., 2016). C9orf72 is the most common of these and is also the 
most common genetic cause of the amyotrophic lateral sclerosis variant of motor 
neuron disease (Wood, 2011, Hsiung et al., 2012, Liu et al., 2013). 
1.3.6 MILD COGNITIVE IMPAIRMENT 
Unlike the dementia subtypes described in this chapter - which are pathologically 
defined, Mild Cognitive Impairment (MCI) is a neuropsychological construct that 
attempts to bridge the gap between normal cognitive ageing and dementia. This 
gap has now been further divided by the term subjective cognitive impairment 
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which intervenes between normal cognitive ageing and MCI. The most common 
presentation is amnestic (aMCI), however a range of different presentations, both 
clinically and pathologically, have been described (Busse et al., 2006, Bolivar and 
Saladie, 2016).  
Epidemiology: 
Given the term itself has often been disputed, it is no surprise that estimates for 
the prevalence of MCI in the population have varied greatly (Busse et al., 2006, 
Petersen et al., 2014, Eshkoor et al., 2015, Petersen, 2016, Chung et al., 2017). 
To reflect this difficulty, Ganguli et al report a prevalence of amnestic MCI of 
2.18% in an American population over 65yrs old, a prevalence of Expanded MCI 
of 17.6%, but evidence of mild functional impairment (evidenced by a Clinical 
Dementia Rating  (CDR) scale score of 0.5) in 25.4% (Ganguli et al., 2010). 
Similarly Busse et al., report prevalence estimates ranging from 9% to 42% 
depending on the MCI criteria which are used (Busse et al., 2006).  
Clinical Features: 
Of all of the conditions discussed in this section, Mild cognitive impairment (MCI) 
is the most contested and problematic. In the minds of many it is considered to 
be a precursor to Alzheimer’s disease (Winblad et al., 2004, Albert et al., 2011, 
Lopez et al., 2016). However, whilst 80-90% (Eshkoor et al., 2015) of patients 
diagnosed with MCI will later be diagnosed with AD, this progression is not 
inevitable nor is the interval between these two diagnoses uniform. Moreover, 
studies have consistently reported that some patients diagnosed with MCI show 
cognitive stability over time, and in some cases even improvement (Lopez et al., 
2006, Chung et al., 2017).  
Much like in AD, the predominant presentation of MCI is amnestic and patients 
typically first report a decline in their short term memory, whilst other cognitive 
domains are typically well-preserved (Petersen, 2016). The dividing line between 
MCI and AD is sometimes unclear, in part because, in current clinical guidelines, 
the distinction is made by the way in which sufferers describe their symptoms and 
the effects this cognitive impairment has on their day-to-day functioning (Albert 




Given the variable clinical course that MCI can take - some patients will get worse, 
but some will not, and some may even show improvement - it is not surprising 
that MCI does not have set pathological criteria as is seen in AD, DLB or even 
the collection of pathological findings as described in FTD (Chung et al., 2017). 
However, given that most patients with MCI will progress to a diagnosis of AD, 
these patients commonly show early changes consistent with AD pathology - 
namely amyloid beta deposition (Alexopoulos et al., 2013, Insel et al., 2018). 
These changes can be seen on dedicated amyloid imaging techniques or on 
measurement of CSF amyloid levels. Higher levels of amyloid burden in MCI 
patients are predictive of progression to AD. Patients with MCI are also more 
likely to have cerebral microvascular changes than cognitively normal individuals 
(Scott et al., 2018). 
1.3.7 COMMON PATHWAYS FROM DEMENTIA TO EPILEPSY 
As I have described, the term dementia refers to a series of conditions with 
clinical, pathological and epidemiological heterogeneity. Nonetheless, these 
conditions are typically considered together due to their underlying commonality 
- progressive cognitive impairment. Broadly speaking, these conditions all have 
as their final common pathological pathway degeneration of the underlying 
structure of the brain and premature atrophy of specific regions within it. It is 
because of these structural changes, and the alterations to neuronal excitability 
that they produce, that all can potentially lead to an increased risk of epileptic 
seizures (Brown et al., 2011, Garcia-Cabrero et al., 2013, Tamagnini et al., 
2015b). 
1.4  DEFINING EPILEPSY 
1.4.1 PATHOPHYSIOLOGY OF EPILEPSY 
Epileptic seizures have myriad different presentations, all related to the 
anatomical structures which are affected at the time of the seizure, and whether 
this abnormal activity remains localised or becomes more widely generalised. 
Underlying epileptic seizures of all types however is the abnormal synchronous 
firing of neurons. A diagnosis of epilepsy is confirmed when two or more 
unprovoked seizures occur more than 24 hours apart (Fisher et al., 2014). The 
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international league against epilepsy (ILAE) has recently provided updated 
guidance on the diagnosis of epilepsy and the classification of different seizure 
types (Fisher et al., 2017).  
1.4.2 TEMPORAL LOBE EPILEPSY 
Temporal lobe epilepsy is the most common form of adult onset focal epilepsy 
(Helmstaedter and Elger, 2009, Javidan, 2012, Fisher et al., 2014). Epilepsy 
involving the temporal lobes can result in a wide range of clinical presentations 
(Lanteaume et al., 2009, Pizzi et al., 2009, Blair, 2012), relating to the broad 
range of functions performed by temporal lobe structures and the even wider 
range of connections to structures outside of the temporal lobes that pass through 
them. This can include motor automatisms involving the hands (such as fumbling, 
picking or fidgeting), or mouth (swallowing, chewing, lip-smacking), vocalisations, 
speech / behavioural arrest, and altered consciousness (Blair, 2012). Moreover, 
seizures involving this region can also cause symptoms such as déjà vu, olfactory 
hallucinations and amnestic attacks. As this list suggests, temporal lobe seizures 
can be either focal onset (motor or non-motor) or focal onset with secondary 
generalisation, based on recent diagnostic classification (Fisher et al., 2014, 
Fisher et al., 2017).  
1.5  DEFINING TRANSIENT EPILEPTIC AMNESIA 
1.5.1 A BRIEF HISTORY OF TEA 
TEA is a syndrome of temporal lobe epilepsy in which the principal manifestation 
of a seizure is a brief episode of amnesia during which other mental functions are 
predominantly or entirely preserved (Zeman et al., 1998, Butler et al., 2007). 
Unlike transient global amnesia (TGA), where a single episode of  2-24 hours is 
the norm (Bartsch and Butler, 2013), patients with TEA typically report recurrent, 
brief attacks which last less than one hour and often only a few minutes  (Asadi-
Pooya, 2014, Felician et al., 2015). Episodes typically occur at roughly monthly 
intervals (Butler et al., 2007), and most patients report at least some episodes on 
awakening. 
Approximately two-thirds of patients with TEA describe other phenomena 
associated with temporal lobe epilepsy, including olfactory and gustatory 
hallucinations and oroalimentary automatisms, occurring in some or all attacks 
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(Butler and Zeman, 2011). Interictal routine or sleep-deprived EEGs show focal 
epileptiform abnormalities which help to confirm the diagnosis in around 1/3 of 
cases (Butler et al., 2007). Patients are usually sensitive to anticonvulsant 
treatment, which typically prevent the attacks completely (Butler et al., 2007, 
Mosbah et al., 2014).  Ictal records indicate that the amnesic episodes in TEA 
can be either ictal or immediately post-ictal manifestations (Zeman and Butler, 
2010).  
1.5.2 AETIOLOGY OF TEA 
Whilst our understanding of the clinical features of TEA continues to increase, the 
aetiological mechanism(s) behind its onset remain less well known. In the 
majority of patients neuroimaging investigations have been normal (Butler et al., 
2007, Lapenta et al., 2014, Mosbah et al., 2014) (see below). However, in-depth 
volumetric studies have identified subtle atrophy in mesial temporal and 
orbitofrontal regions (Butler et al., 2013). EEG recordings in these patients have 
persistently uncovered epileptiform abnormalities in the temporal lobe, 
corroborating this region as the epicentre of activity in this condition (Del Felice 
et al., 2014, Mosbah et al., 2014, Burkholder et al., 2017), but this does not readily 
provide clues as to the underlying pathology in these cases. A recent case study 
has described TEA in a patient with NMDA receptor antibody mediated 
encephalitis (Savage et al., 2019b), implicating autoimmunity and inflammation 
as possible causative factors in TEA. 
In transient global amnesia, an acute physical or psychological stress is often 
reported at the time of, or soon before the onset of the amnestic episode (Bartsch 
and Deuschl, 2010, Bartsch and Butler, 2013). The same has not been 
consistently reported in the case of TEA, although in their cohort of TEA patients 
Mosbah et al., identified a negative life event (illness, death of a relative, 
retirement) in 50% of patients, and a past or current history of depression in 33% 
(Mosbah et al., 2014).  
The largest case series to have investigated TEA examined the prevalence of 
cardiovascular diseases in these patients; concluding that there was no 
compelling evidence for an increased prevalence of cardiovascular risk factors 




1.5.3 NEUROIMAGING FINDINGS IN TEA 
Although structural MRI is typically normal in TEA, imaging investigations in TEA 
patients have pointed to a seizure source in the medial temporal lobes (MTLs). If 
structural abnormalities are present, they usually lie in the MTLs. A case report 
of a TEA patient with frequent seizures identified high signal in the hippocampus, 
accompanied by hypermetabolism on PET, which resolved with successful 
treatment of his epilepsy (Butler and Zeman, 2008a). 
A group study of patients with TEA revealed subtle, bilateral hippocampal atrophy 
with volume loss of 8% (Butler et al., 2009).  Automated measurement of cerebral 
regions identified additional atrophy of perirhinal and orbitofrontal cortices (Butler 
et al., 2013). A functional imaging study of autobiographical recollection in 
patients with TEA revealed reduced activation in the posterior right 
parahippocampal gyrus (Milton et al., 2012). Hypometabolism of the bilateral 
middle frontal gyri (BA6), left medial, superior, precentral and paracentral gyri 
(BA6, BA31) has been identified on FDG-PET studies. Additional areas of 
hypometabolism within the right posterior hippocampus (BA36) and left uncus 
(BA28) have also been confirmed with use of a medial temporal mask (Mosbah 
et al., 2014). 
1.5.4 NEUROPSYCHOLOGICAL FINDINGS IN TEA 
Whilst the cornerstone of the TEA diagnosis is a transient period of ictal amnesia, 
more than two thirds of patients also report three ‘atypical’ forms of memory 
impairment between these episodes: accelerated long term forgetting (ALF), 
autobiographical (or ‘focal retrograde’) amnesia and topographical amnesia. 
Patients with ALF complain that information learned recently fades more rapidly 
than they would expect (Butler and Zeman, 2008b). On objective testing, these 
patients show normal acquisition of new information, performing within the normal 
range on standard neuropsychological tests which measure immediate recall and 
at an interval of 30 minutes after learning, but exhibit a more rapid rate of 
forgetting than usual over longer delays (Manes et al., 2005, Hoefeijzers et al., 
2013, Elliott et al., 2014). Studies show loss of both the amount and the quality 
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of memories which begins within hours (Hoefeijzers et al., 2015) and is most 
pronounced during the first 24 hours of retention (Muhlert et al., 2010). 
As well as a more rapid rate of forgetting for recently acquired information, these 
patients often report what has been described as a patchy ‘focal retrograde 
amnesia’.  This characteristically involves a loss of memory for salient personal 
events, and is sometimes described as ‘holiday amnesia’ as it often comes to 
light when discussing these memorable, discrete, autobiographical events (such 
as a friend or family member’s wedding). It can extend across most or all of the 
lifespan, affecting memories formed well before the onset of seizures. Personal 
and public semantic memories are also affected but less severely (Milton et al., 
2010). Describing this amnesia as ‘focal’ and ‘retrograde’ is controversial 
(Kopelman, 2000). Many patients with TEA have ALF, an atypical form of 
anterograde amnesia which would be expected to cause a cumulative amnesia 
for past events over time. The term ‘focal retrograde amnesia, is defensible, 
however , given the contrast between the relatively normal performance often 
demonstrated on standard measures of anterograde memory, and their marked 
difficulties when they contemplate remote events, often ones they could 
previously recall.  
Patients with TEA also commonly report a topographical amnesia. This will 
typically manifest as difficulty in remembering familiar routes as well as in 
recognising familiar landmarks (Zeman et al., 2013).  
1.5.5 TEA PROGNOSIS 
Many patients diagnosed with TEA are initially suspected of suffering from 
dementia and many more are concerned that this is a possibility prior to 
consulting with their doctor. This is understandable given the persistent memory 
symptoms that these patients can experience. However, as is shown by their 
good performance on standard neuropsychological testing, the cognitive deficits 
experienced by patients with TEA are typically different to those exhibited by 
patients with dementia.  
Despite the memory symptoms reported by these patients, recent studies have 
suggested that the risk of dementia is not increased by a diagnosis of TEA 
(Savage et al., 2016). The cognitive deficits remain stable, declining only to a 
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degree expected with ageing and comparable to an age matched control 
population without TEA (Savage et al., 2016).  However, given that the 
prevalence and clinical features of epilepsy in patients with dementia are not 
conclusively known, the degree to which these two conditions can resemble each 
other is incompletely understood. Neuropsychological testing may prove to be a 
helpful discriminator between TEA and epilepsy in dementia. 
1.6  MAKING THE DISTINCTION BETWEEN EPILEPSY IN DEMENTIA AND 
MEMORY LOSS IN EPILEPSY 
When someone experiences a decline in memory, which is either noted by 
themselves, or by those nearest to them, the next step will likely be to make an 
appointment with their GP. From there, the probable next step, once it has been 
confirmed that a persistent problem exists, will be a referral to the memory clinic. 
In the UK memory clinics are designed to provide a one-stop service for the 
investigation, diagnosis and onwards management of memory problems, most 
commonly Alzheimer’s disease (Van der Cammen et al., 1987, Jolley et al., 
2006). Given the nature of problems caused by epileptic seizures in dementia as 
well as the memory problems which occur in patients with TEA, it is likely that 
patients with both of these conditions will be seen in this setting. With that in mind 
a further goal of this thesis is to aid the prompt diagnosis of these clinical 
presentations. This process often involves the differentiation of multiple other 
causes of amnesia - both transient and persistent.  
1.6.1 CAUSES OF TRANSIENT AMNESIA 
Work on TEA has expanded our understanding of the diagnostic possibilities 
among patients who present to hospital with one or several episodes of transient 
amnesia. The archetypal example of acute onset transient amnesia and the one 
of which hospital staff are most aware, is Transient Global Amnesia (TGA). It is 
defined by the following criteria (Fisher and Adams, 1964, Bartsch and Butler, 
2013): 
 Presence of an anterograde amnesia that is witnessed by an observer 
 No clouding of consciousness or loss of personal identity 
 Cognitive impairment limited to amnesia 
 No focal neurological or epileptic signs 
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 No recent history of head trauma or seizures 
 Resolution of symptoms within 24 h 
 Mild vegetative symptoms (headache, nausea, dizziness) might be 
present during the acute phase 
Clues to a diagnosis of TEA in contrast to TGA include the brevity of the attacks 
– typically less than one hour in TEA, several hours in TGA – and their frequency 
– typically around one/month in TEA, usually single or very infrequent in TGA. 
Attacks which occur on waking, prominent interictal memory difficulties and the 
presence of abnormalities on EEG would also make a diagnosis of TEA more 
likely (Lanzone et al., 2018). 
In addition to these causes, a number of other diagnoses should be considered 
in a patient who presents with transient amnesia. These include transient 
ischaemic attacks and stroke (Gupta et al., 2014, Amuluru et al., 2015), head 
injury, infective and auto-immune encephalitis (Garcia Garcia et al., 2013, 
Navarro et al., 2016), and the effects of drugs and sleep inertia (Ferguson et al., 
2016, Hilditch et al., 2016). Clues obtained from the history, neurological 
examination and appropriate investigations usually make it possible to 
differentiate between these causes, all of which will require different treatments 
and management strategies. 
1.6.2 TRANSIENT AMNESIA IN DEMENTIA AND MCI 
On the surface, epilepsy occurring in dementia and memory loss occurring in 
epilepsy (TEA) are very different: one is a progressive neurodegenerative 
disease in which patients experience global deficits and on top of this, experience 
epileptic seizures; whereas the other is a condition that is defined by transient 
episodes of amnesia during which other cognitive functions remain intact. 
However, patients experiencing epilepsy as part of their dementia report transient 
periods of worsened confusion and amnesia, different to their baseline cognitive 
impairment, and patients with TEA report some persistent memory deficits that 
extend beyond their seizure episodes. Moreover, recent studies comparing TEA 
and MCI have highlighted the potential similarities between these two conditions 




1.7  STRUCTURE OF THIS THESIS 
This thesis aims to answer a number of outstanding, and clinically important, 
questions about epileptic seizures occurring in patients with dementia as well as 
TEA. In terms of the former – what is the prevalence of epilepsy in this group, 
who is most at risk, what do these seizures look like, and in the longer term, what 
effects do seizures have in this population? Chapter 2 provides a review of 
epilepsy in dementia. Chapter 3 reports on the prevalence and clinical features 
of epileptic seizures in a cohort of 144 patients recruited from a regional memory 
clinic. Chapter 4 presents the 12-month follow up from this cohort, to establish 
whether patients that experience epilepsy as a feature of their dementia progress 
in different ways, or more quickly than those that do not.  In Chapter 5 I report on 
the largest cohort of TEA patients to date and compare them with previous TEA 
cohorts in order to establish, with greater certainty than has previously been 
possible, the key demographic and clinical features (both ictally and inter-ictally) 
of this largely under-recognized syndrome of temporal lobe epilepsy. Chapter 5 
also provides a review of the literature in this field, including our own cohort in 
order to move towards a greater understanding of this condition. In Chapter 6 I 
will review one of the prominent interictal features of TEA, accelerated long-term 
forgetting (ALF), in order to understand the importance of this neuropsychological 
phenomenon in TEA as well as other conditions. In Chapter 7 I compare and 
contrast epilepsy in dementia and TEA, in order to establish how they can be 
more easily identified and differentiated in clinical practice. Both of these 
conditions involve similar regions, cause related problems (impairment of 













CHAPTER TWO: A NARRATIVE REVIEW OF EPILEPSY IN DEMENTIA 
 
2.1  INTRODUCTION 
The prevalence of dementia is increasing worldwide and is expected to exceed 
115 million by 2050 (World Health Organization, 2012). It is therefore not 
surprising that it has been recognised by the World Health Organisation (WHO) 
as a global health priority. It has been established for over a century that people 
with dementia are at risk of developing epileptic seizures. As the prevalence of 
dementia increases, it is inevitable that there will be a commensurate increase in 
the number of people who experience epileptic seizures as a feature of their 
illness. However, whilst it is recognised that the risk of epilepsy is increased in 
Alzheimer’s disease (AD), the degree of this increased risk is less clear. There is 
also uncertainty about whether this risk is similar across all dementia subtypes or 
whether it is also increased in patients with mild cognitive impairment.  
In this narrative review I will report broadly on the collected published evidence 
on epileptic seizures in dementia. I will discuss the prevalence of epilepsy in a 
range of dementia subtypes. In addition I will discuss the features of seizures in 
these conditions, their EEG findings and the proposed pathophysiology of 
seizures in dementia. Finally I will also review the role of anti-epileptic treatments 
in these conditions as well as the longer-term effects of seizures in this 
population.  
2.2  METHODS  
Multiple searches of the medical literature were performed to identify case series 
and case reports of epilepsy in MCI and dementia (table 2.1). Three search 
platforms were used: MEDLINE (from 1966), EMBASE (from 1974) and 
PSYCINFO (from 1806) up to September 2018. Titles and abstracts were 
reviewed and further hand-searching using reference lists was performed to 
identify further published papers. All papers where search terms appeared in the 
title were assessed to ensure verified diagnostic criteria had been applied to 
dementia diagnoses.   
 
Reasons for exclusion included papers where epilepsy and dementia were 
considered separately rather than in combination, or where dementia occurred in 
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the setting of chronic or genetic epilepsy syndromes; as well as papers not 
available in the English language. A proportion of search results using all terms 
were conference abstracts; whilst these were reviewed, they were not included 
in estimates of seizure prevalence due to insufficient information regarding data 
acquisition and case selection being available. 
 
Search Terms Used 
  Search Platform   
Total Medline Embase PsycINFO unique 
(alzheimer* or dement*) and (epilep* or seizure*) 38007 4916 11505 21586 +++ 
(alzheimer* and (epilep* or seizure*) 25228 2511 6280 16437 +++ 
("mild cognitive impairment" or MCI) and (epilep* or 
seizure*) 4694 139 615 3940 4481 
(frontotemporal or FTD) and (epilep* or seizure*) 4134 431 1045 2658 3572 
lewy and (epilep* or seizure*) 1962 83 379 1500 1835 
("vascular dementia" and (epilep* or seizure*) 1440 52 166 1222 1368 
 "Down Syndrome" and (epilep* or seizure*) 3819 540 1150 2129 3218 
(huntington* and (epilep* or seizure*) 6368 637 1900 3831 +++ 
"creutzfeldt-jakob disease" and (epilep* or seizure* 1444 173 745 526 1209 
  abstract only 
  Total  Medline Embase PsycINFO unique 
(alzheimer* or dement*) and (epilep* or seizure*) 11156 3732 5781 1643 +++ 
(alzheimer* and (epilep* or seizure*) 5637 2013 2842 782 3309 
("mild cognitive impairment" or MCI) and (epilep* or 
seizure*) 452 112 279 61 306 
(frontotemporal or FTD) and (epilep* or seizure*) 1224 367 701 156 774 
lewy and (epilep* or seizure*) 240 63 141 36 160 
("vascular dementia" and (epilep* or seizure*) 161 42 95 24 108 
 "Down Syndrome" and (epilep* or seizure*) 835 269 437 129 493 
(huntington* and (epilep* or seizure*) 1187 427 593 167 724 
"creutzfeldt-jakob disease" and (epilep* or seizure* 391 128 218 45 246 
  title only 
  Total  Medline Embase PsycINFO unique 
(alzheimer* or dement*) and (epilep* or seizure*) 803 274 389 140 453 
(alzheimer* and (epilep* or seizure*) 384 123 195 66 202 
("mild cognitive impairment" or MCI) and (epilep* or 
seizure*) 28 7 16 5 16 
(frontotemporal or FTD) and (epilep* or seizure*) 47 16 23 8 23 
lewy and (epilep* or seizure*) 21 7 10 4 11 
("vascular dementia" and (epilep* or seizure*) 7 1 5 1 5 
 "Down Syndrome" and (epilep* or seizure*) 150 47 79 24 82 
(huntington* and (epilep* or seizure*) 38 15 18 5 23 
"creutzfeldt-jakob disease" and (epilep* or seizure* 98 37 49 12 49 
 
Table 2.1: search terms used in literature review (+++ indicates too many 
results for search platform to deduplicate) 
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My aim in this chapter is to give an overview of the topic of epilepsy in dementia. 
Therefore, I chose to perform a narrative review of the literature rather than a 
systematic review in this instance in light of the broad scope of this narrative 
review and the heterogeneity of the literature identified.  
  
2.3  RESULTS AND DISCUSSION 
2.3.1 PREVALENCE OF EPILEPSY IN DEMENTIA 
Few studies have looked at the prevalence of epilepsy across multiple dementia 
subtypes. However, where this has been done there is evidence that dementia of 
all forms can be associated with epileptic seizures (Hommet et al., 2008, Ashour 
and Abou-Hagar, 2012, Sarkis et al., 2016, Beagle et al., 2017). This risk appears 
to be greatest in AD: in their cohort of 77 patients with dementia and epilepsy, 
Sarkis et al., found that 83% had AD, 5% AD and vascular dementia, 1% vascular 
dementia, 5% Dementia with Lewy Bodies, and 5% Frontotemporal dementia 
(Sarkis et al., 2016). 
2.3.2 PREVALENCE OF EPILEPSY IN SPORADIC AD 
Despite having been described by Alzheimer himself, the risk of epileptic seizures 
in Alzheimer’s disease is not clear. Prevalence estimates vary widely and no clear 
consensus has been reached. Whilst some studies have reported that the 
prevalence is equal to, or only mildly increased when compared to the general 
population (Scarmeas et al., 2009, Irizarry et al., 2012, Imfeld et al., 2013, Giorgi 
et al., 2016), others have identified rates of greater than 50% (Risse et al., 1990, 
Cabrejo et al., 2006). These studies are summarised in table 2.2. 
There are several potential reasons for this variability, including the definitions of 
both Alzheimer’s disease, and epilepsy, the means by which data is collected, 
and the populations which have been investigated. I will review these factors in 
turn and address how different studies have approached them and how this has 















Clinical setting / study design 
Risse 1990 USA 28 64 Hospitalised male patients with advanced Alzheimer’s disease. Prospective cohort study  
Cabrejo 2006 France 21 57 Autopsy study from patients with APP mutation. Retrospective case series 
Samson 1996 Netherlands 198 45 Population based study of patients with early-onset Alzheimer’s disease 
Vossel (2016) 2016 USA 33 42.4 Prospective study of patients with AD investigated using MEG and overnight EEG 
Letemendia 1958  UK 17 41 Retrospective review of EEG data in patients found to have AD pathology at autopsy 
Volicer 1995 USA 75 36 Hospitalised patients with probable Alzheimer’s disease. Cross-sectional study 
Horvath 2018 Hungary 42 24 Mixed retrospective and prospective study of patients with AD investigated with 24hr EEG 
Sjogren 1952 Denmark 18 22 Pathological comparison study of patients with AD and Pick’s disease 
Mendez 1994 USA 446 17 Autopsy series from a brain bank. Retrospective study. 
Rauramaa 2018 Finland 64 17 Clinicopathological study of patients with AD recruited to a longitudinal cohort study 
Romanelli 1990 USA 44 16 Patients with mild AD. Prospective case-control study 
Heyman 1987 USA 92 15 Investigations of hospitalised patients with early-onset dementia 
Beagle 2017 USA 1320 13.4 Retrospective review of electronic medical records for patients who met criteria for AD 
Hersdorffer 1996 USA 145 11 Population-based case-control study 
Hauser 1986 USA 81 10 Autopsy study of patients with Alzheimer’s disease. Retrospective 
Forstl 1992  UK 56 10 Prospective clinical and neuropathological study, in patients with autopsy-proven AD 
Bernardi 2010 Italy 145 9.7 Patients with probable AD in single centre. Retrospective cohort study 
McAreavey 1992 UK 208 9 Hospitalised patients with dementia. Cross-sectional retrospective study 
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Sulkava 1982 Finalnd 71 8 Multi-biomarker analysis (including EEG) of patients with AD 
Amatniek 2006 USA 233 7.75 3-centre study of patients with mild probable AD. Prospective study 
Lozsadi 2006 UK 177 6.8 Outpatient dementia clinic, at time of AD diagnosis. Retrospective cohort study 
Cheng 2015 Taiwan 937 4.7 Retrospective population-based study from National Health Insurance Database 
Vossel (2013) 2013 USA 1024 4.1 Retrospective observational study 
Rao 2009 USA 1738 3.6 Single-centre study of patients with mild dementia / MCI. Retrospective cohort study 
DiFrancesco 2017 Italy 1371 2.8 Patients with pre-symptomatic dementia. Retrospective study 
Giorgi 2016 Italy 1223 2.45 Key-word searching of database in a tertiary centre. Retrospective study 
Bell 2011 Finland 28093 2.1 Retrospective analysis of anti-epileptic prescribing from dementia population database 
Cook 2015 USA 11042 2 Data from electronic medical records. Retrospective study 
Sherzai 2014 USA 3491795 1.5 Data from database of hospitalised patients. Cross-sectional study 
Scarmeas 2009 USA 453 1.5 3-centre study of patients with clinical diagnosis of mild AD. Prospective cohort study 
Imfield 2013 Switzerland 6932 1.3 UK-based general practice research database. Retrospective case-control analysis 
Irizarry 2012 USA 3078 0.5 Patients with mild to moderate AD, previously enrolled in AD studies. Cohort study 
 
Table 2.2: Summary of studies investigating epilepsy in AD (ranked from highest prevalence to lowest) 
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i. Defining Alzheimer’s disease 
The 2011 diagnostic guidelines for AD provide clear criteria for the diagnosis of 
AD, and emphasise continuing reliance on clinical decision making (McKhann et 
al., 2011). However, post-mortem studies have consistently shown that the 
clinical diagnosis is imperfect with some cases having little or no evidence of AD 
pathology and other cases where mixed pathologies predominate (Beach et al., 
2012). In one study, the diagnostic accuracy for a clinical diagnosis of AD was 
shown to be 77% (Sabbagh et al., 2017). Therefore, studies need to make clear 
not just what diagnostic criteria have been used, but also how they have been 
used - for example whether CSF biomarkers have been utilised, or where 
biomarker imaging has been implemented. These measures have been shown 
to increase the diagnostic accuracy for AD to greater than 90% in terms of both 
sensitivity and specificity (Chiu et al., 2014, Lewczuk et al., 2018). However, the 
use of these biomarkers is not yet standard clinical practice around the world 
(Blennow et al., 2015, Villemagne et al., 2015, Olsson et al., 2016, Simonsen et 
al., 2017), particularly in the developing countries in which the prevalence of AD 
is increasing most rapidly as a result of changes in population demographics and 
improved life expectancy. 
In keeping with advances in the use of biomarker technologies and their more 
widespread usage over recent decades, studies of epilepsy in dementia show 
significant variability as to how AD has been defined / diagnosed.  Some studies 
outlined in table 2 use a gold-standard post-mortem diagnosis of AD (Hauser et 
al., 1986, Cabrejo et al., 2006, Rauramaa et al., 2018), whereas others have 
based the diagnosis purely on clinical features (Romanelli et al., 1990, Amatniek 
et al., 2006), supplemented by the use of biomarkers in more recent studies 
(Vossel et al., 2016, Horvath et al., 2018). 
ii. Defining Epilepsy 
Similarly, the definition of epilepsy is, on paper, relatively straightforward (Fisher 
et al., 2014). However, the diagnosis relies on recurrent episodes witnessed by 
a reliable informant, and clinically this can be difficult to obtain. The diagnosis 
does not require an EEG recording, although this test is often sought to provide 
supportive evidence (Sulkava, 1982). As computational approaches to EEG 
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analysis have become increasingly complex, so the rate at which abnormal 
findings are identified in the AD population has also increased. Recent studies 
have shown a proportion of patients with AD have epileptiform EEG changes, 
even where no history of seizures can be identified (Vossel et al., 2016, Horvath 
et al., 2018). As a result it is important that a strict and clear definition of what 
constitutes epilepsy is used in studies where the prevalence of epilepsy in AD is 
investigated. Furthermore a distinction should be made between the occurrence 
of a single seizure, as opposed to recurrent episodes which would be required 
for a diagnosis of epilepsy to be made.  
Many of the studies which have identified a higher prevalence of epilepsy in the 
AD population have obtained more prolonged EEG recordings, or have used 
additional methods such as magnetoencephalography (MEG) (Vossel et al., 
2016, Horvath et al., 2018). In these studies the quoted rates for the prevalence 
of epilepsy sometimes comprise clinically overt seizures as well as subclinical 
epileptiform activity. 
iii. Research methods 
Retrospective reviews of medical records rely on the accurate reporting and 
recording of information in order for it to be extracted at a later date. Evidence 
has suggested that the majority of epileptic seizures in patients with AD are focal 
in onset, and often subtle in appearance. As a result, these events may not have 
been reported by the patient or carer and not recorded in medical notes. It is 
therefore not surprising that the studies that have shown the lowest prevalence 
rates for seizures in the AD population have relied on a retrospective approach 
to data collection (Bell et al., 2011, Irizarry et al., 2012, Sherzai et al., 2014, 
Cheng et al., 2015, Cook et al., 2015). Moreover, the search terms used to 
identify epilepsy through this method vary greatly. Where some studies have just 
searched medical notes for ‘epilepsy’ or ‘seizure’ (Rao et al., 2009, Sherzai et al., 
2014) others have used a far more extensive list of search terms (Giorgi et al., 
2016, Beagle et al., 2017). The prevalence rates increase even further when the 
list of search terms used includes myoclonus; the incidence of which has 
repeatedly been shown to be increased in patients with AD (Hauser et al., 1986, 
Heyman et al., 1987, Beagle et al., 2017, Vossel et al., 2017). 
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The largest study to have investigated the prevalence of epilepsy in AD has done 
so through reviewing inpatient records where the primary indication for admission 
was epilepsy (Sherzai et al., 2014). Whilst this provides useful information 
regarding the rate at which patients with AD who experience seizures require 
hospital admission as a result of a seizure, it very likely underestimates the 
prevalence of seizures in this population overall. No data are available for the 
likelihood of a seizure occurring in a patient with dementia leading to a hospital 
admission. 
iv. Study population 
The studies which have reported the highest rates of epileptic seizures in AD 
have often looked at specific subpopulations of the condition in which we know 
the rate is most increased: in hospitalised and institutionalised patients (Risse et 
al., 1990, Volicer et al., 1995), in patients with advanced disease (Hauser et al., 
1986, Risse et al., 1990), and in patients with early onset, autosomal dominant 
AD (Letemendia and Pampiglione, 1958, Samson et al., 1996, Cabrejo et al., 
2006). Where prevalence rates for epilepsy in AD are quoted, the study 
population that has been examined for the study should be made clear. In 
contrast, studies where low prevalence rates have been detected have typically 
focussed on early or even pre-clinical cases of AD (Irizarry et al., 2012, 
DiFrancesco et al., 2017). 
Historically, epileptic seizures have been viewed as a manifestation of advanced 
dementia, occurring as a consequence of extensive neurodegeneration and 
atrophy in these patients (Hauser et al., 1986, Heyman et al., 1987, Romanelli et 
al., 1990, Mendez et al., 1994, Giorgi et al., 2016). However, whilst conventional 
understanding has viewed epilepsy as a late-stage manifestation of AD, many 
more recent studies have identified seizures occurring early in the clinical 
disease, and in some cases even before cognitive symptoms present (Picco et 
al., 2011, Vossel et al., 2013, Sarkis et al., 2016). 
Taking the above into account, the evidence is overwhelmingly in favour of an 
increased prevalence of epilepsy in AD when compared to an age-matched 
population without dementia (Amatniek et al., 2006, Friedman et al., 2012, Irizarry 
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et al., 2012, Pandis and Scarmeas, 2012, Imfeld et al., 2013, Cheng et al., 2015, 
Nicastro et al., 2016).  
Recent studies have elucidated genetic risk factors for sporadic AD. By far the 
strongest and most widely studied of these is Apolipoprotein E (APOE) (van Es 
and van den Berg, 2009, Koffie et al., 2012, Kanekiyo et al., 2014, Bangen et al., 
2016, Liu et al., 2017, Shi et al., 2017). Patients who are homozygous for the 
APOE4 genotype have an increased risk of developing AD. In addition, these 
patients often experience an earlier onset of disease and a more rapid 
progression of symptoms. What is less well known at this point is whether the 
APOE4 genotype also confers an increased risk for epileptic seizures and this 
would likely benefit from further research (Irizarry et al., 2012). One study in which 
the association between APOE4 and epilepsy in AD patients was investigated 
did not find a significant association (Rauramaa et al., 2018). Outside of APOE 
genotype, several other studies have identified other genetic loci which can 
increase susceptibility for AD including TREM2 and PLCG2 (Manolio et al., 2009, 
van Es and van den Berg, 2009, Lambert et al., 2013, De Jager et al., 2014, 
Escott-Price et al., 2017, Sims et al., 2017, van der Lee et al., 2018). 
2.3.3 PREVALENCE OF EPILEPSY IN FAMILIAL AD 
The highest risk of epilepsy in AD has been shown to exist for patients who have 
early onset, hereditary forms of the disease. Autosomal dominant early onset AD 
is caused by mutations within one of three genes: Presenilin 1 (PSEN1, 14q24.2), 
presenilin 2 (PSEN2, 1q42.13), amyloid precursor protein (APP, 21q21.3), or by 
duplication of the APP gene. Of these PSEN1 is the most common cause, in 
which over 185 different mutations have been reported. All four of these genetic 
alterations are associated with an increased prevalence of epileptic seizures 
(Velez-Pardo et al., 2004, Larner, 2011, Born, 2015). The highest risk of epilepsy 
appears to be in cases of APP duplication, but in all four instances the percentage 
of patients who develop seizures is greater than 40%, with an overall rate of 
47.7% (Zarea et al., 2016). The lowest risk appears to be in APP mutation 
carriers. Zarea et al., found that seizures in this population occurred only in 
patients for whom 5 or more years of follow-up was available (Zarea et al., 2016). 
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Patients with these familial forms of AD typically experience the onset of cognitive 
symptoms at an earlier age and frequently experience a more rapid progression 
of symptoms than is seen in the sporadic AD population (Samson et al., 1996, 
Larner, 2011).  It has also been suggested that these factors (age of onset and 
rate of progression) may be associated with a higher risk for the development of 
seizures in the population with sporadic AD (Cabrejo et al., 2006).  
2.3.4 PREVALENCE OF EPILEPSY IN MCI 
As approximately 80% (Del Felice et al., 2014) of patients with MCI will 
subsequently be diagnosed with dementia it would be expected that a proportion 
of these patients will also experience epileptic seizures. However, as epileptic 
seizures have often been thought of as a feature of dementia only when it is 
clinically and pathologically advanced, it could also be predicted that the 
prevalence of epileptic seizures in patients with MCI should be low. 
Given the prevalence of mild memory symptoms in patients with epilepsy 
(Motamedi and Meador, 2003, Hoppe et al., 2007, Lanteaume et al., 2009) a 
number of studies have compared patients with epilepsy and those with MCI 
(Griffith et al., 2006, Holler and Trinka, 2014, Galioto et al., 2015). These studies 
have shown similar cognitive impairments in these two conditions, although 
patients with chronic epilepsy have been found to exhibit more widespread 
deficits than the predominantly amnestic changes seen in MCI (Griffith et al., 
2006). Recent insights from the study of Transient Epileptic Amnesia, and 
accelerated forgetting have shown further similarities between this temporal lobe 
epilepsy syndrome and amnestic MCI / early AD (Rabinowicz et al., 2000, Manes 
et al., 2008, Cretin et al., 2014, Reiman, 2018, Weston et al., 2018) 
Whilst some studies have compared the findings on memory testing in patients 
with MCI and those with epilepsy, there is little in the literature to describe the 
prevalence of new onset epilepsy in patients with MCI. One study, however, has 
shown a prevalence of epilepsy in an MCI population of 6.25% (Dhikav et al., 
2017). This figure is higher than in some studies which have focussed on the 
prevalence of epilepsy in early stages of AD (Cretin et al., 2017, DiFrancesco et 
al., 2017). However, given increasing evidence that the risk of epilepsy in AD is 
increased even from the early, and even pre-clinical stages of the disease; this 
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figure appears in keeping with a condition which is often viewed as a precursor 
to a diagnosis of AD (Vossel et al., 2013, Sarkis et al., 2016).  Further isolated 
case reports of MCI and epilepsy occurring at the same time in patients with a 
third comorbidity have been described, including alcohol dependence (Ishii et al., 
2013) and Becker muscular dystrophy (Lerario et al., 2018). 
2.3.5 PREVALENCE OF EPILEPSY IN VASCULAR DEMENTIA 
Given that it is the second most common form of dementia, it is not surprising 
that the association between vascular dementia and epilepsy has also been 
investigated (Imfeld et al., 2013, Hatanpaa et al., 2014). Moreover, it has been 
well established that vascular injury in the brain (in the form of stroke, 
haemorrhage, or ischaemia) can predispose a patient to epilepsy (Berg, 2003, 
Camilo and Goldstein, 2004, Ryvlin et al., 2006, Lahti et al., 2017). It has also 
been shown that epileptic seizures occurring in the aftermath of a stroke are 
themselves an independent predictor for the development of dementia in these 
patients (Cordonnier et al., 2007). 
As a result of the frequency with which vascular and AD pathologies co-occur, it 
is inevitably difficult to determine the relative contributions of either pathology 
when seizures occur in such patients. In patients with AD, the presence of 
vascular risk factors (such as hypertension and hyperlipidaemia) has been shown 
to increase the risk of epilepsy also (Amatniek et al., 2006, Bernardi et al., 2010, 
Cheng et al., 2015). Imfeld et al., were able to show that the risk of epilepsy is 
increased in both AD and vascular dementia when compared to age-matched 
controls without dementia. In summary, patients with AD or vascular dementia 
were at a much higher risk of developing seizures or epilepsy than dementia‐free 
patients. In contrast to some studies looking at epilepsy in AD, this study did not 
report that younger age, younger age at dementia onset, or use of 
acetylcholinesterase inhibitors were associated with an altered risk of developing 
epilepsy. Patients with a longer duration of AD dementia (≥3 years) did have a 
higher risk of developing seizures, whereas in patients with vascular dementia 
the contrary was observed (Imfeld et al., 2013). The relative risk estimate for 
developing seizures or epilepsy in this study was similar in AD and vascular 
dementia (AD: odds ratio 6.6, vascular dementia: odds ratio 5.7). In other studies 
the risk of epilepsy in vascular dementia has been reported as 16.7% (Manso-
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Calderon et al., 2014) and 20% (Webb et al., 2013). Webb et al., were also able 
to show that dementia related seizures were associated with a more rapid 
cognitive decline (MMSE score fall of 1.75 points/year in seizure groups vs 0.51 
points/year in seizure-free group (Webb et al., 2013). 
2.3.6 PREVALENCE OF EPILEPSY IN LEWY BODY DISEASE 
Studies have reported a prevalence of epilepsy in DLB of between 4.7% and 
14.7% (Campora et al., 2015, Beagle et al., 2017). Whilst the underlying 
pathological hallmarks of DLB are different to those of AD, the nature of these 
changes - the presence of cortical degeneration related to the deposition of 
abnormal proteins might be expected to increase epilepsy risk. However, studies 
which have investigated the relationship between DLB and epilepsy are far less 
common that those investigating seizures in AD (Ogunyemi et al., 2013, Campora 
et al., 2015, Beagle et al., 2017).  
Lewy body dementia is often differentiated from Alzheimer’s disease clinically, in 
part, by an increased rate of cognitive fluctuation from one day to the next, but 
also within a single day, which is not typically a feature of AD. As epileptic 
seizures in AD can be a cause of increased levels of fluctuation it is not surprising 
that papers linking DLB and epilepsy describe one as a mimic of the other, and a 
cause of diagnostic uncertainty (Park et al., 2014, Sun et al., 2014, Tun et al., 
2017). Given the fluctuation seen in many DLB patients, seizures may often be 
suspected but can be more difficult to confirm (Walker et al., 2000). An increased 
incidence of epilepsy related myoclonus is seen in DLB in comparison to AD and 
FTD (Beagle et al., 2017).  
2.3.7 PREVALENCE OF EPILEPSY IN FRONTOTEMPORAL 
DEMENTIA 
If epileptic seizures in AD are related to the abnormal deposition of tau, then one 
might anticipate an increased incidence of epileptic seizures in frontotemporal 
dementia, where the pathological process in some cases is also a tauopathy 
(Bang et al., 2015). 
Despite this there is little in the literature describing epilepsy in patients with FTD 
subtypes. In addition no studies have compared the prevalence rate of epilepsy 
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in these different pathological forms of FTD. Some case reports and small series 
do describe epilepsy occurring in FTD generally (Garcia-Cabrero et al., 2013, 
Castro-Suarez et al., 2016). One case was identified where seizures had 
occurred in the setting of FTD were attributed to polydipsia rather than as a 
consequence of the FTD pathology directly (Appleby and Tanase, 2014).  Beagle 
et al,. compared the incidence of epileptic seizures in AD, DLB and FTD and have 
shown that in FTD this risk is lowest (AD 13.4%, DLB 14.7%, FTD 3.0%) (Beagle 
et al., 2017). In part this difference may be a result of structural differences of the 
tau implicated in these conditions. In AD 3- and 4-repeat (4R) helical tau filaments 
are the predominant form. In FTD, linear 4R tau is more commonly seen 
(Taniguchi-Watanabe et al., 2016, Gibbons et al., 2018). A recent study has 
identified that this difference results in changes in how and where the tau spreads 
and the effect it has on neurons (Cope et al., 2018). 
2.3.8 EPILEPSY IN OTHER NEURODEGENERATIVE DISEASES 
Epileptic seizures have been described in a number of other neurodegenerative 
diseases, in which cognitive impairment is also a feature, including Huntington’s 
disease (HD) and sporadic Creutzfeldt - Jakob disease (CJD). 
Epileptic seizures are a rare feature of HD, but as in AD are more common in 
patients with earlier onset of the disease, particularly juvenile onset (Schiottz-
Christensen, 1969, Gambardella et al., 2001, Chuo et al., 2012, Cloud et al., 
2012, Sipila et al., 2016).  In these patients, the most common seizure type 
appears to be generalised tonic-clonic seizures, although tonic, myoclonic, and 
staring spells are also described (Cloud et al., 2012). In HD as in AD, there is a 
correlation between age at onset and the rate of cognitive decline which is likely 
a factor in the prevalence of epilepsy in both conditions. Why this is the case is 
not clear, although in both conditions earlier age of onset is associated with a 
more rapid accumulation of the pathological hallmarks of these diseases: due to 
an increased likelihood that younger patients have a genetic form of AD, and due 
to a higher CAG-repeat count in younger HD patients as a result of anticipation. 
A variety of seizure presentations have been reported in CJD including non-
convulsive and generalised status epilepticus, as well as focal motor seizures 
(Rossetti and Dunand, 2007, Ogawa et al., 2011, Ng et al., 2014, Alobaidy et al., 
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2016, Mahboob et al., 2018, Miyake et al., 2018). Whilst the cognitive changes 
seen in prion diseases such as CJD are typically more extensive and rapidly 
progressive than those of AD, the pathological features of both conditions have 
been shown to be associated with increased neuronal hyperexcitability (see 
below) and in both this is considered to be the underlying mechanism behind 
epileptic seizures in these patients (Bertani et al., 2017). 
Whilst not a neurodegenerative condition, Down’s syndrome is worth mentioning 
here given that dementia and epilepsy so commonly occur in this condition (Lott 
et al., 2012, Barca et al., 2014, Aller-Alvarez et al., 2017). Moreover, Down’s 
syndrome is caused by trisomy of chromosome 21, which is the location of the 
gene for APP, one of the commonest causes (both through duplication and 
mutation) of familial AD (Collacott, 1993, Lott et al., 2012, Gholipour et al., 2017). 
Almost 40% of those with Down’s syndrome who are 60 years of age or older are 
diagnosed with dementia (Hanney et al., 2012) . There is a bimodal distribution 
in the age of seizure onset, with one peak in the first decade and a second 
occurring in the 5th and 6th decades, likely a result of neurodegenerative 
processes.  Seizure features in this population typically include both generalised 
and focal epilepsies as well as late-onset myoclonic epilepsy, and are associated 
with an increased incidence of dementia and earlier mortality than in those 
without epilepsy.  
2.3.9 EEG IN DEMENTIA 
Whilst recent years have seen an increase in the clinical utility of biomarkers in 
the diagnosis of dementia, the use of EEG has not become a routine element of 
the diagnostic process. Nonetheless numerous studies have looked at the use of 
EEG in different dementia subtypes in an attempt to investigate whether it can be 
used to discriminate between them (Bonanni et al., 2016, van der Zande et al., 
2018a). These studies have identified differences between EEG recordings in AD 
vs DLB patients, even when mixed pathology is present. As described by van der 
Zande et al., these differences included a higher prevalence of diffuse 
abnormalities (consisting of posterior dominant frequency below 8 Hz, diffuse 
slow wave activity or decreased reactivity of the background pattern to eye 
opening) in DLB/AD+ and DLB/AD- vs AD patients as well as a significant 
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difference between both DLB groups and AD for global alpha band Phase Lag 
Index (a measure of functional connectivity) (van der Zande et al., 2018a).  
In addition, the use of EEG to investigate the relationship between Alzheimer’s 
disease and epilepsy has also increased. In part this is a result of findings from 
animal studies of AD pathology, in which epileptic seizures were identified (Palop 
et al., 2007, Palop and Mucke, 2009, Ziyatdinova et al., 2011, Born et al., 2014, 
Ziyatdinova et al., 2016).  These studies, particularly focussed on APP transgenic 
mice, have shown EEG signatures of neuronal hyperexcitability in the presence 
of Amyloid-beta (Aβ) deposition in mice that exhibit clinical seizures as well as 
those that do not (Booth et al., 2016, Ziyatdinova et al., 2016). These findings 
have proven harder to replicate in human studies, as a consequence of EEG 
changes which are evident in the ageing brain and make EEG evaluation more 
difficult in this population, and also because the animal studies in which 
epileptiform activity was identified utilised deep EEG electrode placement into 
mesial temporal lobe structures which are harder to record when surface EEG 
placement is used. 
To overcome the mesial temporal lobe’s resistance to interrogation, extended 
EEG recording - either in the form of ambulatory EEG or through sleep EEG - has 
emerged as a more consistent means of identifying abnormalities (Vossel et al., 
2016, Horvath et al., 2017). However, longer duration EEG recording, particularly 
in the hospital setting does pose significant practical challenges for patients with 
dementia (Horvath et al., 2016). Studies that have adopted this approach have 
identified a number of different findings which have increased our understanding 
of this area. It has been shown that a 1 hour EEG recording during night-time 
sleep has the same sensitivity for the identification of epileptiform discharges as 
at least 8 hours of awake daytime recording (Horvath et al., 2017). Where 
abnormal findings are identified, these most commonly include increased slow 
wave activity, across temporal regions in the early stages, and more diffusely 
later on (Visser et al., 1987, Rice et al., 1990, Malek et al., 2017). These changes 
are in keeping with the progression and location of pathology in advancing AD.  
Moreover, increased delta and theta rhythms over the temporal regions have 
been shown to correlate with cognitive performance, to differentiate patients with 
dementia from controls, and to predict progression in MCI (Prichep, 2007, 
Kroigard et al., 2018).  
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More recently, more complex mathematical modelling techniques, including 
graph theory, have been applied to EEG recording in patients with dementia in 
an attempt to identify electrophysiological signatures that may enable the use of 
EEG as a non-invasive means of early diagnosis in these conditions and improve 
our understanding of their pathophysiology (Stam et al., 2009, Vecchio et al., 
2016, Smailovic et al., 2018, Weiler et al., 2018). Results from this work have 
shown changes in cortical network topology, with reduced network efficiency and 
reduced connectivity in prodromal and mild dementia due to AD (Vecchio et al., 
2016, Franciotti et al., 2018).  
More complex or invasive methods of EEG recording, such as MEG and foramen 
ovale electrode placement have also been shown to identify an increased rate of 
epileptiform abnormalities and in some cases silent seizures in AD patients (Lam 
et al., 2017).  
It has been shown that these complex EEG biomarkers, such as functional 
network efficiency and the functional brain connectome, can be predictive of 
progression to AD in patients with MCI (Poil et al., 2013, Wang et al., 2013, 
Babiloni et al., 2018). Moreover, EEG abnormalities including delta and theta 
slowing involving the temporal lobes, have also been shown to be associated with 
an earlier age of onset and cognitive decline in patients with MCI and AD 
(Prichep, 2007, Vossel et al., 2013). 
Studies looking at EEG in DLB have reported extensive generalised slowing and 
a higher prevalence of frontal intermittent rhythmic delta activity (FIRDA) (Calzetti 
et al., 2002, Roks et al., 2008, van der Zande et al., 2018a). In 2016, Cromarty et 
al reviewed the evidence for a range of neurophysiological techniques in order to 
identify biomarkers for DLB (Cromarty et al., 2016), including MEG and 
transcranial magnetic stimulation (TMS) as well as more conventional EEG 
methods. As before, an increase in posterior slow-wave activity was found to 
differentiate DLB from both controls and patients with AD, a finding which is also 
supported by evidence from a MEG study (Bosboom et al., 2009). They conclude 
that further research is indicated in order to maximise the diagnostic specificity 
and sensitivity of these techniques.  
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FIRDA is also seen in early stages of sporadic CJD, but more pronounced 
changes such as periodic sharp wave complexes (PSWC) become more 
common as the disease progresses. PSWC, either lateralised or generalised, 
have been identified in the majority of CJD patients during the course of their 
disease (Malek et al., 2017). 
EEG changes have been reported in patients with Frontotemporal lobar 
degeneration and have been shown to  correlate with the degree of impairment 
in these patients (Chan et al., 2004). EEG abnormalities in these patients include 
disruption of the alpha rhythm and slow wave changes. 
2.3.10 SEIZURE SEMIOLOGY IN DEMENTIA 
In his 1911 account of Johann F, Alzheimer described an epileptiform seizure, 
lasting a few minutes, with twitching of the face and a facial palsy that was still 
the following day. More recent literature has shown that patients with dementia 
can experience a broad range of seizures, some obvious and self-evident, some 
more subtle, and as we have seen, some subclinical epileptiform activity which 
can only be identified on prolonged EEG recordings. The findings of studies which 
have looked at seizure semiology in AD are summarised in Table 2.3. These 
studies reflect an evolution in our understanding of seizures in this population, 
with non-convulsive and non-motor seizures being increasingly recognised in 
more recent studies (Vossel et al., 2013, Horvath et al., 2018). However, even 
the earliest study described in this table recognizes the difficulty in identifying and 
recording partial seizures in this population (Hauser et al., 1986). 
 
Author Year Seizure Semiology 
Hauser 1986 100% had generalized convulsions 
Heyman 1987 
71% recurrent, severe generalized seizures; 29% had myoclonus, 75% of whom 
developed major motor seizures during follow-up 
Mendez 1994 generalized tonic-clonic seizures in 90% 
Scarmeas 2009 
"changes in level of attention" in 100%, "whole body convulsion” in 86%, "clinical 
semiology of lateralised findings" in 29% 
Bernardi 2010 
93% complex partial seizures, 7% generalised attacks: For most patients with 
partial complex seizures the informant reported initial motor signs including head 





complex partial seizures in 47%, 36% apparent generalised seizures, 17% simple 
partial seizure. 55% had only nonconvulsive seizures (jamais vu, deja vu, sensory 
phenomena, psychic phenomena, speech/behavioural arrest, aphasia, and 
amnestic spells) 
Horvath 2018 
generalized tonic-clonic seizures in 11% and focal onset seizures with impaired 
awareness in 72%. Fifty-five percent of seizures were non-motor 
(Table 2.3: Seizure semiology in AD) 
 
Whilst seizure prevalence in differing dementia subtypes appears to vary, 
whether the same is true of the seizure semiology is less clear, although the 
seizure features in these patients do not seem to be specific to a particular 
neurodegenerative syndrome (Beagle et al., 2017). Moreover the range of 
seizure features seen in this population is in keeping with the seizure semiology 
seen in patients with temporal lobe epilepsy without a history of pre-existing 
dementia (Fogarasi et al., 2007). 
The reported seizure semiology in dementia has been shown to depend, to a 
degree, on the means of data acquisition. In studies where retrospective data 
collection has been used, generalised seizures appear more common, whereas 
prospective studies are more likely to identify seizure types which are more 
subtle. Recent literature has shown that focal onset seizures, with loss of 
consciousness, appear to be the most common seizure type (Sarkis et al., 2016). 
Difficulty in recognising epileptic seizures is a recurrent problem and it has been 
noted that complex partial seizures, presenting as brief moments of altered 
awareness, staring, behavioural arrest, or transiently increased confusion, can 
easily be confused for worsening or fluctuation of the dementing illness as 
opposed to epileptic seizures (Mendez and Lim, 2003). Transient amnestic 
spells, déjà vu, jamais vu and unexplained emotions are all reported seizure 
features in this population and pose challenges in identification in patients with 
dementia (Rabinowicz et al., 2000, Cretin et al., 2012, Cretin et al., 2014, Vossel 
et al., 2017). Many of these seizure features are in keeping with the primary sites 
of pathology in patients with AD, being representative of focal seizures originating 
in the mesial temporal lobe / hippocampus.  
Myoclonus, quick, involuntary muscle jerks, have myriad causes but can be a 
feature of epilepsy. Studies have shown that epileptic myoclonus is a common 
feature (and one which is often overlooked) in patients with dementia (Risse et 
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al., 1990, d'Orsi and Specchio, 2014, Beagle et al., 2017). In patients with AD, 
myoclonus has been shown to be both cortical and subcortical in generation, 
most commonly affecting the fingers. Myoclonus appears to be more common in 
familial forms of AD than in later onset sporadic forms, and the prevalence has 
been shown to increase as the disease progresses (Hallett and Wilkins, 1986, 
Ugawa et al., 1987, Eberhardt and Topka, 2017).  
2.3.11 PATHOPHYSIOLOGY OF SEIZURES IN DEMENTIA 
To better understand the risk of epilepsy in dementia, a clear pathological 
mechanism should be identified that connects these two conditions. This has 
been the focus of increased interest over recent years, following the identification 
of epileptic seizures in transgenic mice which exhibit AD pathology (Palop et al., 
2007, Palop and Mucke, 2009). A number of different murine models have been 
used, and whilst many of these display similar pathologic features to each other, 
and to those seen in human patients with AD, there are also differences. Whilst 
this could be viewed as a drawback (mouse models do not perfectly replicate 
human AD and therefore findings from these studies should be interpreted with 
caution), there are also benefits which add to our understanding of the precise 
pathologic mechanisms underlying the relationship between epilepsy and 
dementia (Yan et al., 2012). For example, some of these models exhibit only Aβ 
pathology, and not tau, whereas others demonstrate tau but not Aβ, extending 
our understanding of how each of these proteins contributes to the clinical 
findings of AD. 
Palop showed that one of these models, hAPP-J20, experienced epileptic 
seizures and that this resulted in a more rapid decline in their performance on 
cognitive tasks when compared to their litter mates. This study suggests that 
chronic exposure to high levels of Aβ sensitizes at least some neuronal networks 
to overexcitation, thereby precipitating seizures. Moreover it was also found that 
this neuronal overexcitation led to compensatory remodelling of inhibitory circuits 
which ‘end up constraining the functional agility of specific excitatory circuits’ and 
consequently adding to the cognitive impairments in these animals (Palop et al., 
2007, Noebels, 2011).  
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Numerous studies have further investigated the potential for Aβ deposition in the 
setting of transgenic mouse models of AD to lead to neuronal hyperexcitability 
and epileptic seizures (Chan et al., 2015, Stargardt et al., 2015, Tamagnini et al., 
2015b, Tamagnini et al., 2015a). This amyloidopathy has been shown to cause 
alterations in intrinsic excitability leading to persistent hyperexcitability and 
potential recurrent epileptic seizures (Gurevicius et al., 2013, Tamagnini et al., 
2015b). It has been suggested that this hyperexcitability may at first be a 
compensatory mechanism to counter excessive levels of Aβ deposition during 
early, pre-clinical stages of AD, but that once a threshold level is reached and 
deposition exceeds the capacity for clearance, synaptic dysfunction occurs 
leading to disease progression (Stargardt et al., 2015), and neuronal loss 
(Scharfman, 2012). Evidence for this theory comes again from animal models, 
where environmental enrichment has been shown to lead to increased synaptic 
transmission and plasticity, and as a consequence of this, increased Aβ 
clearance (Eckert and Abraham, 2013, Stargardt et al., 2015). Importantly it has 
been shown that Aβ disrupts neural circuits at early stages of AD disease models, 
independent of, and prior to, Aβ plaque formation (Hsia et al., 1999). 
In contrast, it has also been shown that Aβ oligomers can reduce synaptic 
transmission, both at pre- and post-synaptic levels, thereby exerting the cognitive 
effects of AD through reduction in synaptic plasticity (Sepulveda et al., 2009). It 
has been posited that this effect of Aβ to keep neuronal excitation in check, may 
in fact block epileptiform activity in hippocampal neurons. 
Whilst the majority of studies looking at the interplay of epilepsy and dementia 
have focussed on the role of Aβ in this relationship, some studies have looked at 
how the other pathological hallmark of AD, phosphorylated tau, could also play a 
role. It has been shown that tau is released as a product of cell death and can 
accumulate as a result of this. In addition, tau can also cross synapses, a process 
known as trans-synaptic spread, which is facilitated by neuronal hyperexcitability 
(Pooler et al., 2013). It has been suggested that the neuronal excitability seen in 
the brains of patients with AD leads to an accelerated propagation of tau 
pathology, and that this process is further accelerated in the presence of epilepsy 
(Lewis and Dickson, 2016). A relationship between excess tau pathology and 
cognitive decline has also been shown in a study of patients with temporal lobe 
epilepsy (Tai et al., 2016). In this study of temporal lobe resections in patients 
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with refractory epilepsy, more extensive tauopathy was correlated with 
accelerated cognitive decline in verbal learning and Graded Naming Test scores. 
In some of these patients the distribution of tau pathology was similar to that seen 
in patients with AD 
2.3.12 PROGNOSIS OF SEIZURES IN DEMENTIA 
There is evidence that the presence of seizures in dementia is related to an 
increased rate of cognitive decline in these patients. This includes a decline in 
language ability as well as other indicators of disease severity including overall 
executive function (Volicer et al., 1995, Vossel et al., 2016). However, other 
studies have shown that epilepsy in this population does not affect the course or 
duration of disease (McAreavey et al., 1992, Samson et al., 1996, Amatniek et 
al., 2006). 
Epileptic seizures occurring in the setting of MCI are also a predictor of 
progression to AD (Babiloni et al., 2018).  
2.3.13 TREATMENT OF SEIZURES IN DEMENTIA 
There are no randomised controlled trials comparing the efficacy and tolerability 
of different anti-epileptic treatments in patients with dementia.  
The treatment of seizures in dementia is inevitably complicated by the nature of 
the patients in whom this combination occurs. Older patients with dementia 
typically have multiple comorbidities and are already coping with the 
polypharmacy associated with their conditions, on top of which other age related 
physiological and pharmacokinetic changes such as reduced renal function and 
impaired hepatic clearance mechanisms can make the decision to initiate a new 
medication for the management of epilepsy a harder one than it would otherwise 
be (Mendez and Lim, 2003, Carter et al., 2007, Sivaraaman and Vajjala, 2015). 
Monitoring these changes and their effects can be especially difficult in patients 
with dementia. 
Whilst some patients with dementia will experience many seizures, leading to a 
diagnosis of epilepsy, in others only a single seizure occurs, and therefore anti-
seizure medication may not be indicated. In a further proportion seizures may be 
very infrequent and therefore on balance the decision is often made not to initiate 
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treatment (Mendez and Lim, 2003). Evidence suggests that there is an increased 
risk of seizure recurrence in younger patients, those in more advanced stages of 
dementia and those in whom an EEG identifies grossly epileptiform activity and 
the presence of these features will influence decisions surrounding the use of 
anti-convulsant medications. The risk of recurrent seizures increases further 
comorbidities are also present: such as stroke, or Down syndrome (trisomy 21) 
(Menendez, 2005). 
In 2016 the treatment of epilepsy in patients with Alzheimer’s disease was the 
topic of a Cochrane review (Liu et al., 2016). This review concludes that no 
significant difference exists in terms of seizure freedom between two of the most 
commonly used medications - Levetiracetam and Lamotrigine, and that whilst 
Levetiracetam may improve cognition but worsen mood, Lamotrigine could 
worsen cognition and improve mood. Ultimately the review notes that the level of 
evidence in this area is very low and further studies are required to determine 
how effective and well tolerated epilepsy treatments are in patients with AD. 
Broadly speaking, newer anti-epileptic drugs appear to be better tolerated and 
less prone to side-effects than older medications. Sodium valproate, one of the 
most widely used drugs in the treatment of epilepsy, has been shown to increase 
the risk of agitation in patients with dementia (Baillon et al., 2018). 
Several studies have shown that the use of anti-epileptic medications can 
improve cognitive performance in mouse models of dementia (Horvath et al., 
2016). However, many of these studies report on relatively short-term use of 
these medications as opposed to the more enduring use which would be required 
in older adult human populations (Qing et al., 2008, Ziyatdinova et al., 2011, 
Sanchez et al., 2012, Devi and Ohno, 2013); therefore limiting how much can be 
inferred from these findings. Nonetheless where the use of medication in patients 
with dementia has been investigated there is evidence that seizure control is 
achieved relatively easily, often with low doses of medication (Sarkis et al., 2016). 
The use of sodium valproate has been shown to reduce Aβ production in mouse 
models of AD (Qing et al., 2008) and subsequently provide protection against 
neuronal loss (Long et al., 2013). Levetiracetam treatment has also been shown 
to reduce epileptiform activity and lead to some cognitive improvements when 
used in similar mouse studies (Sanchez et al., 2012, Devi and Ohno, 2013, 
Musaeus et al., 2017). In addition, there is evidence showing a cognitive benefit 
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in human studies using Levetiracetam in patients with AD (Belcastro et al., 2007, 
Cumbo and Ligori, 2010, Bakker et al., 2012, Bakker et al., 2015).  
Further studies of the sustained use of antiepileptic treatment in patients with AD 
are indicated. Given that a small proportion of patients with AD experience 
clinically evident seizures, but that a larger proportion exhibit epileptiform activity 
on prolonged EEG recording, patient selection for these studies is clearly a 
complex issue. Moreover, given that extensive neuronal hyper-excitability has 
been shown to increase the deposition of Aβ it may be possible that antiepileptic 
treatments can have a beneficial effect on patients with AD even in the absence 
of clearly epileptiform changes on EEG recordings.  
2.4  CONCLUSIONS  
Extensive evidence shows an increased risk of epilepsy in all forms of dementia, 
but particularly in Alzheimer’s disease, in which the risk of epilepsy reported in 
the literature varies greatly, and has been found in some studies to be over 50% 
(Risse et al., 1990, Cabrejo et al., 2006). Recent years have seen an expansion 
in our understanding of the underlying mechanisms which may lead to seizures 
in these patients and point towards a bidirectional relationship in which AD 
pathology increases the risk of seizures which are in turn associated with an 
increase in the rate at which AD pathology accumulates and the anatomical 
regions where it aggregates.  
However, numerous questions remain, not least for the clinician whose job it is to 
diagnose and manage patients with dementia. What should we tell patients about 
the overall risk of epilepsy in dementia, and for their risk in particular; are there 











CHAPTER THREE: THE PREVALENCE AND CLINICAL FEATURES OF 
EPILEPTIC SEIZURES IN A MEMORY CLINIC POPULATION 
 
3.1 INTRODUCTION 
Patients with dementia are at risk of developing epileptic seizures (Amatniek et 
al., 2006, Lozsadi and Larner, 2006, Rao et al., 2009, Scarmeas et al., 2009, Sen 
et al., 2018). This was reported by Alzheimer himself in his description of Johann 
F in 1911 (Moller and Graeber, 1998). However, the extent to which this risk is 
increased has been disputed and remains unclear (Horvath et al., 2016). 
Estimates of the prevalence of epilepsy in patients with Alzheimer’s disease 
range from 0.5% (Irizarry et al., 2012) to 64% (Risse et al., 1990). Moreover, 
whilst conventional wisdom has considered epilepsy to be a feature of advanced 
disease in these patients (Cheng et al., 2015), more recent evidence has reported 
patients developing epilepsy early in the course of clinical disease (Vossel et al., 
2013) and in some cases even before a diagnosis is made (Sarkis et al., 2016). 
In addition, studies have suggested that epileptic seizures may contribute to and 
even accelerate the cognitive decline seen in these patients (Vossel et al., 2016). 
Finally, whilst several studies have looked at the prevalence of epileptic seizures 
in Alzheimer’s disease, these studies have typically focussed on tertiary specialist 
centres, with a higher proportion of patients with early onset Alzheimer’s disease, 
in which the increased prevalence of epileptic seizures is well-described (Cabrejo 
et al., 2006, Larner, 2011), and complex cases, in which features such as 
seizures, are again likely to be more common (Giorgi et al., 2016). I aimed to use 
the memory clinic, the most common setting for dementia diagnosis in the UK, as 
the pool for our participants, in order to provide a real-world and clinically relevant 
estimate for the prevalence of epilepsy in this population. 
In the UK, the diagnosis of dementia, or of mild cognitive impairment (MCI) is 
usually made at a memory clinic in secondary care. These clinics have been 
established throughout the UK following a governmental initiative, and provide a 
rapid, ‘one-stop’, method of assessment for patients with memory disorders 
(Philpot and Levy, 1987, Jolley et al., 2006) . Patients, typically referred by their 
general practitioner (GP), attend alongside a reliable informant (most commonly 
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their spouse) and undergo assessment by several members of the mental health 
team, yielding a cognitive profile and diagnostic formulation.  
In the Presentation of Epileptic Seizures in Dementia (PrESIDe) study I 
investigate the prevalence and characteristics of epilepsy in a cohort of memory 
clinic patients. While this does not strictly provide a community-based sample, 
the National Institute for Health and Care Excellence (NICE) recommends referral 
to the memory clinic for all patients in whom dementia is suspected (NICE, 2017). 
As the memory clinic is the first contact patients will have with a specialist clinician 
in this field, determining the prevalence of epilepsy in this population is of great 
clinical value.  
Given that seizures occurring in the context of dementia can be subtle, and are 
probably underreported (Sarkis et al., 2016, Horvath et al., 2018), I designed a 
proforma to elicit symptoms suggestive of seizures for use in interviews with 
patients and informants (appendix 1). I used accepted current diagnostic criteria 
to confirm dementia diagnoses. The main aims of our study were therefore to 
establish the prevalence of epilepsy in a relatively unselected group of patients 
with MCI/early dementia and to determine their clinical features. I compared the 
prevalence of epilepsy in the patient group with the prevalence assessed using 
the same approach in a group of healthy participants matched for age, sex and 
years of education. Our findings underline current uncertainties regarding the 
appropriate management of epilepsy occurring in early dementia.  
3.2 MATERIALS AND METHODS 
 3.2.1 PARTICIPANTS 
144 patients and 80 age- and gender-matched control participants were recruited 
to the study. The size of these samples was determined using a power calculation 
(α level P=0.05, power 80%) in order to detect a 5% difference in the prevalence 
of epilepsy between the dementia and MCI population vs the control population. 
Patients were identified through their attendance at the memory clinic in Exeter, 
Devon, UK, and were considered eligible for inclusion if a diagnosis of MCI or 
dementia (of any kind) was made at their memory clinic assessment. All eligible 
patients who had attended the memory clinic over an 18 month period (January 
2016 - June 2017) and who had consented to take part in research were 
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approached. Patients from the total memory clinic population were excluded if a 
diagnosis other than dementia or MCI had been made (for example subjective 
memory impairment), where consent to be contacted was not provided, or where 
a reliable informant was not available to accompany the participant for the 
interview. The control group was identified with the help of the Exeter 10,000 
study. The Exeter 10,000 (EXTEND)/Peninsula Research Bank (PRB) was set 
up to collect and store genetic, biological, clinical and lifestyle information on 
10,000 adult individuals living in Exeter. This has established a sampling 
framework from which individuals can be selected, on the basis of (genetic/non) 
genetic predisposition/protection factors, to be invited for further research into the 
mechanisms of health and common disease. It is managed through the NIJR 
Exeter Clinical Research Facility (Exeter CRF) 
https://crf.exeter.ac.uk/web/content/exeter-10000-peninsula-research-bank. In 
the control group there was no reported history of cognitive impairment, and these 
patients had not previously been seen by the memory clinic. A preceding history 
of epilepsy was not an exclusion criterion. I used regional postcodes as a 
surrogate marker of socioeconomic status between the control and study 
populations. 
 3.2.2 CLINICAL INTERVIEW 
I interviewed patients with a diagnosis of MCI or dementia at their own home, in 
the company of a reliable informant, who was subsequently seen independently. 
The interview was guided by a standardised proforma designed for this purpose 
(appendix1). Validated diagnostic criteria (Albert et al., 2011, McKhann et al., 
2011, Sachdev et al., 2014, McKeith et al., 2017) were used to specify the clinical 
dementia diagnosis. 
Background demographic data were gathered. Subsequent questioning focussed 
on three main areas 1) past medical and family history 2) history of dementia / 
MCI symptoms and 3) presence of clinical features suggestive of epilepsy.  
Cognitive testing using the Addenbrooke’s cognitive examination – version III 
(ACE-III) (Hsieh et al., 2013) was performed (appendix2). This examination had 
been performed on all participants at the time of their memory clinic appointment. 
It was repeated at the time of initial study assessment after a mean delay of 235.5 
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days (SD 106.5 days). Diagnostic criteria state that individuals with MCI are 
typically 1 to 1.5 standard deviations below the mean for their age and education 
matched peers, although these ranges are for guidance rather than cut-off scores 
(Albert et al., 2011). For this study I chose to use the memory component of the 
ACE-III for this purpose. In keeping with diagnostic criteria MCI was defined as a 
score >1 standard deviation below the mean in this test, but with preservation of 
independence in functional abilities.  Informants were asked to complete two 
further questionnaires: the Cambridge Behavioural Inventory - Revised (CBI-R) 
(appendix3) and the Clinical Dementia Rating (CDR) (appendix 4). These 
validated questionnaires were chosen to provide an additional insight into the 
impact of the cognitive impairments experienced by our study participants, as 
witnessed by those closest to them (Morris, 1997, O'Bryant et al., 2008). The CBI-
R has been shown to effectively discriminate between different dementia 
subtypes (Wear et al., 2008).  The CDR- sum of boxes (CDR-SOB) is a 
summated score which incorporates the different domains examined in this 
questionnaire. 
Expected seizure phenotypes in this population were identified from reviewing 
previous literature comprising generalised tonic-clonic seizures, behavioural 
arrest, amnesia on waking, olfactory hallucinations, abnormal movements 
including myoclonus, and the presence of a clear aura preceding the abnormal 
episode (Vossel et al., 2013, Vossel et al., 2017). Patients were categorised in to 
one of three groups: epilepsy probable, epilepsy possible, no clinical evidence of 
epilepsy (NCEE). The criteria for this categorisation are outlined in table 3.1. 
 
Epilepsy Probable 
At least 2 stereotyped episodes suggestive of epilepsy 
witnessed by a reliable informant 
Epilepsy Possible 
Single witnessed episode suggestive of epilepsy, or at least 
2 episodes but not both reliably witnessed 
No Clinical Evidence of 
Epilepsy 
No suspicious episodes reported by patient or informant  
Seizure features: altered responsiveness, speech / behavioural arrest,  oral/pharyngeal 
automatism, olfactory / gustatory aura, involuntary movements suggesting focal motor seizure, 
other sensory phenomena (including hallucination), amnesia on waking 




Cognitive performance of the control group was assessed using the ACE-III, and 
the same seizure identification questions were asked to each control participant 
and a reliable informant to determine the prevalence of epilepsy. On average, the 
duration of interviews was approximately 2 hours. I performed all interviews for 
patients and controls in their own home setting. 
 
 3.2.3 STATISTICAL ANALYSIS 
I performed between-group analysis of demographic features, cognitive test 
performance and informant completed questionnaire scores using independent 
sample t-tests. Chi-square testing was performed to compare proportions 
between participants and controls. Multiple linear regression analysis was 
performed to assess the relationship between dependent and independent 
variables. A Bonferroni correction was made to adjust for multiple comparisons. 
Statistical significance was judged as any p-value <0.05. IBM SPSS statistics 
22.0 and STATA were used to perform data analysis.  
Ethical approval for this project was awarded through the Integrated Research 




 3.3.1 DEMOGRAPHIC CHARACTERISTICS  
From a pool of 300 memory clinic patients who met eligibility criteria for study 
involvement, I recruited 144 patients to the study: 53% male, 47% female. The 
age at onset of memory symptoms varied from 51yrs to 91yrs (mean 75.10, SD 
7.07). The age at memory clinic assessment ranged from 57yrs to 94yrs (mean 
77.98, SD 6.75).The demographic features of the memory clinic sample are 
similar to the memory clinic population in whom a diagnosis of dementia or MCI 
was made (n=300) from which they were recruited: age - mean 76.82 (SD 9.94), 
52% male, 48% female. The standard deviation for the memory clinic population 
is greater than the study population. This is a result of younger patients being 
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more likely to be excluded (no diagnosis of dementia or MCI made) and older 
patients less likely to consent to study participation when contacted. Of the 156 
patients who were initially contacted but did not take part in the study, 102 
(65.38%) declined involvement. 43 (27.56%) patients did not respond to follow-
up telephone calls to discuss their potential involvement. 11 (7.05%) patients 
were not appropriate for inclusion as a result of not being able to name an 
appropriate reliable informant to take part in the study. 
The control group (n= 80) was well-matched for gender (55% male, 45% female) 
and age (mean= 77.39, SD = 4.31) with the patient group.  The size of the control 
group was determined through a calculation in order to detect a statistically 
significant difference (α level P=0.05, power 80%). There was no significant 
difference between the control group and the study group in terms of total years 
of education. The only significant difference between the study group and the 
control population was, as expected, cognitive function as measured by the ACE-
III examination (table 3.2). 
 
Table 3.2: demographic and ACE-III features in seizure categories 
 
The memory clinic cohort and the control group were also compared in terms of 
medical comorbidities. No significant differences between these groups were 









memory clinic sample (n=300) 76.82, 9.94 156:144 73.97,  14.21 
PrESIDe total (n=144) 77.98, 6.75 76:68 74.16, 11.94 
No clinical evidence of Epilepsy 
(n=107) 
77.74, 6.65 54:53 74.39, 12.31 
Epilepsy Possible (n=19) 79.11, 8.39 12:07 72.42, 11.81 
Epilepsy Probable (n=18) 78.25, 5.36 10:08 74.61 10.13 
















Hypertension 34 29.9 45.9 37.5 P=0.600 
Atrial Fibrillation 14.6 14 16.2 13.75 P=0.862 
Stroke 9.7 8.4 13.5 7.5 P=0.581 
Transient 
Ischaemic Attack 
6.9 5.6 10.8 10 P=0.414 
Myocardial 
Infarction 
6.3 6.5 5.4 11.25 P=0.193 
Migraine 3.5 2.8 5.4 3.75 P=0.923 
Depression 9 7.5 13.5 8.75 P=0.950 
Table 3.3: comparing percentage of patients with common conditions in study 
groups 
 3.3.2 DIAGNOSIS  
102 participants were diagnosed with Alzheimer’s disease. Of the remainder, 20 
received a diagnosis of MCI, 16 a diagnosis of vascular dementia, 4 dementia 
with Lewy bodies, 1 FTD and 1 posterior cortical atrophy (PCA) variant of AD. At 
the time of memory clinic assessment the duration of memory symptoms reported 
by the patients ranged from 6 months to 120 months (mean 31.9, SD 15.4). 
 3.3.3 COGNITIVE TESTING  
A decline in ACE-III scores was seen in all three seizure categories between their 
initial memory clinic assessment and study interview (figure 3.1). The difference 
between these two time points was significant only in the no clinical evidence of 
epilepsy group. The difference in the size of decline between the different groups 
was not significant. One participant (EX035) had a mini-mental state examination 
(MMSE) performed at the time of their memory clinic appointment, instead of an 
ACE-III. This participant has therefore been excluded from comparisons of 
















Figure 1. Change in ACE-III score by seizure category (boxplots indicate first 




 3.3.4 SEIZURE PREVALENCE  
I determined a diagnosis of epilepsy in 37 (25.69%, 95% CI 19%-33%) patients 
(table 3.4) using the diagnostic criteria described above. 18 patients (12.50%) 
were categorised as ‘Seizure Probable’, 19 (13.19%) as ‘Seizure Possible’ and 
107 (74.31%) as ‘No Clinical Evidence of Epilepsy’ (NCEE). The rate of ‘Seizure 
Probable’ participants is significantly higher than in the control population, in 
whom only one patient was found to have a remote history of epilepsy while none 
of the remaining 79 control patients were found to have any of the seizure 
features investigated in this study (χ2(1, N=224)=8.347 (p=0.004) . Illustrative 




This suspicion of epilepsy had been documented in 10 patients prior to their 
assessment as part of the study. In the remaining 27 there was no previous 
evidence that epilepsy had been suspected. 
This statistically significant difference in prevalence between groups was also 
seen upon restricting the group only to patients who received a diagnosis of 
Alzheimer’s disease (102/144). Of these patients, 29/102 (28%) reported features 
suggestive of epilepsy, (χ2(1, N=182)=23.45 (p<0.001)). 
There was a significantly higher rate of epilepsy in the MCI group than in the 
control group when combining probable and possible cases (χ2(1, N=100)=4.17 
(p=0.041).  
In patients with a primary diagnosis of vascular dementia 3/16 patients (18.75%) 
were included in the epilepsy probable group and 1/16 (6.25%) were included in 
the epilepsy possible group. This represented a significant increase compared to 
controls for the combined probable and possible patients (χ2(1, N=96)=15.08 
(p<0.001). 
 
 3.3.5 SEIZURE FEATURES  
The most common seizure type was impaired awareness / behavioural arrest 
seizures. This was seen in 15 of the Probable Epilepsy group (83%). 4 patients 
in this group (22%) experienced generalised tonic-clonic seizures. A range of 
further seizure features were also seen (table 3.4). These included motor 
automatisms, sensory abnormalities (including olfactory hallucinations), amnesia 





Table 3.4: characteristics of patients in epilepsy possible and probable groups 
 
 


























EX084 AD 84 83 71 2 years AW, MA, A, GTC 
EX138 AD 74 72 66 8 years before AR, AW, MA, GTC 
EX001 AD 78 71 84 2 years AR, AW, MA, A 
EX017 AD 60 62 81 2 years AR, AW, MA, A 
EX054 AD 89 89 76 6 months AW, MA, OH 
EX096 AD 60 53 70 18 months AR, AW, MA 
EX134 AD 73 72 74 3 years AR, AW, MA 
EX062 VASC 68 62 74 1 year AR, AW, GTC 
EX026 LBD 53 68 71 since childhood MA, A, GTC 
EX059 AD 67 73 83 1 year AR, AW 
EX095 AD 72 85 72 18 months AR, SA 
EX108 AD 79 86 72 6 months AR, A 
EX145 AD 86 81 79 since childhood AR, MA 
EX149 VASC 76 70 73 same time AR, FOS 
EX131 MCI 96 89 79 2 years AR, AW 
EX080 AD 84 83 72 6 months AR 
EX139 AD 79 69 75 2 years AR 














EX015 LBD 89 56 72 4 years AR, AW, MA 
EX048 AD 66 63 75 3 years AR, AW, MA 
EX119 AD 84 82 75 3 years AW, MA 
EX018 AD 43 56 66 18 months AR, AW 
EX028 AD 75 77 89 1 year AR, AW 
EX032 AD 63 62 89 2 years AR, AW 
EX043 AD 83 77 75 18 months AW, MA 
EX112 AD 73 84 51 5 years AW, MA 
EX005 AD 79 83 81 18 months AR 
EX027 AD 86 85 79 3 years AR 
EX035 AD 
22/30 
(MMSE)  53 86 2 years AW 
EX037 AD 67 66 83 6 months AR 
EX065 AD 88 81 87 12 months AR 
EX081 AD 78 74 65 2 years AR 
EX083 AD 69 66 74 1 year AW 
EX117 AD 70 60 80 1 year AR 
EX136 AD 78 74 77 2 years AR 
EX042 VASC 85 85 75 2 years AR 
EX107 MCI 89 92 69 6 months AR 
key: Diagnosis: AD - probable Alzheimer's disease, VASC - vascular dementia, LBD - Lewy Body dementia, MCI - 
Mild Cognitive Impairment.  Seizure Features: AR - altered responsiveness, AW - amnesia on waking, MA - motor 
automatisms, GTC - generalised tonic-clonic seizures, OH - olfactory hallucination, FOS - focal onset seizure, A - 
aura, SA - sensory abnormality 
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Combining the epilepsy possible and epilepsy probable groups, the mean 
reported duration from the onset of memory symptoms until the first seizure, 
based on informant accounts was 12.2 months (median 18 months, range -96 to 
60, excluding two patients with onset of epilepsy in childhood) (Figure 3.2). 
 
 
Figure 3.2: time from memory symptom onset to seizure onset in epilepsy 
possible and probable participants 
 
The results of the informant completed questionnaires (CBI-R and CDR 
questionnaires) are shown in table 3.5, revealing a significant difference in both 
measures when the epilepsy probable group (and the combined probable and 











CBI-R (mean, SD) 
PrESIDe total 3.96 (2.76) 0.74 (0.48) 40.40 (26.58) 
No clinical evidence of 
Epilepsy 
3.52 (2.47) 0.68 (0.45) 35.32 (24.40) 
Epilepsy Possible  4.56 (2.65) p=0.130 0.81 (0.4) p =0.280 54.27 (24.5) p=0.006 
Epilepsy Probable 6.19 (3.1) p<0.001 1.03 (0.65) p=0.007 54.29 (30.91) p=0.006 
Combined possible and 
Probable 
5.39 (3.0) p<0.001 0.92 (0.55) p=0.016 54.28 (27.64) p<0.001 
(P-values for epilepsy groups vs no clinical evidence of epilepsy) 
Table 3.5: comparing informant questionnaires across seizure categories 
 
 3.3.6 MEDICATION 
Of the 144 patients in our study 40 were taking a medication (Donepezil (29), 
Rivastigmine (7) or Memantine (4)) specifically licenced for the treatment of 
dementia in the UK. There was no significant difference in the prevalence of the 
use of these medications between the combined epilepsy group (11/37, 29.7%) 
and the NCEE group (29/107, 27.1%). Six patients in the epilepsy probable group 
were prescribed an anti-epileptic medication at the time of assessment 
(Lamotrigine (2), Levetiracetam (2), and Sodium Valproate (1), Phenobarbitone 
(1)). This group included the two patients with seizures since childhood, and one 
patient who had experienced seizure onset 8 years prior to the onset of memory 
symptoms. Of the remaining patients, 2 had experienced generalised tonic-clonic 
seizures and one had experienced focal onset seizures following a stroke. In 
addition, one patient in the NCEE group was currently prescribed Carbamazepine 
for the treatment of neuropathic pain. No other participants were on anti-epileptic 
medication for any other indication. Therefore 66.67% patients in the probable 
group and 100% in the possible epilepsy group were not on anti-epileptic 
treatment at the time of the study. 
3.4 DISCUSSION 
The prevalence of epilepsy is increased among patients with dementia but the 
extent of this increase remains controversial. I have identified a prevalence of 
clinically diagnosed epilepsy of between 12.5 and 25.7% in a memory clinic 
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population with MCI and early dementia, using a standardised proforma to elicit 
symptoms suggestive of epilepsy in interviews with patients and their carers. To 
our knowledge, this is the first UK based study that has recruited a population of 
participants from the memory clinic, with all dementia diagnoses, and aimed to 
investigate the prevalence of epilepsy in this group.  
The seizures were predominantly subtle and non-convulsive, and started on 
average less than two years after memory symptom onset. While cognitive 
performance did not differ between patients with or without epilepsy, patients with 
epilepsy were more impaired on standard measures of behavioural performance 
assessed by informant interview. Given suggestive evidence (Belcastro et al., 
2007, Vossel et al., 2013, Vossel et al., 2016) from other work that epilepsy can 
accelerate cognitive decline in patients with dementia, these results may 
challenge current practice which tends to overlook subtle seizures in patients with 
dementia and to be reluctant to treat epilepsy given the potential side-effects of 
anti-epileptic medication (Mendez and Lim, 2003, Larner, 2010, Liu et al., 2016). 
I consider each of these main findings in turn before considering limitations of our 
study. 
 3.4.1 PREVALENCE 
The prevalence of epilepsy in our memory clinic sample was significantly 
increased when compared to a population without cognitive impairment matched 
for age, gender and education. This increase was seen for the memory clinic 
population as a whole, but also for patients with Alzheimer’s disease, vascular 
dementia and MCI when these conditions were considered separately. Patients 
with seizures did not differ from those without epilepsy in age at dementia 
symptom onset, duration of symptoms or cognitive test score. Epileptic seizures 
were not a feature of advanced disease in these patients. 
 3.4.2 CLINICAL FEATURES 
The seizures in our patients were often subtle and easily missed. Brief periods of 
unresponsiveness, behavioural arrest and staring were common. In many cases, 
these features had been noted previously, but had been considered a feature of 
the underlying dementia, rather than as evidence of epilepsy. The features 
described in our participants are in keeping with previous research in this area 
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which has shown that only a minority of patients experience generalised tonic-
clonic seizures (Belcastro et al., 2007, Vossel et al., 2016, Horvath et al., 2018). 
Moreover, it is in keeping with the reported semiology of temporal lobe epilepsy, 
where more subtle features such as staring, blinking and behavioural arrest are 
frequently described, particularly in more elderly populations (Villanueva and 
Serratosa, 2005, Fogarasi et al., 2007, Blair, 2012). The spectrum of mesial 
temporal lobe epilepsy also includes transient epileptic amnesia (TEA), in which 
seizures are characterised by brief periods of amnesia during which other 
cognitive functions remain intact (Butler et al., 2007, Mosbah et al., 2014). It is 
possible that seizures of this nature also occur in patients with dementia, but 
would be particularly difficult to identify given the baseline cognitive deficits in 
these patients. However, the presence of olfactory hallucinations, and episodes 
of amnesia on waking in our group, which have frequently been described in 
patients with TEA (Atherton et al., 2014, Savage et al., 2017), suggests that 
seizures similar to those described in TEA can occur in patients with dementia, 
as previously reported (Krishnan and Larner, 2009, Cretin et al., 2014). 
 3.4.3 COGNITIVE DECLINE 
The ACE-III examination scores for the group as a whole were significantly lower 
at the time of study assessment than at memory clinic baseline. In all three 
seizure sub-groups there was a drop in the ACE-III score between baseline 
memory clinic assessment and study assessment. This drop was largest in the 
epilepsy possible group, but only reached statistical significance in the large 
NCEE group, probably as a result of its size and the resulting statistical power to 
detect such a change. The differences between groups was not significant at 
either time point. 
However, the CDR-SOB was significantly higher in the epilepsy group than in the 
NCEE group. This difference suggests that seizures in these patients are 
associated with accelerated impairment in terms of activities of daily living and an 
increased disease burden as identified by the people spending the most time with 
these patients – typically their spouse. This score, which reflects observations by 
carers over a number of weeks or months is likely to be more sensitive to global 
impairment than a single cognitive test result (O'Bryant et al., 2008, O'Bryant et 
al., 2010, Eldholm et al., 2018).  
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It is unclear from our data whether the seizures in our patients are a cause of 
more severe impairment – i.e. lead to accelerated decline – or reflect a more 
severe form of disease which independently causes accelerated functional 
impairment with epileptic seizures as an incidental feature, However, numerous 
studies, looking at mouse models of dementia have investigated this question 
(Palop et al., 2007, Gurevicius et al., 2013, Ovsepian and O'Leary, 2015). These 
studies report that the pathological changes seen in Alzheimer’s disease are 
associated with neuronal hyperexcitability which increases the potential for 
epileptic seizures to occur (Palop et al., 2007, Brown et al., 2011, Stargardt et al., 
2015, Booth et al., 2016). In addition further studies have shown that the epileptic 
seizures seen in these models facilitate the more rapid and anatomically diffuse 
spread of Alzheimer’s pathology which has been associated with an accelerated 
cognitive decline in these animals (Palop and Mucke, 2009, Scharfman, 2012).  
Current trials investigating the effects of anti-epileptic medication in both human 
patients with dementia and epileptic seizures, and others studying animal models 
of these conditions, will shed further light on this issue (Bakker et al., 2015, 
Nygaard et al., 2015).   
 3.4.4 IMPLICATIONS 
It is clear that patients and their carers are rarely aware themselves of the risk of 
epileptic seizures in dementia and have not been prepared to recognise them if 
they occur. Providing education about the risk of epilepsy for those caring for 
people with dementia would help to identify patients with seizures earlier in the 
clinical phase of their illness and therefore increase the window of opportunity to 
provide anti-epileptic treatment. 
 3.4.5 LIMITATIONS 
I diagnosed probable and possible epilepsy in this study based on clinical 
grounds. Whilst the clinical history obtained in these patients is suggestive of 
epileptic seizures and in keeping with the seizure phenotypes described 
elsewhere (Vossel et al., 2013, Vossel et al., 2016) it would be beneficial to have 
confirmatory evidence, provided by EEG recordings, of the presence of abnormal 
epileptiform activity to support this diagnosis. However, as has been shown in 
previous work (Liedorp et al., 2010, Horvath et al., 2016), standard clinical EEG 
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is not a sensitive means of identifying abnormalities in these patients. Research 
has shown that more prolonged EEG recordings, especially those that involve 
overnight recordings and sample sleep, are particularly valuable in these patients 
(Horvath et al., 2017). In our study, participants were routinely asked if they had 
had an EEG performed, only two patients recalled this. In both cases the reports 
of these recordings were reviewed. In one case clear epileptiform abnormalities 
were identified (Left fronto-temporal (EX138)). In the other case no clear 
abnormalities were reported (EX149).   
I diagnosed and subtyped dementia in this study on clinical grounds, supporting 
the diagnosis of MCI using standard neuropsychological testing. Whilst recent 
developments in the use of biomarkers have shown these to be useful in 
confirming diagnoses, clinical decision making based on the history provided and 
the findings on examination remains a sensitive means of reaching a diagnosis 
in these patients. This is the approach advocated by the diagnostic criteria for AD 
which emphasise that the core clinical criteria provide very good diagnostic 
accuracy and that whilst biomarker evidence ‘may increase the certainty’ that the 
diagnosis is due to AD pathology they are often uninformative when a diagnosis 
of probable AD is made (McKhann et al., 2011). The utility of these biomarkers 
increases when the diagnosis is less certain, in atypical cases of dementia, in the 
earlier stages of disease, or in predicting the likelihood of progression from MCI 
to dementia (Blennow et al., 2015, Olsson et al., 2016, Simonsen et al., 2017). 
I report the prevalence of epileptic seizures in patients recruited from a regional 
memory clinic. Given that all patients in whom there is a suspicion of dementia 
should be referred to this service, our results should also reflect prevalence rates 
for patients with MCI or dementia in the community more widely. However, as this 
is not a true community-based study our findings should be extrapolated with 
caution. Likewise, whilst the memory clinic could be considered to represent 
patients who are early in the course of clinical disease, I have shown a wide 
variation in both the duration of memory symptoms prior to assessment in the 
memory clinic and the cognitive performance as measured by ACE-III testing at 
this time and therefore our group does not definitively represent the prevalence 
of epilepsy in patients with MCI or early dementia. I can, however, be confident 
that the patients recruited to this study are representative of the memory clinic 
population more broadly, in terms of age, gender and cognitive function.  
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As indicated above, our data cannot answer the question of whether dementia-
related seizures accelerate cognitive or behavioural decline. There is suggestive 
evidence that this may be so (Vossel et al., 2016) and current trials will help to 
answer the question of whether anti-epileptic medication is beneficial (Bakker et 
al., 2015, Musaeus et al., 2017). At present many clinicians are reluctant to 
prescribe anti-epileptic medications in these patients due to concerns with their 
cognitive side effects, compliance, interaction with other medications and 
potential for commonly used medications to lead to problems with sleep. In our 
study the only patients currently prescribed anti-epileptic medication were those 
with seizure onset during childhood/adolescence, with a long interval (8 years) 
from the onset of seizures to the onset of memory symptoms, or who had had 
witnessed generalised tonic-clonic seizures, or focal onset seizures following a 
stroke.   
3.5 CONCLUSION 
The prevalence of epileptic seizures is increased in patients diagnosed with MCI 
or dementia. The onset of seizures in our patient group occurred within two years 
of the reported onset of memory symptoms. At the time of seizure onset, patients 
with seizures were not different to those without seizures in terms of age or 
cognitive test score, but were significantly more impaired on measures of the 
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CHAPTER FOUR: THE PRESENTATION OF EPILEPTIC SEIZURES IN 
DEMENTIA: A 12-MONTH FOLLOW-UP STUDY 
 
4.1 INTRODUCTION 
The prevalence of epileptic seizures is increased in patients in the early clinical 
stages of dementia when compared to an age-matched cognitively normal 
population (Cheng et al., 2015, Cook et al., 2015, Nicastro et al., 2016). In The 
Presentation of Epileptic Seizures in Dementia (PrESIDe) study I identified a 
prevalence of epilepsy between 12.5 and 25.7 percent in these patients (Baker 
et al., 2019). These findings are comparable to those of recent studies in this field 
(Vossel et al., 2013, Vossel et al., 2016, Horvath et al., 2017, Horvath et al., 
2018). However, the long-term sequelae of epilepsy in this population remain 
unclear. Does the presence of epileptic seizures impact the progression of 
dementia and what is the nature and extent of this effect? 
The aim of this study is to answer these questions through a 12-month follow-up 
assessment of patients initially recruited to the PrESIDe study. Our goal is to 
ascertain the rate of cognitive decline in patients in whom a suspicion of epilepsy 
has been identified and to compare this with those in whom there was no 
suspicion of epilepsy. The initial findings of the PrESIDe study did not identify a 
significant difference in cognitive performance between these groups at the time 
of their initial memory clinic assessment or at the time of their recruitment in to 
the study. However, there was a difference in scores on informant completed 
questionnaires (Cambridge Behavioural Inventory - Revised and Clinical 
Dementia Rating (CBI-R and CDR)) which suggested increased difficulty in 
completing activities of daily living (ADLs) and greater care requirements in 
patients with dementia who also experienced epileptic seizures. 
4.2 MATERIALS AND METHODS 
I recruited patients to the PrESIDe study as outlined previously in chapter 3. 11 
months after their initial study assessment, participants were contacted via a 
letter to remind them of the study and to outline a plan to review them again. 
Letters were followed by a telephone call to schedule a follow-up visit. These 
interviews were to be performed 12 months (+/- 2 weeks) after their initial visit, 
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where possible in the same location, at the same time of day and in the presence 
of the same informant who was in attendance for the initial interview. To minimise 
sampling bias contact details were stored on a separate spreadsheet to diagnosis 
and previous suspicion of epilepsy and the telephone contact protocol (a three-
strike system) was employed for all participants). 
Assessments consisted of a brief interview to identify whether any further 
episodes suggestive of epilepsy had occurred, or if none had been identified at 
the time of the first interview, whether this had changed; as well as brief 
questioning to update information on medical history (any changes to medication, 
recent illnesses / surgery etc.) over the intervening 12-months. Subsequently, 
cognitive testing was repeated using the Addenbrooke’s Cognitive Examination - 
Version III (ACE-III). At the same time, the informant was asked to complete the 
same two questionnaires (CDR and CBI-R) in order to compare these with those 
previously completed. 
Between-group analysis of demographic features, cognitive test performance and 
informant completed questionnaire scores was performed using independent 
sample t-tests and chi-square testing. Multiple linear regression analysis was 
performed to assess the relationship between dependent and independent 
variables.  Statistical significance was judged as any p-value <0.05. IBM SPSS 
statistics 22.0 and STATA were used to perform data analysis. 
Ethical approval for this project was awarded through the Integrated Research 
Application System (IRAS) and provided by the London – Bromley Research 
Ethics Committee. 
4.3 RESULTS 
 4.3.1 PATIENT DEMOGRAPHIC FEATURES 
144 patients were assessed and included in the initial study. Between the initial 
visit and the 11-month mail-out 8 patients had died (Figure 4.1). From this 
remaining sample of 136, the research team was unable to contact 22 patients 
and 12 patients declined further assessment. This resulted in a total of 102 





























Figure 4.1: flow-diagram showing size of PrESIDe cohort 
 
The demographic features of the group (n=102) are summarised in Table 4.1 
alongside the features of the total group seen at initial assessment (n=144) for 
comparison. The participants seen for follow-up assessment did not differ 
significantly from the total group seen at baseline in terms of age, gender or ACE-






 (Table 4.1: comparing baseline characteristics of total PrESIDe group with 
group seen for 12-month follow-up) 
 
  
 4.3.2 COGNITIVE TEST SCORES 
The differences between the no clinical evidence of epilepsy (NCEE) and the 
epilepsy groups (probable and possible, both combined and individually) were 
not significant at either the memory clinic or study baseline time points (Table 
4.2). However, at the 12-month follow-up appointment the NCEE group had a 
significantly higher ACE-III test score than the epilepsy possible (E-Po) group 
(p=0.023) and the combined epilepsy (comb) group (p=0.007). There was a trend 
towards a similar difference between the NCEE group and the epilepsy probable 










Age at baseline (mean, SD) 77.98, 6.75 77.79, 6.97 P=0.83 
Gender (M:F) 76:68 56:46 P=0.743 
ACE-III (at memory clinic) 76.25, 11.2 78.7, 10.2 P=0.081 
ACE-III (at baseline visit) 74.17, 11.94 76.5, 11.1 P=0.122 
Dementia Diagnosis: 
 
   
Alzheimer’s Disease 102 (70.8%) 71 (69.6%) P=0.84 
Mild Cognitive Impairment 20 (13.9%) 16 (15.7%) P=0.695 
Vascular Dementia 16 (11.1%) 11 (10.8%) P=0.94 
Dementia with Lewy Bodies 4 (2.8%) 2 (2%) P=0.691 
Frontotemporal Dementia 1 (0.7%) 1 (1%) P=0.798 
Posterior Cortical Atrophy 1 (0.7%) 1 (1%) P=0.798 
Seizure Diagnosis: 
 
   
Probable (E-Pr)  18 (12.5%) 17 (16.7%) P=0.354 
Possible (E-Po) 19 (13.2%) 16 (15.7%) P=0.581 
No clinical Evidence of 
Epilepsy (NCEE) 









change baseline to 
12/12 
Total (n=102) 78.71 (10.12) 76.5 (11.14) 72.45 (13.62) -4.05 (5.60) 
NCEE (n=69) 79.84 (10.07) 77.36 (11.46) 74.93 (12.94) -2.43 (4.3) 
E-Po (n=16) 76.6 (8.45) 73.88 (11.09) 66.31 (15.53) -7.56 (7.27) 
E-Pr (n=17) 76.29 (11.43) 75.47 (9.93) 68.18 (12.20) -7.29 (5.92) 
Comb (n=33) 76.44 (9.98) 74.70 (10.37) 67.27 (13.72) -7.42 (6.5) 
Table 4.2: ACE-III test scores at different time points, with subjects categorised 
by suspicion of epilepsy, figures in bold indicate significant difference (p<0.05) 
when compared to NCEE group)  
 
The decline in ACE-III scores between the baseline and 12-month follow-up 
assessment was significantly larger when comparing both the E-Po (p<0.001), E-
Pr (p<0.001) and Comb (p<0.001) groups to the NCEE group (Figure 4.2). There 
was no significant difference between the E-Po and E-Pr groups at any time point 
in this measure. Whilst all groups showed a decline in ACE-III scores between 
baseline and 12-month assessments this difference was only significant in the 






















With the exception of the language domain in the NCEE group, all groups 
demonstrated a decrease in score in all domains at 12-month follow-up when 
compared to their baseline assessment (Table 4.3). Patients in whom epilepsy 
was suspected (probable, possible and combined groups) experienced a greater 
decrease in test scores in all cognitive domains tested by the ACE-III. The size 
of this difference was greatest in the attention and fluency domains.   
 
 
  Att Att (2) +/- Mem 
Mem 
(2) 
+/- Flu Flu (2) +/- 
Total 82.3 76.6 -5.7 65.4 59.4 -6 56.7 50.6 -6.1 
NCEE 82.9 79.9 -3 65.1 60.5 -4.6 58.6 54.6 -4 
E-Po 78.8 69.8 -9 66.3 55.8 -10.6 48.2 41.1 -7.1 
E-Pr 83.3 69.9 -13.4 65.6 58.4 -7.2 57.1 43.7 -13.4 
Comb 81.1 69.9 -11.3 66.0 57.1 -8.9 52.8 42.4 -10.4 
  Lang 
Lang 
(2) 
+/- Vis Vis (2) +/- 
   
Total 87.6 86.8 -0.8 86.7 84.1 -2.6    
NCEE 89.0 89.4 0.4 87.9 86.2 -1.6    
E-Po 85.1 81.3 -3.8 84.8 77.3 -7.4    
E-Pr 84.6 81.4 -3.2 83.8 82.0 -1.8    
Comb 84.8 81.4 -3.5 84.3 79.7 -4.5    
Table 4.3: ACE-III domain scores at PrESIDe baseline and 12-month follow-up 
(bold figures indicate significant difference (p<0.05) when compared to NCEE 
group) 
 
At the 12-month follow-up interview significant differences between the NCEE 
and Comb groups were present in the attention domain (p=0.010), fluency 
domain (p=0.007) and language domains (p=0.004) (Figure 4.3). The largest 
mean decline in raw score in the memory domain was seen in the E-Po patients 
(-10.6 points). However, there was no significant difference between groups in 




Figure 4.3. ACE-III total score and sub-domain scores (NCEE vs COMB) 
  
  
4.3.3 INFORMANT COMPLETED QUESTIONNAIRES 
All groups demonstrated an increase in CDR-SOB scores between baseline and 
12-month interviews (Table 4.4). The increase in CDR was greatest in the NCEE 
group, although there was no significant differences between groups in this 
measure. Whilst the size of the increase in the CDR-SOB score was greatest in 
the NCEE group, the overall score was higher at both the baseline and 12-month 
follow-up interviews in the E-Pr, E-Po and Comb groups. This difference was 
significant between the NCEE and the E-Pr and Comb groups at both the 
baseline (p<0.001 (E-Pr), p=0.004 (Comb)) and 12-month interview (p=0.007 (E-


















































Total  4.01 (2.79) 4.99 (3.55) +0.98 39.91 (25.01) 50.94 (31.29) +11.03 
NCEE 3.37 (2.4) 4.38 (3.29) +1.01 34.05 (21.61) 42.66 (28.13) +8.61 
E-Po 4.38 (2.79) 5.35 (4.05) +0.97 54.92 (24.42) 69.92 (33.32) +15 
E-Pr 6.13 (3.21) 6.97 (3.55) +0.84 51.33 (30.43) 66.06 (30.07) +14.73 
Comb 5.34 (3.1) 6.24 (3.8) +0.9 52.93 (27.47) 67.79 (31.05) +14.86 
 
Table 4.4: Changes in CDR and CBI-R scores between baseline interview and 
12-month follow-up bold figures indicate significant difference (p<0.05) when 
compared to NCEE group 
 
 
 Mem1 Mem2 Change Skill1 Skill2 Change Care1 Care2 Change 
NCEE 12.87 15.69 +2.82 4.13 5.69 +1.56 0.60 1.32 +0.72 
E-Po 14.70 19.69 +4.99 8.17 9.38 +1.21 2.58 3.15 +0.57 
E-Pr 17.13 20.94 +3.81 7.20 8.13 +0.93 2.07 2.75 +0.68 
Comb 16.04 20.38 +4.34 7.63 8.69 +1.06 2.30 2.93 +0.63 
 Behav1 Behav2 Change Mood1 Mood2 Change Belief1 Belief2 Change 
NCEE 2.17 3.08 +0.91 2.40 2.86 +0.46 0.20 0.61 +0.41 
E-Po 6.00 5.54 -0.46 4.75 4.08 -0.67 0.92 2.38 +1.46 
E-Pr 3.67 4.94 +1.27 4.13 4.13 0.00 0.47 0.94 +0.47 
Comb 4.70 5.21 +0.51 4.41 4.10 -0.31 0.67 1.59 +0.92 
  
Eating1 Eating2 Change Sleep1 Sleep2 Change Motor1 Motor2 Change 
NCEE 1.65 1.90 +0.25 2.38 2.54 +0.16 3.10 3.34 +0.24 
E-Po 1.67 3.46 +1.79 3.50 5.15 +1.65 4.67 6.00 +1.33 
E-Pr 3.07 5.00 +1.93 3.53 4.50 +0.97 4.27 5.19 +0.92 
Comb 2.44 4.31 +1.87 3.52 4.79 +1.27 4.44 5.55 +1.11 
  
Motiv1 Motiv2 Change 
      
NCEE 4.55 5.61 +1.06       
E-Po 8.00 8.85 +0.85       
E-Pr 5.80 9.56 +3.76       
Comb 6.78 9.17 +2.39       
 
Table 4.5: mean changes in CBI-R domain scores between baseline and follow-
up assessments, bold figures indicate significant difference (p<0.05) when 





All groups saw a significant increase between interviews in their CBI-R scores 
(Table 4.5). The largest increase was seen in the E-Po group. The increase in 
this group, as well as that of the E-Pr group was significant when compared to 
the NCEE group. On a domain-specific level the size of the mean increase in the 
epilepsy groups was greater than the NCEE group in the memory, belief, eating, 
sleep, motor domains and in addition in the E-Pr (but not E-Po) group in the 
motivation, and behaviour domains. Moreover, whilst the size of the change was 
greater in the NCEE group in the skill, care and mood domains - the overall scores 
at both the baseline and 12-month interviews remained greater in these domains 
in the E-Po (p=0.003), E-Pr (p=0.005) and combined groups (p<0.001).  
 4.3.4 FURTHER SEIZURES 
8 patients reported having further witnessed seizure events between their initial 
study visit and their 12-month follow-up visit. In 3 cases this occurred in patients 
who had previously been classified as E-Po leading to their reclassification as E-
Pr. For the purpose of their analysis in this chapter they have been included in 
their original group. The descriptions of these events are in keeping with those 
described in the previous chapter.  No further generalised onset tonic-clonic 
seizures were reported. Most commonly seizures were focal non-motor onset 
events involving behavioural arrest, cognitive or sensory features. 3/8 patients 
who experienced further seizures were described as having motor automatisms 
at onset. 
4.3.5 DECLINE IN PATIENTS ON ANTI-EPILEPTIC VS NOT ON ANTI-
EPILEPTIC MEDICATION 
6 patients had been taking an anti-epileptic medication between the time of their 
baseline and 12-month assessments. In these patients there was a smaller mean 
decline in ACE-III scores (-5.17) than in those not taking anti-epileptic medication 
(-7.93), which was not significant (p=0.356).  
 4.3.6 OTHER MARKERS OF COGNITIVE DECLINE 
Of the 144 patients seen as part of the initial assessment, 6 had moved from their 
own home to a care setting (nursing home, residential home) by the time of the 
12-month follow-up assessments. This included 4 (3.7%) in the NCEE group, and 
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2 in the epilepsy groups (1 E-Po (5.3%), 1 E-Pr (5.6%)). Over the same period 8 
participant deaths occurred (6 in NCEE (5.6%), 2 in epilepsy group (5.4%)). 
These measures did not differ significantly between groups. 
 4.3.7 CHANGES IN DIAGNOSTIC CLASSIFICATION 
There were no instances where a dementia diagnosis made at the time of initial 
assessment was changed at follow-up assessment. 4/16 (25%) patients 
diagnosed with MCI at initial assessment described a decline in function at their 
12-month follow-up assessment which was significant enough to lead to a study 
diagnosis of dementia (AD in all cases) as outlined by validated diagnostic criteria 
(McKhann et al., 2011). 
4.3.8 DIAGNOSTIC SPECIFIC CHANGES IN COGNITIVE TEST 
SCORES 
A decline in cognitive scores was seen in all diagnostic groups. This change was 
greatest in the AD group (mean change -4.26, SD 5.81) and least in the MCI 
group (mean change -2.56, SD 4.5). Further analysis of the AD specific group is 
described below. 
 4.3.9 RESULTS IN PATIENTS WITH AD 
72 (70.6%) patients seen at 12-months were diagnosed with Alzheimer’s disease. 
The relative size of this group facilitated an independent subgroup analysis of the 
effects of seizures in patients with AD. Comparisons of the ACE-III, CDR and 
CBI-R scores in these patients are shown in tables 4.6-4.9 and figure 4.4. 
 







Total (n=72) 76.79 (9.25) 73.82 (9.92) 69.56 (12.79) 4.26 (5.81) 
NCEE (n=45) 77.6 (9.7) 74.02 (9.83) 72.11 (11.51) 1.91 (3.69) 
E-Po (n=14) 75 (7.86) 71.79 (10.12) 63.71 (14.82) 8.07 (7.62) 
E-Pr (n=13) 75.77 (9.31) 75.31 (10.44) 67 (13.14) 8.31 (5.62) 
Comb (n=27) 75.38 (8.45) 73.48 (9.31) 65.3 (13.87) 8.19 (6.6) 
Table 4.6: ACE-III test scores in participants with AD at different time points, 
with subjects categorised by suspicion of epilepsy, figures in bold indicate 




At the 12-month follow-up interview the ACE-III score in the combined E-Po and 
E-Pr group was significantly lower than in the NCEE group (p=0.028). The ACE-
III score in the E-Po group was also significantly lower than the NCEE group at 
the 12-month follow-up (p=0.030), whereas the E-Pr group was not significantly 
different to the NCEE group (p=0.177). The E-Po, E-Pr and comb groups showed 
a decline in all domains of the ACE-III test, with the largest declines seen in the 
attention, and fluency domains. The decline in all domains in this group was larger 
than those of the NCEE group. This supports the view that patients with 
Alzheimer’s disease who experience epileptic seizures demonstrate a larger, 
multi-domain, decline in cognitive function than those without seizures. This is in 
contrast to the NCEE group, in whom the largest decline was seen in the memory 
domain, with relative stability in the language and visuospatial domains, and 
smaller declines in the fluency and attention domains. 
 
 
  Att Att (2) +/-  Mem 
Mem 
(2) 
 +/- Flu Flu (2) +/-  
Total 79.6 72.8 -6.8 60.5 54.4 -6 53.1 47.6 -5.5 
NCEE 79.7 75.9 -3.8 58.9 54.5 -4.5 53.7 52 -1.8 
E-Po 76.6 67.1 -9.5 63.5 53.3 -10.2 44.4 36.7 -7.7 
E-Pr 82.5 68.4 -14.1 62.4 55.6 -6.8 60.4 44.5 -15.9 
Comb 79.4 67.7 -11.7 63 54.4 -8.5 52.1 40.5 -11.6 
  Lang 
Lang 
(2) 
+/-  Vis Vis (2) +/-  
   
Total 86.7 85.2 -1.5 85.6 83.4 -2.2    
NCEE 87.6 87.9 0.3 86.8 87.2 0.4    
E-Po 84.3 79.7 -4.7 83.5 74.6 -8.9    
E-Pr 86.1 81.7 -4.4 83.7 79.8 -3.8    
Comb 85.2 80.6 -4.6 83.6 77.1 -6.5    
 
Table 4.7: ACE-III domain scores in AD participants at PrESIDe baseline and 
12-month follow-up, figures in bold indicate significant difference (p<0.05) when 




















Total  4.2 (2.69) 5.2 (3.53) +1 38.77 (22.68) 49.16 (25.26) +10.39 
NCEE 3.62 (2.46) 4.55 (3.26) +0.93 32.69 (20.47) 40.03 (23.78) +7.34 
E-Po 4.67 (2.71) 5.67 (4.05) +1 55 (25.61) 72 (28.0) +17 
E-Pr 5.58 (2.98) 6.79 (3.52) +1.21 43.67 (19.74) 57.92 (23.52) +14.25 
Comb 5.13 (2.83) 6.23 (3.76) +1.1 49.09 (22.95) 64.65 (26.17) +15.56 
Table 4.8: Changes in CDR and CBI-R scores in AD participants between 
baseline interview and 12-month follow-up figures in bold indicate significant 
difference (p<0.05) when compared to NCEE group) 
 
 
Informant completed questionnaires highlighted significant differences between 
the epilepsy and non-epilepsy groups at both time points. However, when the 
analysis was limited to patients with AD, there was no significant difference 
between the NCEE and E-Pr groups on the CBI-R at baseline (p=0.092). The 
CBI-R scores were significantly greater for the E-Po, E-Pr and combined groups 




























NCEE1 COMB1 NCEE2 COMB2
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been the case for the total PrESIDe cohort the CDR-SOB was significantly 
greater in the E-Pr (p= 0.019) and combined groups (p=0.020) at the time of their 
baseline assessments and also at the time of the follow-up assessments 
(p=0.036 (E-Pr), p=0.05 (comb). On this measure there was no significant 
difference between the NCEE and the E-Po group at either time point (p= 0.179 
(baseline), p= 0.294 (12-month)).  
 
  Mem1 Mem2 Change Skill1 Skill2 Change Care1 Care2 Change 
NCEE 13.3 15.6 +2.3 3.8 5.3 +1.5 0.2 0.8 +0.6 
E-Po 14.9 21 +6.1 8.1 10.2 +2.1 2.8 3.5 +0.7 
E-Pr 16.3 19.7 +3.4 6.4 7.1 +0.8 1.5 2.3 +0.8 
Comb 15.6 20.3 +4.7 7.2 8.6 +1.4 2.1 2.9 +0.8 
  Behav1 Behav2 Change Mood1 Mood2 Change Belief1 Belief2 Change 
NCEE 1.8 2.8 +1 2.3 2.6 +0.3 0.1 0.5 +0.4 
E-Po 5.6 5.6 0 4.9 3.9 -1 0.9 2.7 +1.8 
E-Pr 2.5 3.6 +1.1 3.8 3.7 -0.1 0.6 1 +0.4 
Comb 4 4.6 +0.6 4.3 3.8 -0.5 0.7 1.8 +1.1 
  Eating1 Eating2 Change Sleep1 Sleep2 Change Motor1 Motor2 Change 
NCEE 1.5 1.6 +0.1 2.3 2.5 +0.2 3.4 3 -0.4 
E-Po 1.7 3.8 +2.1 3.5 5.4 +1.9 4.4 6 +1.6 
E-Pr 1.9 4.2 +2.3 3 4.1 +1.1 3.5 4.3 +0.8 
Comb 1.8 4 +2.2 3.3 4.7 +1.4 3.9 5.1 +1.2 
  Motiv1 Motiv2 Change 
      
NCEE 3.9 5.2 +1.3       
E-Po 8.1 9.8 +1.7       
E-Pr 4.3 8.2 +3.9       
Comb 6.1 9 +2.9       
Table 4.9: mean changes in CBI-R domain scores in AD participants between 
baseline and follow-up assessments (higher scores indicate greater impairment, 
figures in bold indicate significant difference (p<0.05) when compared to NCEE 
group) 
 
On the CDR, the greatest differences between the combined E-Pr and E-Po 
group and the NCEE group were in the judgement and problem solving domain 
(0.56 points) and the personal care domain (0.47 points). The smallest 
differences were in the memory (0.1 points) and the orientation (0.11 points) 
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sections. In contrast, for the CBI-R the most instructive questions (difference 
>1.0) were found to be Memory 5 (Forgets the names of objects and things), 
Memory 8 (Becomes confused or muddled in unusual surroundings), and Sleep 
2 (Sleeps more by day than before). Sleep 2 demonstrated the largest difference 
between these groups using the CBI-R (1.6 points). 
 4.3.10 DECLINE RELATED TO USE OF DEMENTIA MEDICATION 
25/72 patients diagnosed with AD in our cohort (34.7%), were taking a medication 
prescribed for the treatment of their dementia between their baseline and 12-
month assessments (18 Donepezil, 5 Rivastigmine, 2 Memantine). Whilst both 
groups saw a decrease in their ACE-III scores, this decrease was greater in the 
patients taking medication than in those that were not (-5.36 (SD 6.74) vs. -3.68 
(SD 5.24)). However, this difference was not significant (p=0.246).   
4.4 DISCUSSION (WHOLE COHORT) 
Patients with dementia who experience epileptic seizures exhibit an accelerated 
decline in cognitive function when compared to patients with dementia in whom 
there is no clinical suspicion of epilepsy. This is demonstrated by a fall in the 
mean ACE-III score from 77.36 to 74.93 (2.43 points) in the NCEE group and 
from 74.7 to 67.27 (7.42 points) in the combined epilepsy groups. Whilst the 
NCEE group had a higher ACE-III score at the time of their initial memory clinic 
appointment and their baseline PrESIDe assessment, the difference in scores 
between this group and the combined epilepsy group only became significant at 
the time of the 12-month follow-up assessments. This difference was even 
greater when the study population was restricted only to patients with Alzheimer’s 
disease. In this analysis the decline in ACE-III scores was 1.91 in the NCEE group 
and 8.19 in the combined group (p <0.001).  
Through a domain specific analysis of the ACE-III scores I have shown that a 
decrease in performance occurs in all domains. The largest decreases in the 
epilepsy groups were seen in the attention, fluency and memory components of 
the test. The difference in the decline between the epilepsy and non-epilepsy 
groups was greatest in the attention and fluency elements of the test. Whilst all 
patients with dementia exhibit a decrease in cognitive function over time, those 
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with epilepsy decline in a manner which is both greater and involves more 
domains, leading to the significant difference across the ACE-III total score.  
The main question raised by these results is whether epilepsy is a marker for a 
more severe form of disease in these patients, or whether epilepsy is a driver of 
these more rapid changes. The progression of clinical symptoms in AD is 
associated with the spread of the amyloid-β (Aβ) plaques and phosphorylated tau 
(p-tau) neurofibrillary tangles into different regions of the brain (Braak and Braak, 
1995, Braak and Del Tredici, 2015). In AD patients who experience epileptic 
seizures a more rapid decline occurs across all domains. The reasons for this are 
not clear, although several studies have investigated the association between 
neuronal hyperexcitability and the spread of tau (Lewis and Dickson, 2016, 
Passamonti et al., 2018, Kaufman et al., 2018), suggesting that seizures can 
contribute to the spread of tau through both trans-neuronal (Su et al., 1997, Cope 
et al., 2018, Kim et al., 2018) and trans-synaptic (Liu et al., 2012, Dujardin et al., 
2014, Wang et al., 2017) means. Additionally, studies utilizing tau-PET have 
shown a direct correlation between the distribution of tau and cognitive 
impairment in patients with dementia (Ossenkoppele et al., 2016, Hanseeuw et 
al., 2019). It is possible that in patients with epileptic seizures the more rapid 
decline in cognitive function is related to an accelerated propagation of tau as a 
result of their epileptic seizures (Pooler et al., 2013, Tai et al., 2016). Conversely, 
it is also possible that some patients with AD experience a more aggressive form 
of this disease and that this phenotypic heterogeneity also gives rise to epileptic 
seizures in these patients.    
 4.4.1 FASTEST AND SLOWEST DECLINE 
Of the 10 patients with the largest fall in ACE-III scores between baseline study 
visit and 12-month follow-up (fall of at least 11 points), 7 of these were 
categorised as having possible or probable epilepsy (2 E-Po, 5 E-Pr). Of these 7 
patients, only 1 was taking anti-epileptic medication (Levetiracetam). However, 
not all 10 of these fastest decliners showed evidence of epilepsy; other factors 
may also contribute to the rate of cognitive decline in these patients. These 
factors have previously been investigated and include age (at onset of memory 
symptoms and overall chronological age), duration of memory symptoms, family 
history of dementia and medical comorbidities (Bowler et al., 1998, Suh et al., 
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2004, Musicco et al., 2009, Roselli et al., 2009). Conversely, of the 10 patients 
with the smallest decline in ACE-III scores, 2 of these were in the epilepsy groups 
(1 E-Po, 1 E-Pr). Of the 2 patients with a suspicion of epilepsy in this group, 1 of 
them was on anti-epileptic medication (Sodium Valproate and Lamotrigine). 
 4.4.2 ANTIEPILEPTIC MEDICATION 
I did not identify a significant difference in cognitive decline between patients 
treated with antiepileptic medications and those that were not.  It is possible that 
the lack of a significant difference is a result of the small size of these groups, or 
the limited duration of follow-up obtained. Other studies looking at the role of anti-
epileptic medication in patients with dementia and animal models of dementia 
have reported conflicting outcomes (Belcastro et al., 2007, Cumbo and Ligori, 
2010, Sanchez et al., 2012, Nygaard et al., 2015). These may be explained by 
differences in patient selection, duration of therapy or drug dosage. Improving our 
understanding of the timing and semiology of seizures in patients with dementia 
may lead to the better identification of patients who would be most likely to benefit 
from the initiation of anti-epileptic medication. 
Informal discussion with the clinicians referring into our study indicated hesitation 
about the use of anti-epileptic medications in patients with MCI and dementia, a 
view supported by the small number of patients who received treatment for their 
epilepsy in our cohort. This partly reflected concern about the possible cognitive 
side effects of these medications (Ortinski and Meador, 2004, Cumbo and Ligori, 
2010, Eddy et al., 2011). It is therefore reassuring to know that the use of anti-
epileptic medications was not associated with faster cognitive decline in our 
cohort. However, our study was not designed to interrogate the cognitive effects 
of anti-epileptic medication in these patients and further work is required to 
investigate the potential risk and benefits of the wider use of these medications 
in patients with dementia. Multiple trials are currently underway on this topic 
(Vossel, 2019). 
 4.4.3 ACETYLCHOLINESTERASE INHIBITORS 
No significant difference was identified in the cognitive decline in patients with AD 
taking acetylcholinesterase inhibitors, or other medications licensed for the 
treatment of AD, versus those that were not. In our cohort there was a difference 
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between the ACE-III scores at baseline between these two groups that may 
explain this difference (70.75 in treated group vs 75.35 in untreated group), 
although this difference was not significant (p=0.063). There is however extensive 
evidence of the beneficial role of acetylcholinesterase inhibitors in Alzheimer’s 
disease (Howard et al., 2012, Lee et al., 2015). Our study was not designed to 
investigate the role of these medications and no effort was made to match those 
on these medications with those that were not at the time of their baseline 
assessment. 
 4.4.4 MCI CONVERSION 
In our study, 25% of patients initially diagnosed with MCI at their initial 
assessment subsequently had this diagnosis changed to AD at the time of their 
follow-up assessment. This figure is higher than MCI conversion rates reported 
elsewhere in the literature (Busse et al., 2006, Albert et al., 2011, Petersen et al., 
2014). However, the number of patients in our study with MCI is small. Almost 
90% patients who are given a diagnosis of MCI will be diagnosed with dementia 
in the following 10 years. It is possible that the MCI patients recruited in our study 
disproportionately represented early MCI converters. Moreover, the average age 
of MCI patients in our cohort was 74.3 years. This is older than the average age 
for MCI diagnosis in the literature (Elias-Sonnenschein et al., 2011) and age has 
been shown to predict conversion from MCI to dementia in several studies 
(Vemuri et al., 2009, Oulhaj et al., 2009, Elias-Sonnenschein et al., 2011).   
 4.4.5 INFORMANT QUESTIONNAIRES 
The epilepsy probable group scored significantly higher on both informant 
completed measures at the time of their initial study assessment. This difference 
persisted at the 12-month time-point, and, although the NCEE group showed a 
larger increase in the CDR-SOB measure, this was not significant. This suggests 
that the epilepsy patients attained a milestone in their decline at an early stage 
than the NCEE patients - best shown demonstrated by the 12-month NCEE CDR-
SOB score being the same as the epilepsy possible CDR-SOB score at baseline 
(4.38). Whilst the difference in CDR-SOB at baseline between NCEE and the 
combined epilepsy groups was 1.97, at follow-up assessment this had decreased 
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to 1.86. This change was largely driven by a greater decline in the NCEE group 
(-1.01 points) than in either epilepsy group (E-Po -0.97, E-Pr -0.84).  
 4.4.6 E-Pr vs E-Po 
At all three time points in our study (memory clinic appointment, PrESIDe 
baseline assessment, 12-month follow-up) the two groups in whom epilepsy was 
suspected were very similar. No significant differences were identified between 
them in terms of their ACE-III, CBI-R or CDR scores at either baseline or 12-
month assessments. This is not wholly surprising as the only clinical difference 
between them was whether or not they had had repeated witnessed episodes or 
not.  
 4.4.7 ALZHEIMER’S DISEASE SUB-GROUP DISCUSSION 
The results in the AD only cohort echo the findings of the PrESIDe cohort as a 
whole. This is not surprising as approximately 70% of the PrESIDe group seen at 
baseline and at 12-months was made up of patients with AD. 
Patients with AD who experience epileptic seizures exhibit an accelerated decline 
in cognitive function when compared to patients with AD in whom there is no 
clinical suspicion of epilepsy. This is demonstrated by a fall in the mean ACE-III 
score from 74.02 to 72.11 (1.91 points) in the NCEE group and from 73.48 to 
65.30 (8.19 points) in the combined epilepsy groups. Whilst the NCEE group had 
a higher ACE-III score at the time of their initial memory clinic appointment and 
their baseline PrESIDe assessment, the difference in scores between this group 
and the combined epilepsy group only became significant at the time of the 12-
month follow-up assessments. 
The E-Pr group scored significantly higher on the CDR-SOB at the time of their 
initial study assessment. This difference persisted and even increased at the 12-
month time-point. Whilst the difference in CDR-SOB at baseline between NCEE 
and the combined epilepsy groups was 1.51, at follow-up assessment this had 
increased to 1.68. Likewise, the CBI-R revealed roughly twice the decline in the 
Comb group by comparison with the NCEE group (7.34 points vs 15.56 points) 
These findings again suggest a more rapid accrual of deficits in these patients, 
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identified by those nearest to them, and likely to increase their care requirements, 
and need for additional support.  
4.5 CONCLUSION 
The risk of epilepsy is increased in patients with dementia, of all types, and in this 
population epileptic seizures are associated with an accelerated rate of cognitive 
decline. This cognitive decline occurs across all cognitive domains measured by 
the ACE-III examination. The difference in the size of the decline was greatest in 
the attention and fluency domains of this test, suggesting that executive function 
is especially affected in this population. The difference between epilepsy and non-
epilepsy groups is even more apparent when restricting the analysis only to 
patients with a diagnosis of AD, suggesting that the presence of epileptic seizures 
is a particularly sensitive predictor of rapid cognitive decline in these patients. 
Conventional understanding regarding epileptic seizures in patients with 
dementia suggests that epilepsy occurs as a late-stage feature of dementia, and 
consequently treating seizures is unlikely to impact on the progression of disease 
or to result in any meaningful functional improvement for these patients. However, 
the findings of our study, in keeping with other recent reports (Vossel et al., 2013, 
Sarkis et al., 2016), suggest that epileptic seizures occur in patients at early 
stages of dementia and these are associated with accelerated cognitive decline. 
This finding should encourage clinicians to identify patients who may have 
experienced epileptic seizures following the onset of their memory impairment 
and to consider anti-epileptic medication in these patients, where not 
contraindicated.  
The true incidence of epilepsy among patients with dementia may be even higher 
than I have reported. Several studies looking at the semiology of seizures in 
dementia, and AD in particular have recognised that seizures in this population 
are more likely to be focal in onset, often non-motor and rarely generalised tonic-
clonic (Bernardi et al., 2010, Vossel et al., 2013, Aller-Alvarez et al., 2017). Such 
subtle seizures are easily missed. Several recent studies have looked at the 
prevalence of subclinical epileptiform activity in these patients (Vossel et al., 
2016, Horvath et al., 2017, Horvath et al., 2018). In these studies prolonged EEG 
recording, or the use of more in-depth methods of analysis, such as 
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magnetencephalography have been shown to identify abnormalities even in the 
absence of a clinical history of seizures. 
Randomised controlled double-blind studies of the effects of anti-epileptic 
medications in appropriately selected patients with dementia and epilepsy are 
required in order to evaluate whether their use can lead to a better prognosis for 















Sections of this chapter have been submitted for publication as: Baker, J., Libretto, T., Henley, 
W. & Zeman, A. A Longitudinal Study of Epileptic Seizures in Alzheimer’s Disease. This paper 
was written by me and reviewed prior to publication by TL, WH and AZ. The study design, data 
collection and analysis were all performed by me. TL provided contact details for control 
participants. WH provided support for statistical analysis 
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CHAPTER FIVE: THE SYNDROME OF TRANSIENT EPILEPTIC AMNESIA: A 
COMBINED COHORT OF 115 PATIENTS AND LITERATURE REVIEW 
5.1 INTRODUCTION  
The term Transient Epileptic Amnesia (TEA) was coined in 1993 to highlight the 
existence of a distinctive form of epilepsy causing transient amnesic attacks 
(Kapur, 1993). Their superficial resemblance to the attacks occurring in Transient 
Global Amnesia (TGA) warranted a related but contrasting term. Hughlings-
Jackson (1888) was probably the first author to raise the possibility that transient 
amnesia could be the sole or most prominent manifestation of an epileptic 
seizure, in his description of his physician-patient, Dr Z (Hughlings-Jackson, 
1888). The suggestion was supported by case reports over the following century, 
preceding the definition of TEA (Zeman et al., 1998). Since then, further reports 
have defined an epilepsy syndrome characterised by recurrent brief attacks of 
transient amnesia, often occurring on waking, with a probable male 
predominance and onset typically in middle age (Zeman et al., 1998, Butler et al., 
2007, Mosbah et al., 2014).  
The syndrome is of particular neuropsychological interest as the amnestic 
seizures are frequently accompanied by a distinctive group of persistent interictal 
memory complaints: accelerated long-term forgetting (ALF), autobiographical 
amnesia (AbA) and topographical amnesia (TopA) (Butler and Zeman, 2008b, 
Zeman et al., 2013, Mosbah et al., 2014). ALF is the excessively rapid loss of 
access, over extended intervals, to information that appears to have been 
acquired and stored normally over standard testing intervals of around half an 
hour. AbA refers to the loss of memories for all or part of one’s past life: this often 
comes to light when reviewing family photographs or reminiscing with friends and 
relations, and particularly affects the rich, ‘experiential’ or ‘autonoetic’ recall of 
salient personal events. TopA involves difficulty in recollecting the layout of 
previously familiar environments, often when driving, and/or a failure to recognise 
previously familiar landmarks and locations. While these measurable memory 
problems have been described in other types of epilepsy, and in other clinical 
contexts, they occur particularly commonly in TEA, probably reflecting the central 
involvement of the memory system in this condition.  
96 
 
However, TEA remains a controversial disorder. Through our project website 
(The Impairment of Memory in Epilepsy (TIME Project) 
http://projects.exeter.ac.uk/time/ we receive contacts from patients around the 
world who have self-diagnosed, often following initial misdiagnosis, or have found 
it difficult to locate a clinician familiar with the disorder . Initial misdiagnoses, in 
patients later shown to have TEA, have included TGA, psychogenic amnesia, 
transient ischaemic attacks, incipient dementia, and sleep inertia. The TEA-
associated interictal memory deficits are also under-recognised: clinicians 
continue to reassure concerned patients that their memory is normal in the 
absence of tests of long-term retention of remote memory which can reveal 
otherwise undetectable but relevant memory impairments (Zeman et al., 2018). 
In this chapter I consolidate the scientific description of TEA by summarising my 
experience with the condition in a combined cohort of 115 patients, 65 recently 
studied (‘TIME 2 cases’) and 50 patients reported in a previous series (‘TIME 1 
cases’) (Butler et al., 2007). I review relevant publications postdating an earlier 
review of the topic, discuss key uncertainties about TEA in the context of a novel 
disease model and point to important questions for future research. 
5.2 MATERIALS AND METHODS 
 5.2.1 PARTICIPANTS 
 5.2.1.1 PATIENTS 
Cases of TEA were recruited to the TIME (The Impairment of Memory in Epilepsy) 
study, using Zeman and colleagues’ 1998 diagnostic criteria (Zeman et al., 1998): 
 
(1) A history of recurrent witnessed episodes of transient amnesia;  
(2) Cognitive functions other than memory are intact during typical episodes as 
observed by a reliable witness;  
(3) Other evidence for a diagnosis of epilepsy. This can be provided by any 
combination of: 
(a) Epileptiform abnormalities in EEG,   
(b) The concurrent onset of other clinical features of an epileptic seizure 
(e.g., lip-smacking and olfactory hallucinations), or  




Patients in TIME2 were either referred to the study via a consultant neurologist 
(n = 53), or self-referred (n = 12) after reviewing our project website 
(https://projects.exeter.ac.uk/time/). In this study we include only participants 
referred to our study who were available for clinical and – in most cases – 
neuropsychological assessment in the UK. 
The study was approved by the Multicentre Research Ethics Committee, United 
Kingdom (MREC 03/10/77).  All patients gave written, informed consent in 
accordance with the Declaration of Helsinki. 
 5.2.1.2 CONTROL PARTICIPANTS 
We draw on two sets of control data. For standard neuropsychological measures, 
mood measures and for the assessment of autobiographical memory, data 
previously collected from the 24 healthy controls recruited in the TIME1 series 
were used again for comparison in TIME2.  For measures of accelerated long-
term forgetting, where some adjustment in administration procedures occurred 
between TIME1 and TIME2 (see Neuropsychological Assessment below), a new 
cohort of controls was recruited.  This involved 22 age and IQ-matched healthy 
adults from the Exeter and Oxford areas. 
 5.2.2 CLINICAL INTERVIEW 
Interviews were conducted by a member of the study team. A detailed history 
was obtained from the patient and at least one witness. A standardised data-
collection pro forma (appendix 6) was used to collect information in relevant 
domains (demographics, clinical features of the amnestic attacks, interictal 
symptoms, past medical history, past psychiatric history, epilepsy risk factors, 
current medications, family history). Medical case notes and correspondence 
were reviewed. 
 5.2.3 CLINICAL INVESTIGATIONS 





 5.2.4 NEUROPSYCHOLOGICAL ASSESSMENT 
 5.2.4.1 STANDARD MEASURES 
Participants were invited to complete a comprehensive neuropsychological 
assessment.  This involved the same test battery as our original study, comprising 
measures of: general intelligence (Wechsler Abbreviated Scale of Intelligence -2 
subtest version (Weschler, 1999)), anterograde memory (immediate and 30-
minute delayed recall of a prose passage from Wechsler Memory Scale-III 
(Weschler, 1997); copy and 30-minute delayed recall of the Rey–Osterrieth 
complex figure (Osterrieth, 1944) (appendix 7); the Recognition Memory Test 
(Warrington, 1984)), language (Graded Naming Test) (McKenna and Warrington, 
1980), and executive function (letter and category fluency).   
 5.2.4.2 ACCELERATED LONG-TERM FORGETTING 
To take account of methodological recommendations made by Elliot (Elliott et al., 
2014) we modified the method used to assess accelerated forgetting in our 
previous study (2007). In this second cohort, the threshold for learning was 
lowered from 90% to 80%, with no minimum number of trials (to remove 
overlearning), and a verbal memory ‘wash-out task’ was included to reduce the 
impact of verbal working memory on performance.  
A list of 15 words (from the Rey Auditory Verbal Learning Task) (appendix 8) was 
presented orally over a maximum of 10 trials until at least 12 words (80% 
accuracy) could be recalled within a given learning trial.  Upon reaching this 
criterion, participants were instructed to count backwards out aloud from 100 for 
40 seconds, to prevent rehearsal of words and reliance upon working memory to 
aid recall.  Recall of the words was assessed immediately following this distractor 
task, and at delays of 30 minutes and at 1-week (via telephone). After this last 
free recall trial, recognition memory was tested using the standard list of 30 words 
read aloud by the examiner. Although participants were not forewarned about the 
delayed probes participants were asked not to practice or write down the words 





 5.2.4.3 REMOTE MEMORY 
Autobiographical memory was assessed using the Modified Autobiographical 
Memory Interview (MAMI) as in our previous study. This semi-structured interview 
requires participants to describe two events, relating to specific topics (e.g. 
holidays, weddings, career changes, car ownership, and hobbies) from each 
decade of their lives (from their 20s through to their current decade). For each 
event described, participants answer 5 questions designed to test their personal 
semantic memory (e.g. what type of car did you own in your twenties?) and then 
produce one detailed episodic memory (e.g. can you recall one time when you 
broke down or took it to get repaired / serviced?). Each episodic memory is 
scored out of 5, based on the scheme described by Graham and Hodges 
(Graham and Hodges, 1997) where a score of 0 indicates a failure to recall a 
relevant memory and 5 indicates successful retrieval of a specific episode in 
which event details are described. This generates a personal semantic score (out 
of 10/ decade) and an episodic score (out of 10/ decade).   
 5.2.5 MOOD 
Self-reported symptoms of depression or anxiety were measured through the 
Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983) 
(appendix 9).   
 5.2.6 STATISTICAL ANALYSIS 
Statistical analysis of data obtained through neuropsychological testing was 
performed using IBM SPSS Statistics 25.0.  Analyses of variance (ANOVA) were 
conducted to compare groups’ performances (TIME1, TIME 2 and controls).  
Planned contrasts comparing 1) TIME2 participants with controls and 2) TIME1 
participants with TIME2 participants were included. We applied a Bonferroni 
adjustment of alpha (.05/11) = .0045 to correct for the number of 
neuropsychological measures compared in each instance.  
To examine any change in prevalence of detected memory impairments across 
the two patient cohorts, a Pearson’s chi-squared test was used to compare the 
number of cases identified in each patient cohort (where cases of memory 
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impairment were defined by performance 2 or more SD below the control mean 
on more than one neuropsychological test).  
To investigate long-term anterograde memory performance, word list recall 
scores were compared between TIME2 and a new, matched control group (see 
above) via a repeated-measures analysis of variance (ANOVA), with factors of 
participant group (TIME2 or control) and delay interval (40 seconds, 30 minutes, 
and 1 week). The Huynh-Feldt correction for nonsphericity was applied, where 
needed. Given the differences in procedure, no direct comparisons were made 
between the TIME1 and TIME2 data sets. 
Participants were entered into this analysis if they had satisfied the learning 
criterion (80% recalled) and demonstrated adequate retention over 30 minutes 
(recalling 8 or more words, consistent with a performance 1.5SD below the mean 
in a normative study (Carstairs et al., 2012).   
To evaluate autobiographical memory in our second cohort, the semantic and 
episodic memory scores per decade from the MAMI were analysed using 
repeated-measures ANOVA, with between group factor of participant group 
(TIME2 or control) and the within group factor of decade (20s, 30s, 40s, 50s and 
most recent).   
Only patients with an age of TEA onset >50 years were entered into this analysis, 
in order to compare recall from early adult decades free of the potentially 
confounding effect of epilepsy onset. A separate comparison of recent memory 
(from each individual’s current decade) was also conducted. Lastly, self-reported 
symptoms of anxiety and depression were analysed using ANOVA to compare 
TIME1, TIME2 and healthy controls.   
 5.2.7 LITERATURE SEARCH 
We performed a literature search using the following keywords: “transient 
epileptic amnesia” in MEDLINE, EMBASE and PSYCINFO up to September 
2018.  Studies published prior to 2008 were excluded as these had been 
analysed in a previous review article (Butler and Zeman, 2008b). Titles and 
abstracts were reviewed and further hand-searching using reference lists was 
performed to identify further published papers.  
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5.3 RESULTS  
 5.3.1 CLINICAL FEATURES IN TIME 2 PATIENTS 
 5.3.1.1 DEMOGRAPHICS 
65 patients (51 male, 14 female) were recruited between January 2008 and April 
2016. Mean age at the onset of amnestic attacks was 61.4 years (standard 
deviation [SD] 9.95; range, 26-77 years), and at entry into the study was 65.6 
years (SD 8.67; range, 39-81 years). An illustrative case from the TIME study is 
provided in appendix 10. 
 5.3.1.2 DIAGNOSTIC CRITERIA 
Table 5.1 specifies the grounds for the diagnosis of TEA in each case, 
summarised in Figure 5.1. TEA was the initial diagnosis in only 40% of cases 
(26/65).   Other initial diagnoses were: temporal lobe epilepsy (18/65), TGA 
(10/65), “psychogenic” (5/65), transient cerebral ischemia / stroke (6/65). The 
median delay to the diagnosis of TEA was 4 years (mean, 4.17; interquartile 





















Figure 5.1: Criteria for diagnosis of TEA in TIME2 series patient
32 
Other Seizure Features 
Response to treatment 
Abnormal EEG 




Study ID Sex 
Age at Onset 
(yr) 
Total number of 
attacks 
first to last 
attacks (mo) 










191 M 66 10 21 5-15 minutes Y 3 Epil Autom, Unresp Com 
205 F 57 12 22 15-30 minutes Y 3 Epil 
Olf hall, Autom, 
Unresp Com 
220 M 60 36 36 15-30 minutes Y 3 Epil Autom, Unresp Com 
222 M 62 50 11 5-15 minutes Y 3 Epil Autom, Unresp Com 
235 M 61 50 64 1-5 minutes Y 3 Epil 
Olf hall, Autom, 
Unresp Com 
236 M 66 15 22 
30 minutes to 1 
hour Y 3 Epil Olf hall Com 
243 F 64 10 24 5-15 minutes Y 3 Epil Olf hall Partial 
260 M 44 175 26 
30 minutes to 1 
hour Y 3 Epil Olf hall, Autom Com 
282 F 58 200 4 5-15 minutes Y 3 Epil Autom, Unresp Com 
305 F 26 10  15-30 minutes Y 3 Epil Unresp Com 
336 M 44 50 8 5-15 minutes Y 3 Epil 
Olf hall, Autom, 
Unresp Com 
343 M 54 12 6 1-5 minutes Y 3 Epil 
Olf hall, Autom, 
Unresp Com 
358 M 47 50 76 
30 minutes to 1 
hour Y 3 Epil Autom Com 
360 M 67 20 84 
30 minutes to 1 
hour Y 3 Epil Autom Partial 
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361 F 55 5 4 15-30 minutes Y 3 Epil Olf hall Com 
365 M 53 40 108 1-5 minutes Y 3 Epil 
Olf hall, Autom, 
Unresp Partial 
367 M 60 37 18 15-30 minutes Y 3 Epil Olf hall, Autom Com 
368 F 66 10 12 
30 minutes to 1 
hour Y 3 Epil Olf hall, Unresp Com 
375 M 72 172 22 1-5 minutes Y 3 Epil Autom, Unresp Com 
393 M 69 20 16 1-2 hours Y 3 Epil Autom Com 
195 M 59 4 37 1-2 hours Y 2 Non-spec 
Olf hall, Autom, 
Unresp Com 
213 F 55 24 24 1-5 minutes N 2 Epil  Com 
223 M 72 12 37 1-2 hours Y 2 Normal Autom, Unresp Com 
226 M 66 6 7 15-30 minutes Y 2 Non-spec Olf hall Com 
229 F 76 4 3 1- 5 minutes N 2 Normal Olf hall, Unresp Com 
232 M 66 19 36 1 -2 hours Y 2 Normal Autom, Unresp Com 
238 M 51 16 62 
30 minutes to 1 
hour Y 2 Normal 
Olf hall, Autom, 
Unresp Com 
241 M 52 14 7 2-24 hours Y 2 Non-spec Unresp Com 
251 M 66 2 23 1-2 hours Y 2 Non-spec Unresp Com 
254 M 66 70 16 5-15 minutes Y 2 Normal Autom, Unresp Com 
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272 M 62 100 67 1-5 minutes Y 2 Non-spec Autom, Unresp Com 
277 M 63 4 14 5-15 minutes Y 2 Normal Olf hall Com 
288 M 69 6 86 1-2 hours Y 2 Normal unresp Partial 
292 M 77 30 43 15-30 minutes N 2 Non-spec Unresp Com 
317 F 76 50 23 1-2 hours N 2 Normal Olf hall, Unresp Com 
325 F 66 4 6 1-5 minutes Y 2 Non-spec Unresp Com 
346 F 56 15 44 2-24 hours Y 2 Non-spec Olf hall Com 
349 M 43 20 26 1-5 minutes Y 2 Normal Unresp Com 
351 M 65 24 120 5-15  minutes Y 2 Not done 
Olf hall, Autom, 
Unresp Com 
352 M 54 12 12 15-30 minutes Y 2 Non-spec Olf hall Com 
355 M 56 10 8 15-30 minutes Y 2 Normal Unresp Com 
356 M 67 70 70 15-30 minutes Y 2 Normal Autom, Unresp Partial 
359 M 65 20 33 5-15 minutes Y 2 Normal Olf hall, Unresp Com 
362 M 52 50 2 <1 minute Y 2 Non-spec Olf hall, Unresp Com 
371 M 71 6 1 30 minutes - 1 hour Y 2 Non-spec Olf hall Com 
373 F 70 12 56 15 -30 minutes Y 2 Epil  Com 
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374 M 66 4 6 1-2 hours Y 2 Norm Autom Com 
378 M 65 14 45 15-30 minutes Y 2 Normal 
Olf hall, Autom, 
Unresp Com 
379 M 69 8 12 
30 minutes to 1 
hour Y 2 Non-spec Olf hall, Unresp Com 
380 M 58 6 5 5 - 15 minutes Y 2 Non-spec Olf hall, Autom Com 
383 M 59 13 48 2-24 hours N 2 Normal Olf hall Com 
388 M 67   1-2 hours Y 2 Non-spec Olf hall, Autom Com 
394 M 72 9 10 15-30 minutes Y 2 Not done Autom, Unresp Com 
396 M 73 8 8 1-2 hours Y 2 Not done Olf hall, Autom Com 
193 M 71 15 11 1-2 hours Y 1 Non-spec  Com 
207 M 63 4 21 15-30 minutes Y 1 Not done Com 
217 M 72 2 1 15-30 minutes Y 1 Non-spec  Com 
218 F 42 100 84 
30 minutes to 1 
hour Y 1 Normal  Com 
257 M 57 50 53 2-24 hours Y 1 Normal  Com 
261 M 59 50 52 5-15 minutes Y 1 Normal  Partial 
322 M 66 2 93 15-30  minutes Y 1 Non-spec  Com 
340 F 39 5 6 1-2 hours Y 1 Normal  Com 
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341 M 75 5 7 30-60 mins Y 1 Normal  Com 
363 M 71 17 18 
30 minutes to 1 
hour Y 1 Normal  Com 
376 M 55 6 10 15-30 minutes Y 1 Normal  Com 
 
















5.3.1.3 SEIZURE FEATURES 
Duration, timing and frequency: Median attack duration was 15-30 minutes, with 
a wide variation (range <1minute to days) (Figure 5.2). 61/65 patients (94%) 
reported that at least some of their attacks occurred on waking from sleep. 
However, only 5 patients exclusively experienced seizures at this time. Median 
frequency of attacks per annum prior to diagnosis was 12 (interquartile range 
(IQR) 8-20). Median number of attacks experienced prior to diagnosis was 15 
(IQR 6-36).  
 
 
Figure 5.2:  Annual frequency and duration of epileptic seizures in TIME2 group 
 
5.3.1.4 SEIZURE TYPES 
Amnesia was the sole ictal manifestation in 13/65 (20%) of patients. In 33/65 
(51%) brief unresponsiveness was reported in at least some attacks. 14/65 (22%) 
reported an epigastric aura. 29/65 (45%) described olfactory hallucinations, and 
the same percentage motor automatisms, most commonly (11/65, 17%) 
repetitive chewing or swallowing movements. Tonic-clonic seizures occurred in 
only 7/65 (11%) and were typically isolated or rare events.  
Ictal amnesia: 35/65 (54%) patients were able, on some occasions at least, to 
‘remember not being able to remember’ – i.e. had partial recall of their transient 
amnestic episodes. Repetitive questioning during episodes occurred in 41/65 
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Treatment: All patients were started on anticonvulsant medication, 92% reporting 
complete cessation of attacks.  The most commonly used final medications were 
Lamotrigine (31/65; 48%) followed by Levetiracetam (14/65; 22%), 
carbamazepine and sodium valproate (10/65 or 15% each). Topiramate was 
used in 3 patients (3/65, 4.6%) and Zonisamide was used in one patient (1/65, 
1.5%). Drug changes were required in 24 patients, either due to inefficacy or side 
effects of the initial medication. Final mean daily doses were: Lamotrigine 145mg 
(50mg – 300mg), Levetiracetam 1182mg (500mg to 3000mg), Carbamazepine 
650mg (300mg – 1600mg), Sodium valproate 850mg (400mg -2400mg), 
Topiramate 100mg (50mg-150mg), Zonisamide 400mg (400mg). 
5.3.1.5 INTERICTAL FEATURES 
AbA: 57 patients (88%) reported AbA, ranging from patchy losses for the previous 
1-2 years to loss of memories up to 30 years in to the past. These forgotten 
episodes were frequently noted in conversation with friends and family and 
typically included shared experiences such as wedding, holidays and birthdays. 
ALF: 48 patients (74%) reported ALF, either without prompting or when asked if 
they had experienced memories fading more quickly that they would typically 
expect over hours to weeks. 
TopA: 47 patients (72%) reported TopA.  
Olfaction: 29 patients (45%) reported olfactory hallucinations. 16 (25%) reported 
a reduction in their sense of smell. Overall 34 patients (52%) reported olfactory 
symptoms of some kind.  
Emotionality: 26 patients (40%) reported a state of emotional lability, principally 
involving a tendency for sadness/tearfulness to be provoked by relatively minor 
stimuli (24/26), and sometimes also a feeling of increased irritability (4/26).  
5.3.2 INVESTIGATIONS 
5.3.2.1 MRI RESULTS 
58 participants underwent a clinical MRI scan. Abnormalities were detected in 4 
patients: (1) high signal in the right hippocampus; (2) frontal encephalomalacia 
secondary to previous brain injury, (3) slight signal change in both hippocampi 
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and (4) small cystic lesion on right caudate with small area of gliosis right lateral 
ventricle and left posterior frontal lobe.  
5.3.2.2 EEG RESULTS 
61/65 (94%) patients had undergone interictal EEG (Figure 5.3). Overall, 22/61 
(36%) were epileptiform, 16/61 (26%) showed borderline abnormalities, 23/61 
(38%) were normal. Epileptiform discharges localised to the temporal lobes, 
primarily, or solely, in the left hemisphere in 13/22, right-sided in 6/22, bilateral in 
4/22. Non-specific abnormalities most often involved theta activity, usually 
localised to the temporal lobes (11/16). Other abnormalities included a single 
sharp wave (n=5) or a single sharp-slow complex (n=2). These findings were 
more often bilateral (7/16) or right-sided (6/16) than left-sided (3/16). 
 
 
Figure 5.3: EEG flow-chart for TIME2 cohort (in cases where multiple EEGs 





5.3.3 COMPARISON WITH CLINICAL FEATURES IN TIME 1 SERIES 
Table 5.2 presents the clinical features in the current series, our previous series 
and the two series combined.   
 








   
 





0.872 61.7 (26-77) 
Mean age at presentation 
(SD) 
66 (SD 9) 65.6 (SD 8.67) 0.150 66.7 
Sex distribution (M/F) 34/16 51/14 0.207 85/30 
Seizure Characteristics 
   
 
Median number of attacks 
prior to diagnosis 
10 (IQR 6-30) 15 (IQR 6-36) 0.263 12 (IQR 6-25) 
Median frequency of 
attacks (per year) 
12 (IQR 5-20) 12 (IQR 8-20) 0.953 12 (IQR 5-12) 













Cessation of attacks on 
AED 
96% 91% 1.101 93% 
Amnesia sole 
manifestation of a seizure 
28% 20% 0.318 23.5% 
Tonic-clonic seizures 4% 10.7% 0.186 7.8% 
Some attacks on waking 74% 94% 0.003 85% 
Partial amnesia for attack 56% 54% 0.840 55% 
Repetitive questioning 50% 63% 0.164 57% 
Olfactory hallucinations 42% 45% 0.749 43% 
Motor automatisms 36% 45% 0.333 41% 
Brief unresponsiveness 24% 50% 0.005 39% 
Interictal features 




70% 88% 0.017 80% 
c/o accelerated forgetting 44% 74% 0.001 61% 
c/o topographical memory 
loss 
36% 72% <0.001 56% 




   
 
Interictal epileptiform 
activity on EEG 
36% 33% 0.656 30.6% 
Structural lesion on MRI 2% 7% 0.124 4.6% 
IQR = interquartile range; AED = antiepileptic drug; c/o = complaint of; AML = 
autobiographical memory loss; TEA = transient epileptic amnesia; c/o = complains of; EEG 
= electroencephalogram; MRI = magnetic resonance imaging; where there is a significant 
difference between groups (p<0.05) this is highlighted. 
 
 
Table 5.2: comparison of key features in TIME1 and TIME2  
  
5.3.3.1 DEMOGRAPHICS 
Age at onset and sex ratio were consistent between the two series. . 
5.3.3.2 SEIZURE FEATURES 
Duration, timing, frequency: Seizure duration and frequency were similar in the 
two series. Seizures on waking were reported more commonly in TIME2. 
Seizure types: The frequency of pure amnestic seizures, repetitive questioning, 
olfactory hallucinations, motor automatisms and tonic clonic seizures was similar 
in the two groups. Brief episodes of unresponsiveness were reported more 
commonly in TIME2 than TIME1.  
Ictal amnesia: Partial recollection of attacks occurred with similar frequency in the 
two groups. 
Treatment: Over 90% of patients in both series reported complete cessation of 
seizures following the initiation of medication.  
5.3.3.3 INTERICTAL FEATURES 
AbA, ALF, TopA: These interictal features of TEA were reported more commonly 
in TIME2. 
Emotionality: Increased emotionality was reported more commonly in TIME2 than 




5.3.3.4 INVESTIGATIONS  
EEG and MRI abnormalities were seen with similar frequency in the two series.  
5.3.4 NEUROPSYCHOLOGY 
5.3.4.1 STANDARD NEUROPSYCHOLOGY 
Neuropsychological test results for patients in TIME1, TIME2 and control 
participants are shown in Table 5.3. While full assessments were conducted in 
56 participants, three were excluded from analysis given other neurological 
history which may have confounded test performance (one because of significant 
head injury resulting in structural changes evident on MRI; and two because of 
vascular events evident on MRI).   
 
Neuropsychological Measure TIME2 (n=53) TIME1 (n=50) Controls (n=24) 
WASI (2-subtest IQ) 
115.7 (14.8) 118.3 (12.8) 120.0 (14.4) 
Graded Naming Test (/30) 
21.5 (4.8) 21.4 (5.1) 23.5 (4.2) 
COWAT (letters F,A,S) 
41.8 (13.6) 42.5 (13.9) 43.8 (11.4) 
Animal fluency 
19.5 (6.9)  19.3 (5.9) 22.0 (4.4) 
RCFT – copy (/36) 
33.5 (3.5) * a 34.5 (3.1) 35.5 (1.1) 
    
LM (Story 1) – Immediate (/25) 
11.5 (4.1)** b 14.0 (4.3) 15.9 (3.8) 
LM (story 1) – Delay (/25) 
9.1 (4.7)**  11.7 (5.0)* 14.7 (3.8) 
LM (Story 1) – Recognition (/15) 
12.1 (2.0)**  12.9 (1.4)* 13.6 (1.2) 
RCFT – 30 min delay (/36) 
15.3 (5.9) **a  15.0 (6.5)* 18.6 (6.1) 
RMT – Words (/50) 
43.3 (6.1)**  46.1 (4.7)* 48.3 (1.9) 
RMT – Faces (/50) 
39.4 (5.3)**  40.7 (5.4)** 45.1 (2.9) 
* denotes a significant difference p<.05 when compared with healthy controls, ** denotes p<0.0005 
Healthy control participants from Butler et al 2007  
a based on a sample of n=50 
b denotes a significant difference p <.004 between TEA cohorts across TIME1 and TIME2 
  Table 5.3: Neuropsychological test performance (Mean and standard 
deviation) 
 
All three groups of participants demonstrated above average intellectual ability.  
There were no significant differences between TIME2 and healthy controls on 
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language or executive function tasks, however, significant reductions were 
apparent on all of the anterograde memory tasks.   
 5.3.4.2 ACCELERATED LONG-TERM FORGETTING 
ALF testing was completed in 36 of the TIME2 participants.  Three were excluded 
from analysis due to impaired performance on standard tests of anterograde 
memory (delayed story recall), 8 due to inability to meet the word list learning 
criterion, and 6 due to poor recall at the 30-minute interval.  Nineteen TEA 
participants and 22 age and IQ-matched healthy controls were therefore 
included, subject to the same exclusions listed above (healthy control mean age 
= 63.82, TIME2 subset mean age = 64.77 F [1, 41] =.30, p=.59; healthy control 
mean IQ = 116.86, TIME2 subset mean IQ = 116.38, F [1, 41] =.87, p=.36). All 
participants completed between 3 and 10 learning trials, with no differences 
between the TEA and control groups on the total number of learning trials (F[1,40] 
= .58, p = .45), or average final trial score (85%; F[1,40] = .01, p =.93), suggesting 
an equivalent performance during the learning phase of the task.   
As expected, recall performance declined over time for both TEA and control 
participants (see Figure 4 for mean group results), with the lowest scores 
generated by the TEA group at all delay intervals.  Repeated measures ANOVA 
of recall performance confirmed a significant main effect for group (F [1, 39] = 
10.46, p = .002), a significant main effect for the delay interval (F [1.5, 58.9] = 
153.73, p <.001), and, importantly, a significant group x delay interaction (F [1.5, 
58.9] = 6.29, p = .008).  Planned contrasts to explore group differences across 
the time intervals, showed that while the TEA and control participants did not 
differ significantly from each other in their change shown between 40 seconds 
and 30 minute recall (F[1,39] = .03, p=.86), the degree of forgetting was greater 
in TEA participants compared to controls between the words recalled at the short 
delay intervals (40 second and 30-minute recall) and performance at the 7-day 
interval (F[1,39] = 7.74, p = .008) (see Figure 4). 
Within the TEA group, 13participants had reported symptoms of ALF. To explore 
whether the group x delay interaction was only evident within these participants, 
additional, separate analyses were run comparing control performance firstly with 
TEA participants who did (ALF+) and did not (ALF-) self-report ALF (Table 5.4).  
114 
 
As predicted, the interaction remained significant for ALF+ patients vs healthy 
controls (F [1.53, 66) = 8.12, p=.002, with contrasts confirming that this effect was 
only significant at the final level of delay (p=.003) and not at early intervals 
(p=.97)); but was no longer significant when comparing ALF- patients with healthy 
controls (F [1.57, 40.92] = .40, p =.533, with a significant main effect for delay, 
but no main effect for group)(as seen in Figure 5.4).  
 
 TEA (n=19) HC (n=22) ALF+ (n=13) ALF- (n=6) 
  mean SD mean SD mean SD mean SD 
learning trials (n) 5.05 2.37 4.45 1.84 4.92 2.33 5.33 2.66 
Max. trial score (%) 84.56 5.90 84.85 5.12 84.62 6.32 84.44 5.44 
40 second score 
(%) 70.53 9.25 76.36 10.23 70.77 10.38 70.00 6.99 
30-min score (%) 64.21 9.74 70.61 12.29 65.13 10.59 62.22 8.07 
1-week score (%) 21.75 16.46 43.33 22.98 17.95 15.96 30.00 15.63 




  Figure 4: Mean word list recall performance of transient epileptic amnesia 





























Finally, to check for any associations among seizure variables (total number of 
seizures and frequency of seizures prior to anti-convulsants) and long term 
retention, Spearman’s rho correlations were examined.  There were no significant 
results (1-week retention and total seizures prior to anti-convulsants: rho = -.11, 
p = .662; 1-week retention and seizure frequency prior to anti-convulsants: rho = 
-.10, p = .749). We note, however that, patients were seizure-free at the time of 
testing.  
5.3.4.3 AUTOBIOGRAPHICAL MEMORY 
The MAMI was conducted with 24 TEA participants (17 M, 7 F) from TIME2 who 
met the criteria of TEA onset from age 50 years onwards.  TEA participants were 
age and IQ-matched with 18 healthy controls from TIME1 (TEA mean age = 
67.83, control mean age = 68.17, p=.881; TEA mean IQ = 120.08, control mean 
IQ = 121.50, p=.735).   
Figure 5.5 shows the mean scores by decade for the two groups.  For the 
personal semantic memory component of the test, repeated measures ANOVA 
revealed a significant main effect for decade (F[2.68, 104.61] = 5.758, 
p=.002).  This followed a quadratic function (F[1, 39] = 10.92, p =.002) such that 
memories for the 20s and 50s were better recalled than for the middle 
decades.  A significant main effect was also found  for group (F[1,39] = 20.98, 
p<.001), with average personal semantic recall for controls slightly higher, at 9.58 
out of 10, as compared with 8.53 out of 10 for TEA participants.  However, no 
decade x group effect (F [2.68, 104.61] = 2.65, p =.059) was observed, indicating 
that the pattern of performance of TEA participants, while lower, mirrored that of 
the controls.    
Similar results were found in the episodic domain.  A significant main effect arose 
for decade (F[3,117] = 4.39, p=.006), again with contrast testing confirming a 
quadratic relationship where memories from the 20s and the 50s were better 
recalled that those from the middle periods (F[1, 39] = 11.95, p =.001).  The main 
effect for group was also significant (F[1,39] = 45.20, p<.001), with average 
episodic recall remaining high for controls at 9.14 out of 10, but dropping to an 
average score of 6.23 out of 10 for TEA participants. The decade x group effect 
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was not significant (F[3,117[ = .87, p =.457), indicating that the overall pattern of 




 Figure 5.5: Mean scores on the Modified Autobiographical Memory Interview 
(MAMI) for transient epileptic amnesia (TEA) patients and matched control 
























































To determine the proportion of TEA participants who at an individual level showed 
impaired performances at each decade, cut-off scores were calculated using the 
threshold of 2 SDs below the control mean.   The most recent decade showed 
the greatest frequency of impairment (17/23, 74%), followed by the 20s (14/23, 
61%), 40s, (13/23, 56%), and 30s (10/23, 44%).  Only 2 participants (13%) were 
not classified as impaired on any of the examined decades.  Thus, impairments 
were across the lifespan, but most prevalent for memories formed post TEA-
onset. 
Finally, to check for any associations among seizure variables (total number of 
seizures and frequency of seizures prior to anti-convulsants) with overall 
autobiographical memory performance, Spearman’s rho correlations were 
examined.  There were no significant results (Average MAMI and total seizures 
prior to anti-convulsants: rho = -.11, p = .662; Average MAMI and seizure 
frequency prior to anti-convulsants: rho = -.10, p = .749). 
5.3.4.4 MOOD  
Participants reported relatively few symptoms of anxiety or depression (TIME2 
mean anxiety =6.5; SD = 4.2; TIME2 mean depression = = 3.7 SD =3.1).  There 
were no significant differences between the 3 groups (TIME1, TIME2 and 
controls) for either anxiety (F [2,119] =2.26, p=.108) or depression (F [2,118] = 
2.61, p = .078), with all groups reporting mean levels below the standard clinical 
cut-offs (<8).  
5.3.5 COMPARISON WITH NEUROPSYCHOLOGICAL FEATURES IN 
TIME 1 SERIES 
Performance of TIME1 and TIME2 cohorts was similar on standard 
neuropsychological tests except that the TIME 2 group performed more poorly on 
the immediate recall of a short story (p <.001). At the individual level, a third of 
TIME2 participants (34%) showed significant memory impairment (>2 SDs below 
the control mean on 2 or more memory tests).  Although a slightly higher number 
than observed in the TIME1 cohort (28%), the difference was not significant (n = 
103;2 = .427, p =.531). Thus the findings of standard neuropsychological tests 
of TIME 1 appeared largely replicated in this second cohort.  
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 5.3.6 LITERATURE REVIEW 
Using the search term ‘Transient Epileptic Amnesia’ we identified 322 
publications between 2008 and 2018, after deduplication (Figure 5.6). The results 
were filtered to include only case series and case reports of novel cases of TEA 
this yielded in total, 115 patients with TEA from 23 studies which are summarised 
in Table 5.5, excluding the cases from our previous and current studies. All cases 
satisfied the Zeman criteria for TEA. The relatively small number of larger case 
series (only 4/23 studies included >3 patients) and the heterogeneity of research 
methods utilised precluded a systematic review of the literature. A literature 
review is reported in order to best capture the combined reported cases of TEA.   
Figure 5.6: Flow diagram demonstrating study selection process 
Records identified through 
database searching  





























Additional records identified 
through other sources  
(n = 8) 
Records after duplicates removed  
(n = 322) 
Records screened  
(n = 207) 
Records excluded - not 
TEA case reports or series  
(n = 151) 
Full-text articles assessed 
for eligibility  
(n = 46) 
Full-text articles excluded, 
with reasons  
(n = 23). Not novel TEA 
cases / previously 
reported elsewhere 
Studies included in 
quantitative synthesis 
(meta-analysis)  
(n = 23) 
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Imaging Response to AED 
Huang 2008 1 1 0 67 67 5 hr           L poss metastatic tumour L TL   
Hornberger 2010 1 0 1 43 44 <1min     no no no R MRI normal Complete 
Razavi 2010 1 1 0  67   
 A few 
minutes 
          B MRI normal Complete 
Ioannidis 2011 3 1 2 
53, 62, 
73 






no no R 
R TL angioma, R ant choroidal 
aneurysm, MRI normal 
Complete 
Favre 2011 1 0 1 60 70 30-60   yes       R MRI normal Complete 
Soper 2011 1 0 1 45 47 1-15mins   yes   manual no R asymm HC Complete 
Walsh 2011 1 1 0 55 59   yes   no no Yes L MRI normal No 
Kemp 2012 1 1 0 
20-year 
history 
73 1-10mins yes yes   oral     MRI normal Complete 




<5 mins - 
>1hr 
in 23% In 20% 2/30 oral in 4/30 2/30 17/30 ep. 
normal in 70% (R PL 
meningioma, R hemisphere 
ischaemic sequelae, atrophy 
(cortical, R hippocampal), 
hyperintensity (bilat 
hippocampal, R amygdala)  
Complete in 19 
(73%) of 26 cases, 
>50% reduction in 
seizure frequency in 
the remaining cases 
(27%). 




59.7yrs 2-10mins   yes 1/11 oral in 1/11 3/11 7/11 ep. 
MRI normal in 3, 5 MTL signal 
abnormalities 
Complete in 10/11 
Del Felice 2014 3 3 1   
71.25 (67 to 
75) 
1min-1hr   
yes (in 
2) 
yes oral 1/3 N subtle MTL atrophy Complete 
Nicastro 2014 1 0 1 79 79 90mins yes yes   no No B MRI normal Complete 
Cretin 2014 1 0 1   64 20-60mins   yes   
oral + 
manual 




Table 5.5: features of TEA studies included in review (in order of publication date) Key: AA=anterograde amnesia, Olf hall=olfactory 
hallucination, Unresp= unresponsive episodes, EEG=electroencephalogram, L=left, R=right, B=bilateral, N=normal, HC=hippocampus, 
GBM= glioblastoma multiforme, TL=temporal lobe, PL =parietal lobe, CVD= cerebrovascular disease, IEA= interictal epileptiform 
abnormalities, blanks indicate information unavailable/not reported.
Woollacott 2015 1 0 1 74 76 1hr yes yes   oral Yes L CT - TL atrophy 
Levetiracetam - no, 
Lamotrigine - 
complete 
Sugiyama 2015 1 0 1 75 
5 months 
later  
30mins yes yes no no Yes B 
MRI -small hyperintense 
lesion in R TL 
Complete 
Cunha 2016 3 0 3   74, 67, 70             L MRI normal   
Fouchard 2016 1 0 1 63 68 1-2hrs yes yes   no No L 
MRI - enlarged hippocampal 
volume 
Complete 
Cho 2017 2 1 1   77, 63 10-20mins yes partial   no No R MRI normal Complete 
Burkholder 2017 2 0 2 
12 -18 
months 
50, 59 2-8hrs yes yes     1/2 B MRI normal Complete 
Sekimoto 2017 1 0 1 
6/12 
earlier 
67 15mins yes yes no no no R MRI normal Complete 
Ukai 2017 1 0 1   67   yes     no yes B MRI normal Complete 
Ramanan 2018 31 20 11   
median age 
70 
            20/31 ep. 
6/31 focal abnormalities, not 
further specified 
100% improved 
with AEDs  




20mins - 24 
hrs 
in 40% yes       
IEA in 15/15 
on 24hr EEG 
MRI normal in 11/15 
(thalamic cavernoma, cystic 
pinealoma, bifrontal post-
traumatic lesion, L TL venous 
ectasia) 
complete in 8/15, 




5.3.6.1 CLINICAL FEATURES: DEMOGRAPHICS 
Summing across these studies, the sex ratio was equal (male 58, female 57), 
though three of the four larger series reported a male preponderance (Lapenta et 
al., 2014, Mosbah et al., 2014, Ramanan et al., 2018). The mean age of onset for 
TEA has been reported as 59, 67.2 and 54.9 years in the three larger series 
providing this information, with onset age ranging from 35-78 years. The reported 
interval between symptom onset and diagnosis ranges from around 6 months to 
6.2 years.  
5.3.6.2 SEIZURE FEATURES 
Duration: The majority of reported episodes fall between a few minutes and one 
hour, but  there is extensive variation with seizure episodes lasting from less than 
one minute (Hornberger et al., 2010) up to 24 hours (Lanzone et al., 2018), 
Timing: 13/23 (57%) studies included in this review describe episodes of TEA 
occurring on waking in 27/60 (45%) patients. 
Frequency: The frequency of TEA attacks ranges from several times per week 
(Soper et al., 2011) to less than once per year (Burkholder et al., 2017). 
Comparable data are available for 15/23 studies listed above (46/114 cases). In 
this group 6/46 (13%) report at least one seizure per week, 17/46 (37%) report 
seizures at least once per month but less than weekly, and 23/46 (50%) describe 
less that one seizure per month.  
Seizure types: Pure amnestic seizures are described in between 17% (Mosbah 
et al., 2014) and 64% (Lapenta et al., 2014) of patients. Brief unresponsiveness 
is reported in a total of 9/23 studies. 12/51 (23.5%) cases presented by these 
studies describe this phenomenon. An epigastric aura is described in 3 studies 
(Ioannidis et al., 2011, Kemp et al., 2012, Cretin et al., 2014) and orofacial 
automatisms in 4 (Ioannidis et al., 2011, Kemp et al., 2012, Cretin et al., 2014, 
Burkholder et al., 2017). Generalised tonic-clonic seizures are uncommon (10% 
in Mosbah (2014), 9% in Lapenta (2014). In one case (Walsh et al., 2011), 
persistent generalised tonic-clonic seizures were resistant to anti-epileptic 
treatment leading to a temporal lobectomy.  
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Treatment: Patients with TEA respond well to treatment with anti-epileptic 
medication. 94/96 cases (97.9%) in whom the response to anti-epileptic 
treatment was reported describe a reduction in the number of seizures following 
initiation of medication. In 59 of these patients this is documented as being 
complete seizure cessation, and in 12 this reduction is described as partial (>50% 
reduction in seizures). Ramanan (2018) states that all 22/31 patients for whom 
follow-up was available improved - although it is not clear whether this represents 
a partial or complete improvement (Ramanan et al., 2018). 
5.3.6.3 INTERICTAL FEATURES 
The interictal features described in TEA have not been routinely assessed in 
either case studies or case series of TEA patients and are therefore not as 
thoroughly described. Findings in studies where these features have been 
investigated are described below. 
AbA: 13/23 studies included in this review describe interictal autobiographical 
memory impairments. Mosbah et al. (2014), report that retrograde memory loss 
is greater for the episodic than the semantic component of autobiographical 
memory. Recent memories were especially severely affected, with measurable 
improvement in autobiographical memory for events from the past five years 
following treatment (Mosbah et al., 2014). 
ALF: 9/23 studies describe the presence of ALF in TEA, in 25 patients. In studies 
with multiple patients, this feature was described in 16/30 (53%) (Mosbah et al., 
2014), 1/3 (33%) (Ioannidis et al., 2011, Del Felice et al., 2014) or 1/2 (50%) 
(Burkholder et al., 2017), giving a total of 18/35 (51%). 
TopA: TopA is described in only 2/23 studies (2 patients); described as either ‘a 
tendency to lose her way even in familiar locations’ (Woollacott et al., 2015) or 
simply as ‘topographical amnesia’ (Ioannidis et al., 2011). None of these studies 
measured topographical memory formally using neuropsychological tests.  
Olfaction: A decreased sense of smell, occurring in the setting of TEA was 
described in only 1 study (1 patient) (Ukai et al., 2017). 1/3 cases described by 
Ionnaidis (Ioannidis et al., 2011) features reports of ‘strange and bad smells’ as 
an element of seizure episodes. 
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Emotionality: 2/23 studies describe a clear change in the emotional character of 
their patients with TEA. In one case this change was becoming angry and short-
tempered (Ukai et al., 2017), and in the other low mood and depression was 
reported (Cretin et al., 2014).  
5.3.6.4 INVESTIGATIONS 
EEG: The rate of EEG abnormalities reported in published case series has 
exceeded 50% (57% (Mosbah et al., 2014) 64% (Lapenta et al., 2014)). EEG 
abnormalities have also been common in TEA case reports, most often occurring 
in the right temporal or frontotemporal leads (Hornberger et al., 2010, Ioannidis 
et al., 2011, Soper et al., 2011, Milton et al., 2012, Cho et al., 2017) although 
abnormalities are also frequently found on the left (Walsh et al., 2011, Fouchard 
et al., 2016), and bilaterally (Rabinowicz et al., 2000, Mendes, 2002).  
MRI: In the largest TEA case series, the majority of participants have normal MRI 
scans (25/31 (Ramanan et al., 2018), 21/30 (Mosbah et al., 2014) 11/15 (Lanzone 
et al., 2018). Of the 110 cases where MRI results were reported, 72.7% were 
normal. Where MRI abnormalities have been described, these have most 
commonly involved the temporal lobes (14/30), with findings including mesial 
temporal lobe signal abnormalities (Lapenta et al., 2014), right temporal 
cavernous angioma (Ioannidis et al., 2011), a small hyperintense lesion in right 
hippocampus (Sugiyama et al., 2015) and enlarged hippocampal volume with 
loss of architecture and increased hippocampal tail signal (Fouchard et al., 2016). 
Extra-temporal abnormalities have included bifrontal post-traumatic change 
(Lanzone et al., 2018), right parietal lobe meningioma (Mosbah et al., 2014) and 
a right anterior choroidal aneurysm (Ioannidis et al., 2011). 
5.4 DISCUSSION  
The substantial series of patients described here, combined with those identified 
in our literature review, supports the existence of a treatment-responsive epilepsy 
syndrome characterised by amnestic seizures, often occurring at roughly monthly 
intervals, typically lasting for 15-30 minutes, frequently manifesting on waking, 
with onset in middle age and a possible male predominance; a high frequency of 
interictal memory deficits, especially ALF and AbA, and – principally in our case 
series - both ictal and interictal olfactory disturbance with a tendency to emotional 
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lability, specifically easily provoked tearfulness. I will discuss in turn i) whether 
TEA should be regarded as an epilepsy syndrome, ii) the neuropsychological and 
neurobiological bases of the prominent associated interictal memory disturbance, 
iii) a model designed to capture current understanding of the condition and to 
identify key unanswered questions for future research.  
5.4.1 IS TEA AN EPILEPSY SYNDROME? 
There are compelling grounds for concluding that epilepsy is the underlying cause 
of the disorder described here. The patients we have described collectively show 
epileptiform changes on EEG, exhibit other clinical phenomena suggestive of 
epilepsy, such as paroxysmal alteration of awareness or olfactory hallucinations, 
and show a clear-cut response to anticonvulsant drugs. While opportunities to 
record EEG during an amnestic episode are exceptional, such recordings 
indicate that transient amnesia can occur both as an ictal and as an immediately 
post-ictal manifestation (Butler and Zeman, 2008a).  
If the diagnosis of epilepsy is accepted in these cases, do they belong to a 
distinctive epilepsy syndrome? Epilepsy syndromes involve a ‘complex of signs 
and symptoms that define a unique epilepsy condition’; the complex should 
involve ‘more than just the seizure type’, but is distinct from an ‘epilepsy disease’, 
a condition with a ‘single, specific, well-defined aetiology’ (Engel, 2006). TEA 
precisely satisfies this definition, given its distinctive demographic features, ictal 
characteristics and inter-ictal manifestations. As its aetiology is varied, it is not an 
‘epilepsy disease’. In this section we will consider some potential objections to 
this view, in particular inconsistencies between the features reported in the 
existing literature, the existence of atypical cases and the ‘grey zone’ between 
TEA and other forms of temporal lobe epilepsy. The question of aetiology is 
considered further in section 5.4.3. 
While our two consecutive series of patients with TEA display marked 
commonalities, in demographic features and ictal characteristics, they differ with 
respect to the reported frequency of episodes on waking, interictal memory 
disturbance and emotional lability. In each case, the frequency of these features 
was higher in TIME2 than TIME1. While we attempted to gather clinical data in a 
consistent fashion over time, we suspect that the apparent increase in the 
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frequency of these features reflects increased vigilance, stimulated by our initial 
findings, rather than any true difference between the patient groups. However, 
whether or not this is the case, these modest quantitative differences between 
the two series do not undermine the key elements of the syndrome, outlined 
above. 
The 115 patients described from our centre broadly resemble those reported from 
other centres in most respects, in particular, age of onset and seizure 
characteristics. The interictal neuropsychological features of TEA have been 
reported less frequently in other reports than in ours, but both AbA and ALF have 
been described repeatedly. Olfactory disturbance and emotional lability are much 
more common in our series than in other reports: whether this reflects a true 
difference, or a difference in ascertainment, is unclear. 
Some cases in our current series are atypical with respect to age, length of 
amnesic episode, treatment resistance; one additional case reported provocation 
of amnesic episodes by exertion. Two cases (305, 340) presented below the age 
of 30, more than three standard deviations below the mean age at presentation. 
Case 305 satisfied all three diagnostic criteria, with attacks of typical duration; 
case 340 satisfied one criterion (clear-cut treatment response) with longer than 
usual attacks (1-2 hours); both had attacks on waking. Case 305 had experienced 
26 episodes, case 340 five episodes. 4 patients (241,383, 257, and 346) had 
‘TGA-like’ episodes of amnesia lasting more than 2 hours: three of these patients 
satisfied two criteria each (treatment response and the occurrence of other 
suggestive features, olfactory hallucinations in two cases, unresponsiveness in 
one), while case 257 satisfied one criterion (treatment response). All four patients 
had experienced more than 10 episodes, and three of the four described 
episodes on awakening. All four were in their fifties. 5 patients described an 
incomplete response to treatment (243, 360, 365, 356 and 261). Three (243, 360, 
365) satisfied three criteria, while case 356 satisfied two 
(automatisms/unresponsiveness and treatment response, albeit partial) and case 
261 satisfied one (clear-cut but incomplete treatment response). All had 
experienced frequent events of typical duration (<1 hour), some occurring on 
waking. Three patients were in their sixties, two in their fifties. One patient, an 
overseas patient assessed in the UK but not included in the current series, 
described episodes of typical duration, occurring at roughly monthly intervals, 
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often on waking, and gave a clear description of precipitation of episodes by 
exertion, a feature more often associated with TGA; some episodes were 
accompanied by olfactory hallucinations and video-telemetry confirmed the 
diagnosis of epilepsy. Thus these atypical features generally occurred singly, in 
patients whose characteristics were otherwise typical for TEA, with no suggestion 
of distinct subgroups or likely alternative diagnoses. 
Finally, in some patients the clinical phenotype falls in a grey zone between 
‘typical’ temporal lobe epilepsy and TEA. For example, patients with focal 
seizures with impaired awareness sometimes exhibit a period of prominent post-
ictal amnesia, but these are not the key presenting feature. There is also a group 
of patients with temporal lobe epilepsy who present with notable interictal memory 
disturbance of the kind associated with TEA, accompanied by subtle seizures, 
but who never have amnestic events of the kind required for a diagnosis of TEA. 
The term ‘Epileptic Amnesic Syndrome’ has been proposed to accommodate 
patients with TLE accompanied by such interictal memory disturbance regardless 
of whether they do or do not also have amnestic seizures (Gallassi et al., 1992, 
Gallassi, 2006). The features of such borderline cases do not, however, call into 
question the existence of the core syndrome of TEA. 
Thus TEA is a distinctive epilepsy syndrome, with substantially consistent 
features across the two series of patients described from our centre and in recent 
reports from other centres. The relatively minor inconsistencies between our two 
series are likely to be explained by heightened awareness of the clinical features 
by the time we studied our second series. The existence of ‘atypical’ and ‘grey’ 
cases indicates that there are areas of overlap between TEA and other related 
epileptic conditions, but does not invalidate the proposal that TEA is a distinctive 
epilepsy syndrome.  
5.4.2 THE NATURE OF THE INTERICTAL MEMORY DISTURBANCE IN 
TEA 
The majority of patients with TEA describe characteristic symptoms of interictal 
memory disturbance, in particular symptoms of ALF, AbA and TopA. These are 
often the most prominent and sometime the earliest symptoms of TEA 
(Hornberger et al., 2010, Jansari et al., 2010, Mosbah et al., 2014, Zeman et al., 
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2018). As only ALF and AbA have been studied in detail in the context of TEA we 
will focus on these here.  
These phenomena are now established clinical entities with operational 
definitions. In particular, some individuals with TEA who perform within normal 
limits on standard measures of memory nevertheless have measurable evidence 
of ALF and/or AbA in the presence of corresponding symptoms. There is, 
however, continuing uncertainty about their pathophysiology, specifically 
regarding which phase of memory processing is perturbed (see Figure 5.7) and 
whether the underlying cause is physiological or structural. 
 
 
Figure 5.7: The mechanisms of the three well-studied forms of amnesia 
occurring in TEA in relation to the key stages of memory processing: episodes 
of ictal amnesia (‘TEA’) result from impairment of memory encoding, retrieval, 
or, often, both; accelerated long-term forgetting (ALF) is due to an impairment of 
consolidation processes, with a possible contribution from an encoding 
impairment; the autobiographical amnesia (AbA) probably results from memory 









impairing retrieval, and ALF, affecting consolidation, can also play a part. 
Adapted from (Zeman et al., 2012) 
 
In the case of ALF, the presence of memory impairment at extended intervals in 
patients with apparently normal learning, and intact early recall, suggests an 
impairment of memory consolidation. This interpretation is supported by 
examples of patients with impeccable performance on anterograde tests at 
standard intervals who nonetheless show marked accelerated long term 
forgetting (Butler and Zeman, 2008a, Jansari et al., 2010, Tramoni et al., 2011, 
Witt et al., 2015, Zeman et al., 2016). Existing evidence indicates that ALF is first 
detectable within hours of learning (Hoefeijzers et al., 2015), and that it occurs 
predominantly during wakefulness rather than sleep, perhaps hinting at an 
increased sensitivity to retroactive interference (Atherton et al., 2014, Hoefeijzers 
et al., 2015). However, there is also evidence that patients with TEA show early 
forgetting, over standard intervals, on recognition tests using visual materials 
(Atherton et al, 2019; (Dewar et al., 2015), and some work in patients with TLE 
has suggested that ALF, in fact, flows from an impairment of memory acquisition 
(Cassel et al., 2016). Thus it remains controversial whether ALF reflects a true 
impairment of memory consolidation or rather the increasing sensitivity of 
memory tests at longer intervals to impairments present from, or very close to, 
the point of memory acquisition. We have previously suggested that this may be, 
in part, a false dichotomy, as such impairments will often coexist and interact 
(Zeman et al., 2016, Baker and Zeman, 2017).  
There is also uncertainty over the relative importance of physiological factors, 
particularly ictal or interictal discharges versus structural factors in the causation 
of ALF. Studies – predominantly in patients with TLE - identifying a positive 
correlation between seizure frequency and ALF (Jokeit et al., 2001, 
Mameniskiene et al., 2006, Wilkinson et al., 2012), interictal discharge frequency 
and ALF (Mameniskiene et al., 2006, Fitzgerald et al., 2013), and reduction of 
ALF by anticonvulsant treatment (O'Connor et al., 1997, Midorikawa and 
Kawamura, 2007) and epilepsy surgery (Evans et al., 2014) argue for the 
importance of physiological factors. The apparent reversibility of ALF in some 
cases of TEA also points to a modifiable, physiological cause (Savage et al., 
2019a). However, other studies have failed to identify such relationships (Blake 
 129 
 
et al., 2000, Jansari et al., 2010, Muhlert et al., 2011). Moreover, ALF has recently 
been reported in patients with pre-symptomatic genetically determined 
Alzheimer’s disease (Weston et al., 2018) and in children following head injury 
(Lah et al., 2018), suggesting that epileptiform brain activity may not be required 
for its occurrence. Conversely, Butler et al (Butler and Zeman, 2008a, Butler et 
al., 2013) found no correlation between volumes of limbic structures and the 
severity of ALF, arguing against a straightforward structural explanation of ALF 
in TEA. Thus, just as impairment of both early and later phases of memory 
processing are likely to contribute to ALF, so it seems likely that both 
physiological and structural factors may be relevant, though the evidence in TEA 
somewhat favours the importance of physiological disturbance. In a detailed 
single case study, the resolution of ALF on withdrawal of the inciting agent – high 
dose intrathecal baclofen - clearly demonstrated a reversible, physiological or 
pharmacological, cause (Zeman et al., 2016).  
With respect to the AbA associated with TEA, detailed case studies indicate that 
TEA can erase or render inaccessible previously detailed autobiographical 
memories (Manes et al., 2001, Zeman et al., 2016, Zeman et al., 2018). This 
points to a disorder of storage, or possibly retrieval, although even rich retrieval 
cues failed to elicit recollection in these cases, arguing that in general storage is 
the more likely locus of pathology. We have, however, previously reported one 
patient who unexpectedly ‘recovered’ memories indicating that retrieval failure is, 
at least sometimes, the explanation for AbA in this condition (Milton et al., 2010). 
Finally, individuals with ALF would be expected to develop a degree of AbA over 
time for events occurring after the onset of ALF: the ‘disappearance’ of initially 
detailed memories, of the kind predicted by this hypothesis have been 
documented in the cases of CS (Zeman et al., 2016) and MB (Zeman et al., 2018). 
Mosbah et al (Mosbah et al., 2014) reported an improvement in autobiographical 
recall for recent events following treatment, in keeping with this possibility; 
Savage et al (Savage et al., 2019a) report a similar improvement in patient CS. 
Thus it is likely that AbA in TEA can reflect disorders of several stages of memory 
processing, including consolidation, storage and retrieval. Our working 
hypothesis is that the primary mechanisms of AbA in TEA, particularly in cases 
with temporally extensive memory loss, is degradation of stored engrams. One 
further possibility is worth considering, though there is at present no relevant 
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evidence: that the AbA of TEA is due to a problem with reconsolidation (Nader 
and Hardt, 2009). This could account for the close association between ALF and 
AbA.  
Anecdotal evidence points to a role for epileptic activity in the genesis of TEA-
related AbA but we have not detected a correlation between seizure frequency 
and duration and the severity of AbA in our patient group. The probable though 
controversial association between ECT, which produces iatrogenic seizures, and 
AbA (Fraser et al., 2008) is also in keeping with the hypothesis that TEA-related 
AbA is at least partly the outcome of epileptic activity propagating through the 
autobiographical memory network, resetting the synaptic weights on which 
episodic autobiographical memories are likely to depend. Although there is 
evidence in other contexts that structural brain damage can produce AbA, to date 
there is no evidence of any correlation between volume loss in limbic structures 
and AbA in patients with TEA. Thus the available evidence favours a role for 
epileptiform activity in the causation of AbA in TEA, with a possible, but so far 
unquantified, contribution from structural factors. 
Cognitive deficits occurring in epilepsy are sometimes caused by drug treatment 
and by mood disturbance. However, given that both ALF and AbA can be 
detected in patients with TEA prior to treatment (Mosbah et al., 2014) and that 
there is no evidence for an elevated rate of mood disturbance in the majority of 
patients (Butler et al., 2007, Mosbah et al., 2014); this series), neither explanation 
is likely here. 
In summary ALF and AbA, both common interictal features of TEA, reflect 
disorders of several stages of memory processing, affecting acquisition and 
consolidation in the case of ALF, storage and retrieval in the case of AbA for 
remote memories (with a contribution from ALF in the case of AbA for post-onset 
memories). Current evidence favours a predominant role for physiological factors 
in causing these phenomena in TEA, though structural factors are undoubtedly 





5.4.3 A MODEL OF TEA 
The aim of this section is to summarise current knowledge of TEA, identify 
unanswered questions and propose testable hypotheses regarding the 





Figure 5.8: A model of TEA: white text summarises demographic and 
aetiological factors; the central circle highlights the limbic regions likely to 
contain the seizure focus; white circles summarise the key clinical features, 
which also include interictal memory disturbance, ALF (bold) and AbA (italic). 
The numbers refer to possible mechanisms for ALF and AbA (see main text for 
further discussion); the neocortex interacts with limbic regions in memory 
processing (AbA = autobiographical amnesia, ALF = accelerated long-term 
forgetting, HC = hippocampus, LEs = life events, OFC = orbitofrontal cortex, 
PHC = parahippocampal cortices (including perirhinal cortex), TGA = transient 
global amnesia).  
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The majority of cases of TEA are idiopathic, but its typical occurrence in middle 
aged people, with a probable male predominance, points to an age-related 
susceptibility and the possible relevance of hormonal factors. Although TGA is 
unlikely to result from epilepsy in the majority of cases, the similarity in the ages 
of patients affected by TGA and TEA suggests that common age-related factors 
underlie both conditions.  Rare symptomatic (lesional) cases of TEA are 
described and discussed further below.  We have recently reported a case of TEA 
occurring secondary to NMDAR antibody mediated encephalitis (Savage et al., 
2019b). The significance of the high IQ of the patients in our series is uncertain, 
but we suspect it reflects the need for an articulate description of confusing 
symptoms in the diagnosis of TEA. The possibility that vascular risk factors may 
predispose to TEA was raised tentatively in a previous case control study, with 
associations - on the borderline of significance after correction for multiple 
comparisons - between TEA and cardiac arrhythmia, valve disease and arterial 
aneurysm (Butler and Zeman, 2011). Some patients with TEA have an initial 
episode closely resembling TGA, posing the question of whether TGA can 
sometimes lead to TEA. Mosbah et al noted a high frequency of depression and 
adverse life events preceding the onset of TEA in their cases: we have 
encountered individual cases in which mood disorder and life events are plausible 
triggers, but these relationships require further systematic study before firm 
conclusions can be drawn. Transient amnesia has been described as a seizure 
type among patients with Alzheimer’s disease (Vossel et al., 2013, Vossel et al., 
2017), but the clinical context typically distinguishes dementia related cases of 
epileptic amnesia from those we have described 
5.4.3.2 SEIZURE SOURCE 
Manual and automated measurement of brain structures in TEA has revealed 
mild atrophy of limbic regions, namely bilateral straight gyrus, medial orbital 
gyrus, hippocampus and right perirhinal cortex (Butler and Zeman, 2008a, Butler 
et al., 2013). In the minority of cases with a likely structural cause for TEA, the 
causative lesion lies within or close to this group of regions. In a single case study 
with radiological localisation, an exacerbation of TEA was associated with 
swelling and high signal in the left hippocampus with hypermetabolism in the 
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same region on a 2-Fluoro-2-[18F]-deoxy-D-glucose PET scan which resolved 
with symptom improvement (Butler and Zeman, 2008a). This patient went on to 
develop left hippocampal atrophy. In cases with epileptiform interictal EEGs, or 
ictal recordings, the discharges are temporal or fronto-temporal, in keeping with 
the localisation suggested by brain imaging.  
5.4.3.3 SEIZURE CHARACTERISTICS 
The amnesic episodes in TEA, which typically last around half an hour, are 
unusually prolonged for epileptic seizures: we discuss their mechanism further 
below. Their occurrence on waking is in keeping with a medial temporal seizure 
source (Durazzo et al., 2008, Mirzoev et al., 2012). The high frequency of monthly 
episodes is a striking and puzzling feature, hinting at some underlying process 
with a similar time course involving limbic cortices, but cyclical epilepsy is 
described in other contexts (Cook et al., 2014, Cook et al., 2016, Baud et al., 
2018). Olfactory hallucinations, sometimes prolonged, and both subjective and 
objective alterations in olfaction, are common in TEA, at least in our experience, 
and can provide a diagnostic clue.  
5.4.3.4 SEIZURE MECHANISM 
 Surface EEG recording during an amnesic attack was performed in nine 
literature cases and one TIME case. All recordings showed seizure activity, which 
in 8/10 cases involved both temporal lobes and in the others remained unilateral 
(one left- and one right-sided). Amnesia was observed as an ictal phenomenon 
in six cases and as postictal in four cases. This suggests that the amnesia 
occurring in episodes of TEA can occur both as true ictal manifestations and as 
post-ictal phenomenon, a ‘Todd’s paresis’ of memory.  
5.4.3.5 EMOTIONAL LABILITY 
 We noted a characteristic form of emotional lability in 18% of our first series of 
patients, and in 40% of the current series, a result, we suspect, of greater 
awareness of this feature. This typically involves a heightened emotional 
reactivity to poignant but relatively minor triggers, such as a story or tune on radio 




5.4.3.6 INTERICTAL MEMORY DISTURBANCE 
 Figure 8 indicates potential mechanisms for ALF and AbA. For ALF, ‘1’ refers to 
the possibility that a focal pathology or disturbance in function of limbic structures, 
most likely the hippocampus, disrupts memory acquisition and/or consolidation. 
The pathology could be integral to the underlying cause of the epilepsy, a 
structural result of the epilepsy or reflect an adaptation to the epilepsy: taking our 
observation that an intrathecal-administered GABA receptor B  agonist, Baclofen, 
can cause ALF (Zeman et al., 2016), together with evidence that experimental 
epilepsy can induce compensatory inhibitory mechanisms (Palop et al., 2007), 
we hypothesise that excessive inhibition within the medial temporal lobe (MTL) 
memory system may be a mechanism of ALF (Schmitz et al., 2017). Secondly 
(‘2’), disruption of the normal dialogue between the MTL and the neocortex, 
required for the consolidation of recently acquired memories could play a role 
(Baker and Zeman, 2017). Finally (‘3’) – and not to the exclusion of 1 and/or 2 – 
ictal and interictal discharges may disrupt memory processing.  
In the case of AbA, structural pathology (‘1’) in the MTL, perhaps detectable using 
high field MRI imaging (Comper et al., 2017, Palombo et al., 2018), could underlie 
the depletion of autobiographical memories that occurs in TEA, in keeping with 
the ‘multiple (hippocampal) trace’ model of remote memory (Moscovitch et al., 
2005). Ictal or interictal discharges may delete (‘2’) or render inaccessible (‘3’) 
engrams in the MTL (‘1’) or neocortex (‘4’).  
5.4.3.7 PROGNOSIS 
 We have recently reported 10 and 20 year outcomes in patients with TEA 
followed from the mid-1990s (Zeman et al., 1998) and early 2000s (Butler et al., 
2007, Savage et al., 2016, Savage et al., 2019a). TEA does not reduce life 
expectancy or increase the risk of dementia (Savage et al., 2016). The 
neuropsychological prognosis is broadly benign, with well-preserved cognitive 
function in most domains, alongside evidence of moderate decline in memory 
function over time on standard measures in some (Savage et al., 2016, Savage 
et al., 2019a). Accelerated long-term forgetting resolved in some individuals over 
10 years of follow-up, but persisted at a group level (Savage et al., 2019a). AbA 
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persisted, with evidence of some improvement in memory for events for the most 
recent decade (Savage et al., 2019a).  
5.5 CONCLUSION 
The growing world literature on TEA included 94 cases at the time of our previous 
review in 2008, among them 50 from our first series; in the current paper we 
report a further 65 patients studied at our centre and 114 cases from elsewhere 
reported since 2008. This now substantial patient cohort indicates that TEA is a 
distinctive form of late-onset limbic epilepsy. It gives rise to recurrent episodes of 
transient amnesia, typically lasting for around 30 minutes, often on waking, 
frequently occurring at intervals of around one month. Olfactory hallucinations are 
a common accompaniment and useful diagnostic clue. There is, in several series, 
an unexplained male predominance. Interictal memory impairment, specifically 
ALF and AbA occur in the majority of patients, sometimes associated with a 
distinctive form of emotional lability. The condition is most often idiopathic, and 
such cases have a benign prognosis. TEA occasionally occurs as a result of 
structural pathology and as a manifestation of auto-immune epilepsy. The 
aetiology of idiopathic cases, the monthly occurrence of seizures in some patients 
and the mechanisms and interrelationships of the interictal features – amnestic 
and affective – all warrant further study. The current report establishes TEA as 
an important, treatable cause of memory loss in older people, often mistaken for 






This chapter is soon to be submitted for publication as:  
Baker. J., Savage. S., Milton. F., Butler C., Kapur N., Hodges. J. & Zeman A. The Syndrome of 
Transient Epileptic Amnesia: A combined cohort of 115 patients and literature review.  
My contribution to this chapter has been in production of the manuscript (introduction, methods, 
and results) and literature review. Description of the neuropsychological tests performed and their 
analysis was provided by SS. The discussion was written by AZ. All named authors will have 
reviewed and commented on this paper prior to its submission 
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CHAPTER SIX: ACCELERATED LONG-TERM FORGETTING IN EPILEPSY - 
AND BEYOND 
6.1 INTRODUCTION 
Epilepsy can be associated with a variety of cognitive symptoms and 
impairments. Over the last decade a particular pattern of epilepsy-associated 
memory impairment has attracted increasing attention. Accelerated Long-term 
Forgetting (ALF) is the abnormally rapid forgetting of memories over intervals 
longer than the 30 minutes or so traditionally used to measure ‘delayed recall’ 
during a neuropsychological assessment. People with ALF often report that 
memories ‘leak away’ more quickly than would be expected, and some studies 
have reported a correlation between subjective complaints of memory impairment 
and objective measures of ALF. In this chapter, through a narrative review of the 
available literature, I review the evolution of this concept, clarifying its clinical 
presentation and associations, underlying pathophysiology, and treatment 
options. I review recent evidence that ALF may not be confined to patients with 
epilepsy  
6.2 METHODS 
To inform this narrative review of the topic of ALF, I undertook a literature search 
using PUBMED to identify all relevant articles. A search using the terms 
‘accelerated AND forgetting’ yielded 114 results. Of these, 44 were published in 
the last 5 years and 64 in the last 10 years. This provides a sense of the relatively 
recent development of this term and its proliferation over the last decade (Figure 
6.1). Papers were excluded when English language texts were not available, 
where the cases described had already been reported elsewhere or where no 
formal neuropsychological testing had been performed. The results of the 40 case 
studies / case series, and 5 review papers on the topic of accelerated forgetting 




Figure 6.1. Number of publications on ALF 1996-2016 
6.3 RESULTS 
 6.3.1. DEFINING ALF 
It has long been recognised that TLE is often associated with memory 
impairment, but it has generally been assumed that standard testing intervals of 
half an hour or so are adequate to assess long term retention and forgetting rates. 
The possibility that accelerated forgetting might become apparent in some 
patients over intervals longer than those usually studied was first raised by a 
series of case reports (O'Connor et al., 1997, Kapur et al., 1997, Lucchelli and 







diagnosis Test intervals 
Giovagnoli 1995 24 38 TLE 1h,24h, 3d,6d,13d 
Kapur 1997 1 62 Complex partial seizures 30m, 6w 
O'Connor 1997 1 42 Complex partial seizures 2h, 24h, 48h, 72h, 1w 
Lucchelli 1998 1 65 Complex partial seizures 10m, 60m, 24h, 1w, 41d 
Blake 2000 21 34 TLE 30m, 8w 
Mayes 2003 1 46 Complex partial seizures 30m, 3w 
Bell 2005 42 37 TLE 30m, 24h 
Jokeit 2005 162 38 epilepsy 30m 
Manes 2005 7 57 TEA 30m, 6w 
Bell 2006 25 39 TLE 30m, 2w 



























Mameniskiene 2006 70 33 TLE 30m, 4w 
Butler 2007 24 68 TEA 30m, 1w, 3w 
Davidson 2007 21 12 IGE 30m, 1w 
Manes 2008 10 64 subjective memory complaints 30m, 6w 
Jansari 2010 1 63 TLE 30m, 24h, 1w, 2w, 4w 
Muhlert 2010 11 69 TEA 40s, 30m 24h, 1w, 3w 
Deak 2011 7 44 TLE 30m, 12h 
Galassi 2011 1 58 TLE 30m, 1w 
Tramoni 2011 5 43 TLE 1h, 6w 
Barkas 2012 12 
 
TLE 3w to 6w 
Butler 2012 22 66 TEA 30m, 1w 
Narayanan 2012 14 34 TLE 30m, 4w 
Wilkinson 2012 27 37 TLE 1h, 6w 
Fitzgerald 2013 39 
 
epilepsy 30m, 24h, 4d 
Hoefeijzers 2013 17 66 TEA 30m, 1w, 3w 
Mary 2013 32 
 
healthy adults - sleep 30m, 1w 
McGibbon 2013 1 68 TLE 5m, 30m, 55m, 4h, 24h 
Atherton 2014 11 68 TEA 30m, 12h 
Evans 2014 7 40 TLE 30m, 1w 
Gascoigne 2014 23 13 TLE 30m, 1w 
Hoefeijzers 2014 11 59 TEA 30m, 3h, 8h, 24h,1w 
Tu 2014 7 51 Thalamic stroke 1h, 24h, 1w, 2w, 4w 
Walsh 2014 15 75 MCI 30m, 1w 
Landowsky 2015 42 43 25 with head injury 30m, 4h 
Miller 2015 7 45 Epilepsy 30m, 1w 
Witt 2015 1 35 anti-GAD encephalitis 30m, 1w 
Cassel 2016 18 39 TLE 10m, 1d, 1w 
Zeman 2016 1 52 Spinal injury/baclofen infusion 30m, 1w 
Weston 2016 21 38 AD mutation carriers 30m, 1w 
Bell 2007 Review     
Butler 2008 Review  
   
Zeman 2013 Review  
   
Elliott 2014 Review  
   
Geurts 2015 Review  
   




Subsequent publications have focused on group studies, predominantly in 
patients with temporal lobe epilepsy (TLE) (see Table 6.1). Whereas the early 
case reports involved patients with epilepsy secondary to a previous brain injury, 
the majority of the group studies have reported ALF in patients with no visible 
abnormality on MRI scan, in common with the majority of patients with TLE 
(Manes et al., 2005, Butler et al., 2007) . A number of these single case reports 
and case series have been summarised previously (Bell and Giovagnoli, 2007, 
Butler and Zeman, 2008b, Zeman et al., 2013, Elliott et al., 2014).  
Patients with TLE show a range of memory impairments, and not all of them will 
exhibit ALF. Some will have deficits on standard memory test intervals 
(Mameniskiene et al., 2006); while others will show no impairment even over 
longer delays (Giovagnoli et al., 1995, Bell et al., 2005, Bell, 2006). However, a 
number of studies have found evidence of normal or relatively normal memory 
retention after a 30 minute delay (Blake et al., 2000, Butler et al., 2007) in 
association with accelerated forgetting after that interval.  
ALF is particularly common in association with TEA, a subtype of TLE (Table 6.2). 
Patients with TEA typically report three distinct forms of memory impairment: 
amnestic seizures, retrograde memory impairment (the inability to evoke 
autobiographical memories from the past, often combined with impairment of 
remote topographical memory), and ALF (Zeman et al., 2013). 44% of patients 
with TEA report symptoms suggestive of accelerated forgetting (Butler et al., 
2007). Moreover, Butler et al reported a correlation between subjective memory 
complaints and measures of accelerated forgetting, but not with measures of 
memory obtained at standard intervals (Butler et al., 2009).  
If it is accepted that some patients with epilepsy perform normally on memory 
tests at standard intervals, but show impairment at extended ones, what kinds of 
learning and memory are affected? The phenomenon has been described in the 
context of declarative rather than non-declarative or procedural memory (Muhlert 
et al., 2010), and may especially affect the recall of context-rich episodic 
memories (Jansari et al., 2010, Tramoni et al., 2011). In the following section I 





Definition of TEA (Butler and Zeman, 2008b) 
(1) a history of recurrent witnessed episodes of transient amnesia 
 
(2) cognitive functions other than memory judged to be intact during typical episodes by a 
reliable witness 
 
(3) evidence for a diagnosis of epilepsy based on one or more of  the following: 
 
(a) epileptiform abnormalities on electroencephalography 
(b) the concurrent onset of other clinical features of epilepsy (e.g. lip-smacking, olfactory 
hallucinations) 
(c) a clear-cut response to anticonvulsant therapy 
 
 
Table 6.2: TEA diagnostic criteria (from Butler and Zeman, 2008) 
 
 
 6.3.2 MEASURING ALF 
A careful recent review of the literature by Elliott et al., (2014) concluded that ALF 
is a distinctive and robust clinical phenomenon but also identified a range of 
methodological variations in previous studies which sometimes hampers the 
interpretation of results (Elliott et al., 2014). The sources of variation included: 
i) Selection of control participants: studies have varied in the care with 
which control participants have been matched to patients on measures of 
general cognitive functioning, such as IQ, educational background and 
age. These may all be relevant to long term memory retention and 
forgetting.  
ii) Test material and procedures:  
a) verbal vs visual material: most but not all studies have compared the 
learning and forgetting of verbal and visual material: this is desirable, in 
case there are material specific effects.  
b) assessment procedure: most but not all studies have used measures 
of recall and recognition: this, again, is desirable given evidence that these 
measures may tap into partially separable processes (Aggleton and 
Brown, 1999). Elliott et al. review evidence that subtle differences in 
procedures can affect test results;  
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c) ceiling and floor effects: these have been present in some studies, 
limiting their ability to detect and/or compare forgetting in patients and/or 
controls.  
d) matching initial learning: some but not all studies have succeeded in 
matching initial learning. Where this is not achieved, the interpretation of 
forgetting curves, from different points of departure, is controversial. Elliott 
et al discuss a range of techniques used to match initial learning.  
e) rehearsal effects: there is a risk, in studies of long-term retention, that 
participants may rehearse the material they have learned consciously. 
Differential rehearsal across groups could confound the intended 
comparison. It is not clear that this is a serious practical problem, but some 
researchers have used material that would be difficult to rehearse to 
overcome this obstacle.  
f) Short Term Memory (STM) influence: some but not all studies have 
included a distraction procedure before the measure of immediate recall 
to obtain a result that is not contaminated by working memory.   
iii) Analysing of forgetting rates: As mentioned above, where levels of 
initial learning differ the comparison of forgetting curves is problematic and 
there is a variety of potential approaches to data analysis.   
To minimise these discrepancies, this paper concludes with a series of 
considerations which it suggests should be applied to future studies in this area 
(table 6.3). 
There is a need to develop a reliable approach to the clinical identification of ALF.  
Miller et al., (2015) recently assessed 60 healthy control subjects using three 
standardised measures of memory (Rey Auditory Verbal Learning (RAVLT), 
Logical Memory (LM), and Aggie Figures) with recall delays of 30 min and 7 days 
in order to establish normative values (Miller et al., 2015). 15 patients with focal 
epilepsy were studied using the same tasks. Seven of the patients showed ALF. 
Although this is a small study the suggestion is that this triad of tests, with a recall 
period of 7 days, may be an effective means of identifying ALF in patients with 




Methodological Guidance for Further Studies in ALF (Elliott et al., 2014) 
1. Patient and control groups should be matched, at least for age and intellectual ability. 
2. Ideally, both verbal and non-verbal test material should be used. 
3. Ideally, forgetting should be measured using both recall and recognition tests. 
4. Ceiling and floor effects should be avoided as far as possible. 
5. The potential for rehearsal and repeated recall should be avoided as far as possible. 
6. The immediate delay period should be long enough to ensure information is stored in Long 
Term Memory (LTM) and retrieval is not reliant on STM processes. 
7. Effort should be made to equate initial learning (whilst avoiding overlearning). 
 
Table 6.3: methodological guidance for ALF studies (From Elliott et al., 2014) 
 
 6.3.3. THE FORGETTING INTERVAL IN ALF 
The formation of memories is a highly complex, time-demanding process 
involving a series of biological steps and anatomical regions (figure 6.2). 
Disruption of any of these steps can impair memory (Kopelman, 2002). Initial 
memory acquisition requires  that information gains access to the relevant 
memory system (‘encoding’) with rapid associated changes in synaptic strength 
(‘early’ consolidation) Over time, the fragile early memory trace is strengthened 
(‘late consolidation’), at least in part through processes of ‘replay’. Memories must 
then be stored, and retrieved when required. There is evidence that they remain 
labile during storage, especially at times of retrieval, when they may be 
strengthened or weakened by a process of ‘reconsolidation’. The complexity of 
these processes challenges the simple, traditional distinction in cognitive 
psychology between ‘short’ and ‘long term’ memory, and predicts the existence 
of forms of amnesia corresponding to disruption of these processes. The locus of 
the memory process disturbed in ALF remains unclear but studies of its time 
course are relevant to determining this: if ALF is, in fact, predictable from the point 
of memory acquisition then it may well be due to pathology of encoding or early 
acquisition. If, however, at least in some instances, ALF only becomes apparent 
sometime after acquisition, then later processes of consolidation may be 
involved, though, as I mention below, behavioural evidence alone may never be 











Figure 6.2. Representation of multiple stages in memory process 
 
A variety of different delays has been investigated, from several hours to several 
weeks (see Table 1) 
The onset of ALF over shorter delays has been examined by (Hoefeijzers et al., 
2015). This study investigates the recall of word lists in TEA patients and controls 
at intervals of 30 minutes, 3 hours, 8 hours and 24 hours. Although the TEA 
patients were not significantly different from controls at the immediate and 30 
minute intervals, there were significant differences between 30 minutes and 8 
hours. There was a reduction in recall between 30 minutes and 3 hours but this 
did not reach significance. No further forgetting was observed over the first night 
in either group (i.e., between 8 hours and 24 hours). 
Other studies have identified evidence of ALF just one hour after acquisition 
(Wilkinson et al., 2012, McGibbon and Jansari, 2013). Wilkinson et al., (2012) 
reports accelerated forgetting of both verbal and non-verbal material in a cohort 
of 27 TLE patients. However, the pattern of forgetting was dependent on the 
different materials learnt and on the lateralisation of hippocampal sclerosis. 
Those with left sided abnormalities demonstrated accelerated forgetting of verbal 
material at the 1-hour delay, whereas the right-sided group showed normal 
retention at this interval with accelerated forgetting over a 6-week delay. In 
contrast, patients with right-sided hippocampal sclerosis showed faster forgetting 
over 1-hour of the non-verbal task when compared to those with left sided 
abnormalities (Wilkinson et al., 2012).  
The time course of forgetting has recently been examined in detail by Cassel 
(2016).  In this paper, to clarify the interval after learning at which ALF can be 





said to start, 14 TLE patients were examined using a story and a route learning 
task. Recall was tested at intervals of 30 seconds (following a distractor task), 10 
minutes, one day and one week. It was found that patients’ and controls’ 
performance did not differ at 30 seconds on either task (Cassel et al., 2016). 
However, TLE patients required more learning trials to reach criterion. In the story 
task, accelerated forgetting was progressive from 30 seconds onwards, although 
differences in forgetting rate only became statistically significant after one week. 
In the route learning task, patients showed faster forgetting over the first 10 
minutes with comparable forgetting rates thereafter. These data suggest that in 
this group of patients accelerated forgetting occurs as a consequence of impaired 
acquisition/early consolidation. 
In contrast to these findings, in a reanalysis of data from the study of Butler et al 
(2007), Hoefeijzers et al. (2015) examined the fate of words which had received 
the same number of learning trials and retrievals in patients with TEA and control 
participants in a world list learning study.  There was no significant difference 
between the two groups on an initial recall test at 30 minutes. However, recall 
performance was significantly lower for TEA patients when compared to controls 
after 1 week, suggesting a disruption of ‘late’ consolidation. 
As an aside, I note three relevant complexities: first, it may well be that earlier 
and later processes interact in such a way that an early defect is amplified by its 
effects at later stages: for example, recurrent rounds of ‘replay’ may give rise to 
a widening difference between memories differing slightly in strength at or soon 
after acquisition (Zeman et al., 2016). Second, it is not clear that purely 
behavioural data will ever be sufficient to resolve the question of the locus of the 
underlying impairment in ALF, as I currently have no absolutely reliable 
behavioural measure of memory strength: it is likely, therefore, that settling this 
question will require direct measures of brain activity associated with the various 
stages of memory processing. Third, patients describe the loss of memories over 
varied time-scales, from days to months: it may be that different mechanisms 





 6.3.4. ALF AND SLEEP 
Theories of memory consolidation have placed particular emphasis on the role of 
sleep in the long-term retention of declarative memories. Given the possibility that 
ALF may be a disorder of memory consolidation, its connection with sleep has 
been investigated. In a study of sleep quality and in particular its association to 
ALF, Mary et al., (2013) found that increased sleep fragmentation (‘intra-sleep 
awakenings’) was associated with ALF (Mary et al., 2013). However, this study 
also suggests that this sleep fragmentation was not enough by itself to explain 
the phenomenon and that therefore memory consolidation processes cannot 
depend exclusively on sleep quality after learning. In support of this a number of 
studies have shown that ALF can occur without an intervening period of sleep.  
The frequent occurrence of amnesic attacks on awakening in patients with TEA 
(Butler et al., 2007), raised a suspicion that ALF in this condition might be related 
to disruption of sleep-related memory processing. However, Atherton et al., 
(2014) found ALF patients derived the same benefit from sleep as controls. In this 
study, TEA patients, tested after an 8 hour interval, showed ALF after a day 
awake but not following a comparable period of overnight sleep (Atherton et al., 
2014). This suggests that ALF in TEA may be related more to the effects of 
retroactive interference from novel information than to a disruption of sleep-
related consolidation. This view is supported by other studies examining TEA and 
TLE which have also shown ALF during waking hours which is not worsened by 
an intervening period of sleep (Deak et al., 2011, Fitzgerald et al., 2013, 
Hoefeijzers et al., 2015). 
 6.3.5. ALF IN CHILDREN WITH EPILEPSY 
A number of studies have attempted to identify ALF in children with epilepsy 
(Cronel-Ohayon et al., 2006, Davidson et al., 2007, Gascoigne et al., 2014). 
Assessing ALF in children is not straightforward. However, given the long term 
implications of an accelerated rate of forgetting for young people in full-time 
education, it is certainly clinically important. Although temporal lobe epilepsy is 
the most common form of adult-onset epilepsy, seizures involving the temporal 
lobes are also common in children. Gascoigne et al., (2014) identify twenty-three 
children between the ages of 6 and 16 years of age with temporal lobe epilepsy. 
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7 of these patients had had a temporal lobe resection (Gascoigne et al., 2014). 
ALF was identified in this group for verbal, but not visual information. No 
correlation was identified between epilepsy severity and ALF.  ALF has also been 
observed in children with generalised epilepsy (Davidson et al., 2007). 
 6.3.6. TREATMENT OF ALF IN EPILEPSY 
Several studies have investigated the response to treatments ranging from 
repeated prompting (McGibbon and Jansari, 2013) and medication (Midorikawa 
and Kawamura, 2007, Razavi et al., 2010, Barkas et al., 2012) to surgery 
(Gallassi et al., 2011, Evans et al., 2014). 
At the more conservative end of this spectrum, McGibbon and Jansari, (2013) 
examined the role of repeated recall in reducing the effects of ALF (McGibbon 
and Jansari, 2013).  They found that repeated recall has a protective effect 
against the delayed forgetting seen in ALF. Tramoni et al (2011) reported normal 
performance over 6 weeks in a task in which facts were taught initially to a 
criterion of 90% correct in patients who showed ALF for episodic information 
(Tramoni et al., 2011). Further work examining the value and limits of such 
strategies in patients with ALF would be valuable 
If ALF is a manifestation of ongoing epileptic activity it is reasonable to suppose 
that anticonvulsant medications may have a role in reducing these memory 
symptoms. Midorikawa and Kawamura (2007) showed improvement of ALF but 
not retrograde amnesia in a patient with TEA following the initiation of 
anticonvulsant medication (Midorikawa and Kawamura, 2007). Razavi et al., 
(2010) also found resolution of memory symptoms in their TEA patient following 
the introduction of carbamazepine (Razavi et al., 2010). However Jansari et al., 
(2010) did not find a significant improvement in the rate of long-term forgetting in 
their patient after lamotrigine had been started (Jansari et al., 2010).  
In cases of medically intractable temporal lobe epilepsy, surgery remains the best 
option for seizure control. A number of studies have looked at the role of temporal 
lobectomy in relation to ALF. Results have been mixed. In their case report 
Galassi et al. (2011) show that a left temporal polectomy reduced seizure 
frequency and ALF in a 58yr old male patient with a 20 year history of medically 
intractable epilepsy (Gallassi et al., 2011). Evans et al (2014) report a cohort of 
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seven patients with temporal lobe epilepsy (Evans et al., 2014). A longitudinal 
design was used to assess ALF pre- and post-epilepsy surgery. Visual and verbal 
materials were used with recall and recognition tests. ALF was confirmed prior to 
surgery. The study identified a degree of impairment of initial learning in the group 
post-surgery, in keeping with hippocampal resection, which complicated the 
interpretation of further forgetting. However, retention was unimpaired between 
the 30 minute and one week delays in all 8 subtests following surgery. It is also 
worth noting that at the time of testing in these patients, none had had a change 
in their epilepsy medication, precluding this from being a contributing factor in 
their improvement. Given that the indication for surgery in these patients was 
medically intractable epilepsy, the study concludes that persistent and recurrent 
seizure activity may have had a causative role in the pattern of forgetting before 
surgery. 
Some novel therapeutic approaches have also been investigated. This includes 
the use of the selective serotonin reuptake inhibitor fluoxetine (Barkas et al., 
2012). In this paper it was shown that patients with hippocampal sclerosis show 
impairments of acquisition for a spatial task with accelerated forgetting of this task 
once learned. Administration of fluoxetine reversed the learning deficit, but left 
the pattern of accelerated forgetting unchanged.   
 6.3.7. ALF IN OTHER CONDITIONS 
While ALF has been described predominantly in epilepsy, a growing literature is 
exploring the possibility that it can occur in other contexts. I highlight recent 
papers describing ALF in cases with limbic encephalitis, stroke, subjective 
memory complaints, mild cognitive impairment (MCI) and Alzheimer’s disease 
(Manes et al., 2008, Walsh et al., 2014, Weston et al., 2018) and during 
intrathecal therapy with the GABA (B) receptor agonist, Baclofen. 
In recent years a growing variety of types of autoimmune limbic encephalitis have 
been described, typically presenting with memory disturbance, seizures, 
emotional symptoms and personality change. Witt et al., (2015) describes a case 
of ALF associated with glutamic acid decarboxylase (GAD) antibody related 
limbic encephalitis (Witt et al., 2015). This patient, a 35-year-old male, 
complained of severe anterograde and retrograde memory deficits characterized 
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by accelerated long-term forgetting.  Video EEG monitoring confirmed a left 
temporal epileptic focus and subclinical seizure activity but no overt seizures at 
the time of initial presentation. Cognitive testing identified normal learning and 
initial recall at 30 minutes but significantly impaired recall for information at 1 
week, in keeping with the pattern seen in other ALF patients. He was treated with 
monthly steroid pulses and anticonvulsant treatment and reported an 
improvement in his anterograde memory. 
ALF has also been demonstrated in patients with thalamic stroke (Tu et al., 2014). 
In this study, using a visual task, 7 patients with previous thalamic strokes were 
tested at intervals of: 1 h, 24 h, 1 week, 2 weeks, and 4 weeks. Accelerated 
forgetting of newly acquired contextual information was identified in patients 
within 24 h when compared to healthy controls. 
It is not surprising, given the clinical features and demographics of reported cases 
of ALF, that there has been interest in its potential relationship to  MCI, particularly 
as ALF has been shown to correspond well to subjective memory concerns. 
Manes et al., (2005) in a relatively early paper on the topic of ALF showed that 
accelerated forgetting was identifiable in patients attending a memory clinic with 
subjective memory concerns who performed normally in standard 
neuropsychological tests (Manes et al., 2005).  In this study of 10 individuals with 
complaints of memory loss but normal cognitive evaluation, 7 patients with MCI 
and 9 healthy controls, recall of both verbal and non-verbal information was 
tested immediately and then subsequently at intervals of 3 minutes and 6 weeks. 
There was no significant difference between the control group and the group with 
memory complaints on logical memory or the Rey complex figure at the 
immediate and 30 minute intervals, but a significant difference had developed by 
6 weeks. At this time point the scores of the cognitively normal with memory 
complaints group approached those of the MCI group, with no significant 
difference between them. The relationship between MCI and ALF has since been 
explored further by Walsh et al., (2015). In this study, although MCI subjects had 
an increased rate of forgetting within the first 30-minutes, a greater rate of 
forgetting was also identified between the 30-minute and 1-week recall sessions 
(Walsh et al., 2014). This result is important as it shows that the standard tests 
performed in the memory clinic, which typically involve a delay of 30 minutes, 
may under-estimate the deficits experienced by this MCI cohort.   
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In a very recent study Weston investigated whether ALF may be an early feature 
of Alzheimer’s disease (Weston et al., 2018). In a study of 21 carriers of 
pathological, AD-causing mutations and 11 control patients, matched for age and 
performance on standard memory tests, accelerated long-term forgetting for both 
verbal and non-verbal material was found in the mutation carriers at 7 days. 
These pre-symptomatic AD patients were tested on average 7.2 years before 
their predicted symptom onset.  Patients and controls showed similar 
performance at an initial recall interval of 30 minutes. It is therefore suggested 
that ALF may be an early, pre-symptomatic feature of familial Alzheimer’s 
disease, indeed perhaps the earliest feature of AD-related cognitive decline.  
A recent review by Geurts et al (2015), while highlighting the possible occurrence 
of ALF in early AD, as just discussed, noted a lack of evidence for ALF in 8/11 
studies ranging over Korsakoff’s syndrome, depression (with or without ECT), 
traumatic brain injury and multiple sclerosis (Geurts et al., 2015).  
Finally, ALF has also been described as side effect of medication. Baclofen is a 
GABA (B) receptor agonist.  It is used widely for conditions causing increased 
muscle tone and spasticity, particularly when associated with pain. In a recent 
paper ALF was identified in a patient receiving treatment with an intrathecal 
baclofen pump (Zeman et al., 2016). During a period of dose escalation, the 
patient reported a constellation of memory disorders very similar to those seen in 
TEA: amnestic episodes, ALF and autobiographical amnesia. These were 
confirmed on objective testing. As the baclofen dose was reduced the amnestic 
episodes and ALF resolved while the autobiographical amnesia persisted.  While 
it is possible that baclofen therapy, given at unusually high doses in this case, 
induced TEA, the authors also raise the possibility that signalling at the GABA (B) 
receptor may play a specific role in ALF. 
 6.3.8. PATHOPHYSIOLOGY OF ALF  
Given that ALF appears to be a distinctive clinical phenomenon, two key 
questions about its nature come to the fore: first, is it a disorder of memory 
acquisition and early consolidation or of later phases of consolidation? This has 
already been discussed above, in section 6.3.3. Second, is it a consequence of 
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disturbed physiology, disordered anatomy or some additional factors such as 
mood or drug treatment (table 6.4).  
In the context of epilepsy, might ALF be a direct consequence of seizures?   They 
do not appear to be required for ALF as ALF has been demonstrated in their 
absence, for example in patients with TEA (see e.g. Butler et al, 2007) and  some 
authors, for example Blake et al. (2000),  found no relationship between overt 
seizure frequency and memory performance (Blake et al., 2000). However, 
Mameniskiene et al. (2006) reported a positive correlation between long-term 
forgetting and seizures during their experimental period. They also identified a 
relationship between subclinical epileptiform EEG activity and long-term 
forgetting (Mameniskiene et al., 2006). This relationship was confirmed by 
Fitzgerald et al., (2013) who report evidence that inter-ictal discharges disrupt 
memory consolidation (Fitzgerald et al., 2013). The reduction of ALF by treatment 
in at least some patients also points to a role for disordered physiology in its 
causation. 
 
Possible Mechanisms for ALF in Epileptic Patients 
1. Clinical or subclinical seizure activity 
2. Structural brain pathology 
3. Side effect of anti-convulsant therapy 
4. Psychological mechanisms 
 
Table 6.4: possible mechanisms for ALF in epileptic patients 
 
 
Material-specific differences in learning rates could potentially arise from 
variations in the locations of an epileptogenic focus, and the origin of the epileptic 
activity. However, previous data have not consistently shown that hemispheric 
differences cause material-specificity in ALF. Blake et al. (2000) using a test of 
verbal memory, identified ALF in patients with TLE originating from the left but 
not the right hemisphere (Blake et al., 2000). However, in an earlier investigation, 
Martin et al. (1991) were not able to find a hemispheric effect when testing verbal 
memory. Other studies have also shown ALF for both verbal and non-verbal 
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information regardless of the site of activity (Mameniskiene et al., 2006, Butler et 
al., 2007).  
There is, therefore, some tentative evidence that disordered physiology 
contributes to ALF in at least some patients. Does disturbed anatomy also play a 
role? Several of the early case studies documented ALF in patients with focal 
pathology. Subsequent group studies have identified abnormalities within and 
beyond the hippocampus in patients with Transient Epileptic Amnesia (Butler et 
al., 2007, Butler and Zeman, 2008a, Mosbah et al., 2014). Tramoni et al., 2011 
identified metabolic changes in the temporal lobes using PET and magnetic 
resonance spectroscopy in patients with temporal lobe epilepsy and ALF 
(Tramoni et al., 2011). The occurrence of ALF in patients with preclinical AD and 
MCI which ultimately give rise to structural pathology in the temporal lobes may 
also point to a role for structural pathology. However, this evidence is equivocal 
as anatomical and physiological disturbance go hand in hand in AD (Vossel et 
al., 2013), and, in general, attempts to correlate the degree of structural change 
with the extent of ALF have been unsuccessful. Thus the role of structural 
pathology in ALF remains uncertain.  
It has also been suggested that the pattern of memory impairment seen in ALF 
among patients with epilepsy could be a consequence of anticonvulsant 
medication. This seems unlikely, given that patients often report ALF prior to the 
initiation of anticonvulsant therapies and, as we have seen, often report an 
improvement in memory following the introduction of medications to reduce 
seizure frequency (Gallassi et al., 2011, Butler et al., 2007).  However, there is 
certainly some evidence that antiepileptic drugs can negatively affect cognition 
(Ortinski and Meador, 2004, Jokeit et al., 2005). These negative effects of 
anticonvulsant medications are most commonly seen with higher doses and the 
use of polypharmacy. Jokeit et al., (2005) investigated this question (Jokeit et al., 
2005). It was shown that high serum levels of carbamazepine, phenobarbital or 
phenytoin in patients with refractory temporal lobe epilepsy were associated with 
impaired performance in verbal and nonverbal memory retention tasks when 
compared to patients with lower levels. However, neither high anticonvulsant 
doses nor the use of multiple medications are common among patients with 
epilepsy and ALF. TEA patients, in particular, are typically responsive to low 
doses of a single epilepsy medication (Butler and Zeman, 2008b). Moreover, it is 
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rare for patients with ALF to be treated with the older anti-convulsants, which are 
more prone to cognitive side-effects.  
Historically, discrepancies between subjective reports of memory impairment and 
normal performance on neuropsychological testing have often been attributed to 
low mood or poor self-esteem (Giovagnoli et al., 1995, Elixhauser et al., 1999). 
The development of reliable paradigms for identifying and diagnosing ALF has 
shown that mood is unlikely to play a major causal role in this condition. Several 
studies have reported an absence of correlation between ratings of mood and 
ALF (Blake et al., 2000, Mameniskiene et al., 2006, Butler et al., 2007). If ALF 
were a manifestation of low mood per se we would expect to see an accelerated 
rate of forgetting in patients with depression: this has not been shown on previous 
studies (Lewis and Kopelman, 1998). 
6.4 CONCLUSION 
Since early case reports documented a form of long-term forgetting which 
occurred at delays longer than those utilised as part of standard memory testing, 
the literature on accelerated long-term forgetting has grown substantially. There 
is now a significant body of evidence that ALF occurs as a clinical phenomenon, 
especially in the context of epilepsy. There is also growing evidence that this 
pattern of forgetting occurs in conditions other than temporal lobe epilepsy, 
although this remains the most common cause. Recent studies of ALF in 
amnestic MCI and pre-symptomatic Alzheimer’s disease patients will no doubt 
stimulate further interest in the topic. 
A range of important questions about ALF await a definitive answer. There is 
continuing disagreement and uncertainty about whether ALF results from a deficit 
of memory acquisition/early consolidation or of later phases of consolidation.   
Similarly, the roles of physiological and structural disturbance in causing ALF 
remain uncertain. These various possibilities are not mutually exclusive: It may 
well be that early and late consolidation, physiological and structural pathologies 
are all involved, to varying degrees across differing clinical contexts. Finally, 
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CHAPTER SEVEN: DIFFERENTIATING TRANSIENT EPILEPTIC AMNESIA 
FROM MILD COGNITIVE IMPAIRMENT AND EPILEPSY IN DEMENTIA 
 
7.1 INTRODUCTION 
Patients with TEA experience epileptic seizures characterised primarily by a 
transient impairment of memory. These seizures sometimes include brief periods 
of unresponsiveness and other ictal features, including olfactory hallucinations 
and motor automatisms. As I have also shown, epileptic seizures occurring in 
patients with dementia can lead to behavioural arrest and altered 
responsiveness, as well as periods of increased confusion and amnesia. In 
previous chapters we have described the variety of memory impairments reported 
by patients with transient epileptic amnesia (TEA). The accelerated long-term 
forgetting (ALF) seen in these patients has also been described in patients with 
Mild Cognitive Impairment (MCI) and in the early stages of Alzheimer’s Disease 
(AD) (Cretin et al., 2014, Del Felice et al., 2014). From this evidence it is clear 
that these two clinical presentations (TEA, and epilepsy in dementia) have 
features in common which may lead to diagnostic confusion. In this chapter I aim 
to compare and contrast these conditions with the objective of developing a 
decision aid that will help to distinguish them efficiently in typical clinical settings.  
Through the design of the PrESIDe study, I also collected neuropsychological 
data on a proportion of patients (those diagnosed with MCI in the memory clinic) 
at the time of their baseline PrESIDe assessment, in order to ensure diagnostic 
accuracy. It was also anticipated that some of these patients would have 
progressed from MCI to dementia in the intervening period. Many of these same 
measures were also collected as part of the TIME study. These parallel 
neuropsychological testing regimes enable us to compare these two groups of 
patients (TEA, and MCI) in order to further establish what these two conditions 
may have in common and the ways in which they are different. 
7.2 METHODS 
 7.2.1 PARTICIPANTS 
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This retrospective study examined the case notes of two groups of patients 
enrolled in two separate studies. The Impairment of Memory in Epilepsy (TIME) 
study has established a cohort of 115 patients with TEA. In previous chapters of 
this thesis I have described the clinical and neuropsychological features of this 
group. The Presentation of Epileptic Seizures in Dementia (PrESIDe) study 
assessed 144 patients with MCI or dementia and identified a clinical suspicion of 
epilepsy in 37 (25.7%). Here I compare the relevant demographic and clinical 
features in these patients. 
The PrESIDe cohort includes 39 patients in whom a memory clinic diagnosis of 
MCI was made. This diagnosis was reassessed at the time of their initial PrESIDe 
interview. Using recognised criteria (Albert et al., 2011), the MCI diagnosis was 
confirmed in 20/39 (51.28%). The remainder were given a diagnosis of 
Alzheimer’s disease at the time of their PrESIDe assessment (McKhann et al., 
2011). I am also able to compare these MCI patients to our TEA cohort in order 
to better differentiate these two conditions (TEA and MCI).  
 7.2.2 COGNITIVE FUNCTION MEASURES 
The Addenbrooke’s Cognitive Examination - Version III (ACE-III) scores were 
compared as a measure of cognitive function. A diagnosis of MCI was reached if 
a participant performed 1-1.5 standard deviations below age- and education- 
matched normative data, as per diagnostic guidelines (Albert et al., 2011). Further 
cognitive tests: The Rey-Osterrieth Complex Figure (RCF) (appendix7), Rey 
Auditory Verbal Learning Test (RAVLT) (appendix8), Trail Making Test (TMT - 
versions A and B) (appendix11), and Digit Span (appendix12), were available in 
a proportion of patients in the PrESIDe group (those in whom a diagnosis of MCI 
was made at the memory clinic) and in all of the TIME patients. For the RAVLT, 
the administration was the same as in the TIME study.  A list of 15 words was 
presented orally over a maximum of 10 trials until at least 12 words (80% 
accuracy) could be recalled within a given learning trial.  Upon reaching this 
criterion, participants were instructed to count backwards out aloud from 100 for 
40 seconds, to prevent rehearsal of words and reliance upon working memory to 
aid recall.  Recall of the words was assessed immediately following this distractor 
task, and once again at a delay of 30 minutes. 
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 7.2.3 ANALYSIS OF SEIZURE FEATURES 
In earlier chapters I have described the seizure semiology of these two groups of 
patients. I have identified the prevalence of several key seizure features in both 
the TEA and epilepsy in dementia populations: seizures on waking, pure 
amnestic seizures, generalised tonic-clonic seizures, altered responsiveness, 
motor automatisms, and olfactory hallucinations. Seizure features were 
compared in order to elucidate how patients in these two groups, and those 
closest to them, described these episodes (including the periods preceding and 
following them) and any persisting interictal deficits.  
 7.2.4 NEURORADIOLOGICAL FEATURES 
CT head scan reports were obtained for all patients in the PrESIDe study. Where 
these had been performed, MRI scan results were also obtained. In the TIME 
study, referring clinicians were contacted to request MRI reports for all patients. 
 7.2.5 ETHICAL APPROVAL 
Ethical approval for these two studies was obtained independently and has been 
described in earlier chapters. 
 7.2.6 STATISTICAL ANALYSIS 
Between-group analysis of demographic features and cognitive test performance 
was performed using independent sample t-tests. Chi-square testing was 
performed to compare proportions between participants and controls. Multiple 
linear regression analysis was performed to assess the relationship between 
dependent and independent variables. Statistical significance was judged as any 
p-value <0.05. IBM SPSS statistics 22.0 and STATA were used to perform data 
analysis.  
7.3 RESULTS 
 7.3.1 DEMOGRAPHIC FEATURES 
The 115 TIME patients with TEA and the 37 PrESIDe patients with Epilepsy in 
MCI or dementia were compared in terms of background demographic features 
(Age, gender, educational background). These background demographic 
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features of these cohorts are shown in table 7.1. Whilst in both phases of the 
TIME study TEA has been shown to be more common in men than women, there 
was no significant difference in terms of the gender balance between the two 
cohorts.  A significant difference was identified when the two groups were 
compared in terms of the onset of seizures, and age at diagnosis. The average 
age of seizure onset in the dementia group was 76.91 years, 15 years older than 
in the TEA group.  
 TEA (n=115) PrESIDe (M:F) (n=37) p-value 
Gender 85:30 22:15 0.095 
age at memory symptom onset   75.59 (51-89)   
age at seizure onset 61.7 (26-77) 76.91 (55-91) <0.001 
age at diagnosis 66.7 78.14 (61-92) <0.001 
(Table 7.1: comparison of the demographic features in TIME and PrESIDe) 
 
 7.3.2 COGNITIVE TEST PERFORMANCE 
All patients included in the PrESIDe study underwent cognitive testing using the 
ACE-III examination. Of the 65 participants in the TIME2 study, ACE-III scoring 
was available in 28/65, with subdomain scoring available in 13/65. A comparison 
of the overall ACE-III scores, as well as domain scores in these two groups is 








ACE-III  (mean and 
SD) 91.21 (5.95) 74.7 (10.37) <0.001 95.24 (2.37) 
ACE-III (range) 76-100 53-91  89-99 
Total with ACE-III <88  5 (17.86%) 34 (91.89%) <0.001 0 (0%) 
Total with ACE-III <82 3 (10.71%) 25 (67.57%)  <0.001  
Subdomain:          
     Attention 17.69 (0.63) 14.61 (3.01) <0.001 17.7 (0.60) 
     Memory 22.77 (2.74) 17.15 (4.69) <0.001 24.69 (1.29) 
     Fluency 11.01 (2.99) 7.39 (2.49) <0.001 11.58 (1.35) 
     Language 25 (1.41) 22.06 (2.89) 0.001 25.76 (0.51) 
     Visuospatial 15.46 (0.78) 13.48 (2.53) 0.008 15.51 (0.78) 
(Table 7.2: Comparing the cognitive test performance (ACE-III) of TIME and 





(Figure 7.1: comparison of ACE-III total and domain ACE-III between TIME and 
PrESIDe studies) 
 
Although the number of participants in TIME for whom full subdomain data are 
available is limited, I have identified significant differences between the two 
cohorts both in the overall scores and in all cognitive domains probed by this test 
(Figure 7.1). Conversely no significant differences were identified when the TIME 
participants were compared to the PrESIDe control participants. Whilst the control 
participants performed better in each domain on the test, at no point was this 
difference significant. 
 7.3.3 NEUROPSYCHOLOGICAL PERFORMANCE (COMPARING TEA, 
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39/144 patients in the PrESIDe cohort were given a diagnosis of MCI at their 
memory clinic appointment; in 20/39 (51.28%) the diagnosis was confirmed using 
research criteria at the time of PrESIDe baseline assessment (in the remaining 
19/39 (48.7%) the diagnosis was changed to AD. The delay from memory clinic 
to PrESIDe assessment was 12-52 weeks (median 27). The performance of 
these groups in comparison to the TEA group is outlined in table 7.3. 
On a test of visual memory (RCF) there was no significant difference between the 
two groups on the initial copy of this figure. However, on the recall of this figure 
after 30 minutes the MCI group performed significantly better than the AD 
participants (p=0.033). On the TMT, the two groups were comparable on version 
A (p=0.143) but again the MCI group performed significantly better on version B 
(p=0.008). The MCI participants also outperformed the AD participants on the 
digit span test. Patients with MCI scored significantly better when asked to repeat 
the digit sequence backwards (p=0.012) and in terms of their total score (correct 
responses forwards + backwards) (p=0.02). Interpreting the test of verbal 
memory (RAVLT) was more complicated as several of the AD patients failed to 
meet the specified learning criteria. However, whether or not the patients who 
failed to meet the learning criteria were excluded, MCI patients performed 
significantly better after a brief distraction (counting backwards from 100 for 40 














trials to criteria 5.46 (2.91) 0.436 6.25 (2.90) N/A N/A 
40s (/15) 9.96 (2.08) 0.003 7.25 (3.25) 0.006 4.65 (2.19) 
30 mins (/15) 8.68 (2.87) 0.005 5.42 (3.45) 0.013 2.81 (2.55) 
RCF Copy (/36) 31.74 (4.38) 0.614 31.08 (2.31) 0.596 30.02 (6.64) 
  30 min recall 15.3 (5.9) 0.002 10.67 (3.53) 0.033 6.17 (6.59) 
TMT A (secs) 36.60 (13.23) 0.006 49.72 (11.79) 0.143 60.39 (23.21) 
  B (secs) 93.76 (47.73) 0.345 109.36 (43.32) 0.008 169.30 (66.79) 
Digit 
Span Max forward 6.85 (1.23) 0.651 6.64 (1.21) 0.128 6.05 (0.85) 
Max backward 4.95 (1.47) 0.919 5.00 (0.89) 0.012 4.21 (0.71) 
total score 18.20 (3.74) 0.637 17.55 (3.42) 0.020 14.84 (2.54) 




Patients with TEA performed better on neuropsychological testing than patients 
with MCI. This performance was significantly better on the RAVLT after the 40s 
(p=0.003) and 30min (p=0.005) delays. There was no significant difference in the 
learning trials required to meet criteria. On the RCF the TEA group performed 
significantly better on the 30-min recall (p=0.002). There was no difference on the 
initial copy performance (p=0.614). On TMT the TEA patients performed 
significantly better than the MCI patients on version A, but not version B.  
 7.3.4 SEIZURE FEATURES 
Patients who experience epileptic seizures as part of their dementia were 
significantly more likely to have seizures where loss of awareness is a feature 
(Table 7.4). Automatisms occurred in a similar prevalence across both groups, 
although olfactory hallucinations were significantly more common in the TEA 
group. More than 50% of participants in both groups experienced amnestic 
episodes on waking in the morning, although this phenomenon was reported 
significantly more commonly in patients with TEA. 
 
  
TEA (n=115) PrESIDe (n=37) p-value 
Unresponsiveness 39% 78% <0.001 
Automatisms 41% 38% 0.747 
Olfactory hallucination 43% 5% <0.001 
Seizures on waking 85% 54% <0.001 
Amnesia as sole seizure feature 24% 5% 0.011 
Response to medication 93% 67%* 0.025 
Seizure frequency (median) 12 (IQR 6-25) 6   
Seizure duration (median, 
range) 
15-30 mins (<1 min to 
days) 




(Table 7.4: A comparison of seizure features in TIME and PrESIDe, * 6 patients 




 7.3.5 NEURORADIOLOGICAL FINDINGS 
Standard procedure in the regional memory clinic is for patients to receive a CT 
brain scan. Reports of these scans were available in 37/37 PrESIDe patients. 
Atrophy was reported in 29/37 (78.4%). In 14/29 (48.3%) this was felt to be in 
keeping with / commensurate with the patient’s age. In 7/29 (24.1%) in was clear 
from the report that the atrophy was in excess of the patient’s age. In the 
remaining 8/29 (27.6%) no comment was made as to whether or not the atrophy 
seen was in keeping with the patient’s age. In 24/29 patients the atrophy was 
reported to be generalised / no lobar predominance. In the remaining 5/29, focal 
hippocampal / temporal lobe atrophy was reported.  
The presence of small vessel ischaemic change was reported in 23/37 patients 
(62.2%). There were no small vessel ischaemic changes in 6/37 patients. No 
comment on small vessel ischaemic change was made in the remaining 8 
patients. In the 23 patients in whom small vessel disease was reported, this was 
described as mild, minor or grade 1 in 8/23 (34.8%), and moderate, grade 2 or 
grade 3 in 10/23 (43.5%). In the remaining 5/23 (21.7%) the degree of SVD was 
not described.  
Focal lesions were reported in 6/37 patients (16.2%). In 5/6 cases this lesion was 
an established area of ischaemia (Right internal capsule, right frontal lobe, right 
corona radiata, bilateral basal ganglia, adjacent to temporal horn of right lateral 
ventricle). In the remaining patient the focal abnormality was a probable 
neuroglial cyst within the left putamen.  
MRI scans had been performed in 4/37 (10.8%) of patients. In 2/4 of these 
patients (50%) hippocampal atrophy which had not been reported on the CT scan 
was identified.  
MRI scan reports are available in 59/65 (90.8%) patients in the TIME2 study. 
Small vessel ischaemic changes were reported in 12/65 (18.5%) of patients. In 
only 1/65 patients (1.5%) was hippocampal atrophy reported. Across the two 
phases of the TIME project, structural abnormalities were identified in only 4.6% 





Epileptic seizures in dementia affect a population that is significantly older than 
the population in whom TEA presents. These patients also perform worse than 
those with TEA on cognitive testing (ACE-III). Whilst there are some similarities 
in the seizure semiology of these patients, those that experience epileptic 
seizures as a feature of their dementia are more likely to report episodes of 
unresponsiveness, and less likely to describe olfactory hallucinations and clear 
episodes of amnesia on waking than patients with TEA. Imaging investigations 
are usually normal in TEA, whilst in dementia and MCI focal or global atrophy, 
and changes in keeping with small vessel disease are common. In the following 
section I will discuss each of these points in greater detail.  
 7.4.1 DEMOGRAPHIC FEATURES 
Patients with TEA are younger than those with MCI and dementia who develop 
epileptic seizures. The mean age of onset of TEA is less than 62 years old. This 
is much younger than the average age of onset of epileptic seizures in our cohort, 
as well as global data for the onset of dementia (Qiu et al., 2009, Roberts and 
Knopman, 2013, Rizzi et al., 2014). However, there is an overlap between these 
two groups. 55/115 patients in our combined TIME cohort describe onset of 
seizures when aged 65 or older. Patients with the familial / early-onset form of 
AD do develop dementia at a younger age, typically in the 4th to 6th decades 
(Cabrejo et al., 2006, Rudzinski et al., 2008, Roberts and Knopman, 2013, Rizzi 
et al., 2014). Epileptic seizures are more common in this group of patients 
(Amatniek et al., 2006, Larner and Doran, 2009, Larner, 2011, Ryan et al., 2016). 
However, these patients represent only around 5% of patients with AD (Hugo and 
Ganguli, 2014, Ryan et al., 2016). Moreover, whist I did not find that patients with 
sporadic AD who developed epilepsy were younger than those that did not, this 
has been found in previous research (Amatniek et al., 2006, Sen et al., 2018). 
Consequently, whilst in our cohorts age of seizure onset is significantly higher in 
the dementia group than in TEA patients, it is clearly possible that seizures in 
patients with earlier onset forms of AD can commence at a far younger age, 
making it an uncertain discriminator of diagnosis on an individual level.  
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In our cohort, much the largest single cohort to date, TEA has been shown to be 
more common in males than females. This finding has been reproduced in 
several other case series (Lapenta et al., 2014, Mosbah et al., 2014, Ramanan 
et al., 2018). This is in contrast to epilepsy in dementia which I have shown to be 
equally common in both genders, and to Alzheimer’s disease in general, which is 
also equally prevalent in both males and females (Hugo and Ganguli, 2014, Rizzi 
et al., 2014, Frisoni et al., 2017). However, in our review of the recent TEA 
literature, the prevalence of TEA is not significantly different in males and females 
(Ioannidis et al., 2011, Burkholder et al., 2017, Lanzone et al., 2018).  
 7.4.2 COGNITIVE TEST PERFORMANCE 
Whilst patients with TEA report persistent impairment of memory it is clear from 
cognitive testing using ACE-III that performance is significantly better overall, and 
in all domains tested, when compared to patients who experience seizures as a 
feature of their dementia. Whilst patients with TEA can show impairment on 
standard memory measures, this rarely meets the diagnostic criteria for MCI or 
dementia, and in many cases only becomes apparent over longer delays of hours 
or days (Muhlert et al., 2010, Atherton et al., 2014, Elliott et al., 2014, Lanzone et 
al., 2018).  
I have also shown that patients with dementia and a clinical suspicion of epilepsy 
exhibit significant decline in cognitive function over the course of 12 months. This 
is in contrast to patients with TEA, for whom cognitive function remains 
substantially stable over many years (even as many as 20), with decline as a rule 
only in keeping with age-related changes (Savage et al., 2016, Savage et al., 
2019a).  
Our patients with MCI and dementia were significantly older at the time of 
cognitive testing than those with TEA. However, when compared with age-
matched controls, patients with MCI and dementia demonstrate poorer cognitive 
function than those with TEA. 
 7.4.3 PERFORMANCE ON NEUROPSYCHOLOGICAL TESTS 
On neuropsychological testing, patients with TEA perform better than patients 
with MCI, who in turn perform better than those with AD. Whilst the main focus of 
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this chapter is the differentiation of TEA from epilepsy in dementia, I have also 
been able to look at the performance on neuropsychological testing of patients 
with TEA and those with MCI. This issue is particularly relevant as a number of 
other studies have suggested that patients with MCI may exhibit ALF, or that ALF 
may be an early feature of Alzheimer’s dementia (Larrabee et al., 1993, Walsh et 
al., 2014, Geurts et al., 2015, Weston et al., 2018). As expected, differences 
between MCI and AD were highlighted after only short delays, and in the case of 
the RAVLT, by failure of many AD patients to reach the learning criteria. The 
differences between patients with TEA and MCI were more subtle and emerged 
over longer delays (after 30 mins in the case of the RAVLT and RCF).  
It has been shown in both phases of the TIME study that many patients with TEA 
perform in-line with a control population on neuropsychological tests over 
standard testing delays. In these studies, delays of either 3 or 7 days have been 
sufficient to draw out this difference. In this study, recall of patients with MCI and 
AD was not tested over these more extended delays as impaired performance on 
these tests was apparent over standard delays.   
 7.4.4 SEIZURE FEATURES 
When compared to patients with TEA, patients with epilepsy as a feature of their 
MCI or dementia are more likely to experience seizures involving loss of 
awareness, and less likely to report olfactory hallucinations or amnestic seizures 
on waking.   
Given that in both TEA and AD seizures have frequently been shown to originate 
from the temporal lobes (Liedorp et al., 2010, Vossel et al., 2013, Horvath et al., 
2017), it would be possible that the seizure semiology in both conditions would 
be similar. The main difficulty in comparing these two groups stems from the 
nature of memory impairment in dementia. For patients with TEA, a transient 
period of amnesia, during which other cognitive functions remain unaffected 
represents a clear change from their usual state. However, for patients with 
dementia, this period of amnesia is less easily recognised, as it occurs on top of 
baseline cognitive impairment. Moreover, even in earlier stages of AD, other 
cognitive domains are likely to have a degree of impairment. Our study aimed to 
obtain information from reliable informants, who knew the patients well, regarding 
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this feature, in order to elucidate information about periods of amnesia which 
represented a clear and unexpected increase from their previous level, which 
were transient in nature, and which, as in TEA occurred in a repeating and 
stereotyped manner.  
In TEA, 39% of patients report periods of unresponsiveness. This feature is more 
common in patients who experience seizures as a feature of their dementia 
(78%). However, unlike episodes of amnesia, which are harder to determine in 
these patients, episodes of unresponsiveness are clearer and more memorable, 
particularly in the minds of the carers and informants for these patients, who have 
to cope with the sequelae of these events. Nonetheless it is possible that the 
increased prevalence of generalised seizures and unresponsive episodes in this 
group represents an increased tendency for seizures to spread and become 
generalised when compared to patients with TEA, in whom seizures commonly 
remain confined to the temporal lobes (Horvath et al., 2016, Horvath et al., 2018).  
In our cohort of TEA patients, I have shown that olfactory hallucinations during 
the ictal period are common, occurring in 43% of these patients (Butler et al., 
2007). This proportion is significantly higher than in patients with epilepsy in 
dementia where only 2 out of 37 (5.4%) reported a similar phenomenon. 
However, it is not known whether this difference is a result of under-reporting in 
patients with MCI and dementia (as a result of the extensive memory impairments 
in these patients), or are a reflection of impaired olfaction. In AD, as in several 
other neurodegenerative diseases, patients experience a reduction in their sense 
of smell, even in the early stages (Kjelvik et al., 2014, Attems et al., 2015, 
Devanand, 2016). In is not known whether olfactory impairment has an impact on 
the prevalence of olfactory hallucinations in the setting of a temporal lobe epilepsy 
syndrome such as TEA.  
 7.4.4 NEURORADIOLOGICAL FINDINGS 
In our study a direct comparison of neuroradiological findings is impeded by 
differences in the imaging modalities which have been employed. Patients with 
TEA have largely been investigated with MR imaging, whereas the standard 
memory clinic protocol for patients with dementia is to undergo a CT scan. 
However, I have attempted to make a comparison regarding reported rates of 
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atrophy in these scans as well as comments regarding other abnormalities and 
vascular changes. Our cohorts have shown that MRI scans are typically normal 
in TEA, with structural abnormalities having been reported in only 4.6%. This is 
in contrast to patients with epilepsy in dementia where CT scans reported atrophy 
in 78.4%, small vessel disease in 62.2% and focal abnormalities in 16.2%. 
However, comparison between these two groups is made more difficult by the 
difference in age in these two cohorts. The increased incidence of small vessel 
ischaemia and generalised involutional changes in these patients may relate in 
part to their advanced age. Focal lesions were also uncommon in the PrESIDe 
epilepsy population, again suggesting that seizures in these patients are more 
likely to be related to the underlying pathology of their dementia rather than a 
single structural lesion. Several different mechanisms for epileptogenesis have 
been proposed for patients with Alzheimer’s disease. These include tau-mediated 
excitotoxicity (Decker et al., 2016), alterations in voltage-gated ion channels 
(Verret et al., 2012) and hyper-excitability related to structural alteration of 
dendrites (Siskova et al., 2014) - none of which would be expected to be identified 
on standard CT or even MR imaging.  
In addition to the above several studies have reported MRI findings in patients 
with AD, and in particular patients with dementia and epilepsy (Vemuri et al., 
2009, Madhavan et al., 2013, Vossel et al., 2017). These studies support the 
findings identified on CT in our patients, and further support the differences 
between these imaging investigations in patients with TEA and those with 
epilepsy in dementia. 
7.5 CONCLUSION 
Patients with TEA complain of memory impairment, occurring at the time of their 
epileptic seizures, but also between them. Prior to receiving their diagnosis, many 
are concerned that these symptoms may herald the onset of dementia (Table 
7.5). A diagnosis of dementia is even mistakenly made in some cases prior to the 
correct diagnosis of TEA being provided. However, patients with TEA typically 
perform normally on standard neuropsychological testing, with impairments only 
identified when recall is tested over longer delays (>24hrs), or on measures of 
autobiographical memory. In this they are in contrast with patients who develop 
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epileptic seizures as a feature of their dementia, in whom standard cognitive 
testing is abnormal.  
 
 
In favour of TEA 
In favour of epilepsy in 
dementia 
Age of onset Onset in 6-7th decades Onset in 7th-8th decades 
Seizure 
features 
Pure amnestic seizures; 
seizures  on waking; olfactory 
hallucinations 




Normal performance on 
standard cognitive measures 
Impaired performance on 
cognitive testing 
Neuro-imaging MRI normal 
Atrophic changes and/or small 
vessel ischaemic change on CT 
Prognosis 
Relative stability of cognitive 
function over time 
Clear cognitive decline over 
time 
Treatment 
Excellent response to anti-
epileptic medication 
Response to anti-epileptic 
medication unclear 
Gender 
More common in male sex (but 
see discussion) 
Equal gender distribution 
(Table 7.5: decision aid for diagnosing TEA vs epilepsy in dementia and MCI) 
 
In addition, the semiology of seizures described in these patients are also 
different, with patients with TEA being more likely to describe features such as 
olfactory hallucinations and more likely to experience seizures in which transient 
amnesia is the sole manifestation. However, it is clear that identifying a period of 
amnesia is complicated by the underlying cognitive impairment in patients with 
dementia, and that this same problem also makes it more difficult to obtain a clear 
history of seizure episodes from these patients. 
Cognitive decline over time in TEA is not increased when compared to an age-
matched population and this stands in contrast to patients with dementia who, by 
definition, exhibit a progressive cognitive decline.  
Seizures in TEA respond dramatically to low doses of anti-epileptic medication in 
the majority of patients. However, data on the use of these same medications in 
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dementia in terms of seizure control, side-effect profiles and cognitive decline are 
limited (Belcastro et al., 2007, Cumbo and Ligori, 2010). Only 1 randomised 
controlled trial in this group, comparing Levetiracetam, Lamotrigine and 
Phenobarbital, has been published (Cumbo and Ligori, 2010). This study found 
no significant differences in terms of efficacy, concluding that Levetiracetam was 
less likely to cause negative cognitive side effects than Lamotrigine, but that 
Lamotrigine was less likely to have a negative effect on mood. Both had a 
preferable side-effect profile in comparison to Phenobarbital.  A Cochrane review 
on this topic concluded that the quality of evidence in this field was very low and 
should therefore be interpreted with caution (Liu et al., 2016). Further 
investigation of these medications in patients with a diagnosis of dementia in 
whom epilepsy is suspected is warranted (Larner and Marson, 2011). It would be 
possible to further establish differences between patients with TEA and those 
with epilepsy occurring as a feature of their dementia with additional tests. In the 
PrESIDe study, no electroencephalography was performed. Recent studies have 
pointed towards several features which can be identified on EEG recordings 
which support a diagnosis of AD (Dauwels et al., 2010, Babiloni et al., 2018, 
Smailovic et al., 2018, Gaubert et al., 2019). Moreover, the identification of 
epileptiform features on prolonged EEG recordings of patients with AD and 
epilepsy may help to further differentiate these patients from those with TEA 
(Vossel et al., 2016, Horvath et al., 2017, Horvath et al., 2018). In order to robustly 
differentiate patients with TEA from those with epilepsy as a feature of their 
dementia it would be useful to perform blinded and standardised analysis of both 
groups of patients using MRI and EEG. This is a potential avenue for further 









CHAPTER EIGHT: GENERAL DISCUSSION AND CONCLUSIONS 
 
8.1 INTRODUCTION 
In this thesis, I have described the prevalence and clinical features of epileptic 
seizures occurring in patients with mild cognitive impairment (MCI) and dementia, 
based on a study of 144 patients from the Exeter memory clinic, and a control 
group of 80 participants: the Presentation of Epileptic Seizures in Dementia 
project (PrESIDe). I have then outlined the findings of a review of these patients, 
12-months after their initial assessment, in order to determine what implications 
epileptic seizures have for their prognosis. 
Whilst it has been recognised for over a century that epileptic seizures can occur 
in patients with Alzheimer’s disease (Stelzmann et al., 1995, Moller and Graeber, 
1998), the prevalence of seizures in these patients has continued to be disputed 
and remains unclear (Horvath et al., 2016). I have aimed to clarify this question, 
through the prism of the setting in which many patients with dementia are first 
diagnosed, the memory clinic. Despite longstanding views that seizures occur as 
a feature of advanced disease in these patients (Risse et al., 1990, Volicer et al., 
1995) more recent studies (Vossel et al., 2013, Sarkis et al., 2016) have argued 
that seizures can occur at an early stage of clinical disease, and in some patients 
even before memory symptoms present. This raises the possibility that seizures 
may not solely be a feature of advancing disease, but rather serve to accelerate 
the decline seen in these patients. I have investigated this question, and have 
shown that patients who experience epileptic seizures exhibit a more rapid 
decline in cognitive function than those in whom there is no clinical suspicion of 
epilepsy.  
Alongside the PrESIDe study, I have reported the largest described cohort of 
patients with transient epileptic amnesia (TEA): these patients present with 
prominent memory difficulties in the context of epilepsy, in contrast to the patients 
studied through PrESIDe, who develop epilepsy in the context of a primary 
memory disorder. Combining 65 patients who have not previously been reported, 
with the 50 patients described initially by The Impairment of Memory in Epilepsy 
(TIME) study (Butler et al., 2007), I have clarified the demographic characteristics, 
seizure features and interictal cognitive symptoms of this condition. TEA remains 
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an under-recognised and under-reported condition. By consolidating the clinical 
phenotype of TEA I aim to facilitate a more prompt diagnosis in these patients, 
enabling treatment at an early stage, which has been shown to lead to seizure 
cessation in most patients (Butler et al., 2007, Mosbah et al., 2014, Lanzone et 
al., 2018). I have also compared our own work in the TIME study with the larger 
body of TEA case reports and case series in order to further clarify the nature of 
this condition. 
Finally, I have compared these two groups of patients: those with TEA and those 
who experience epilepsy as a feature of their dementia, in order determine the 
similarities and differences between these two conditions. The aim of this 
comparison is to minimise diagnostic confusion. Both TEA and epilepsy in AD 
can be considered seizure disorders where epileptiform activity is most likely to 
arise from the temporal lobes (Lapenta et al., 2014, Ziyatdinova et al., 2016, 
Horvath et al., 2017, Lanzone et al., 2018). As a result, describing the ways in 
which these conditions are similar, as well as how they are different is of clear 
clinical value.  
Patients with TEA are often concerned that the persistent memory problems that 
they experience may be an early feature of dementia. I have also undertaken a 
comparison of patients with TEA to those with MCI and AD in order to clarify the 
differences in their performance on neuropsychological testing, and to highlight 
the differences in their clinical presentations. As our clinical understanding of 
memory grows, and in particular our recognition of accelerated long-term 
forgetting (ALF) as a clinical phenomenon develops (Larrabee et al., 1993, 
Gascoigne et al., 2012, Elliott et al., 2014, Walsh et al., 2014) - further clarifying 
the differences between TEA and neurodegenerative diseases is an important 
task. 
In this final chapter, I begin by summarising the principal findings of these studies 
in turn. I then highlight a number of outstanding questions and propose some 





8.2 PRINCIPAL FINDINGS  
 8.2.1 PREVALENCE AND CLINICAL FEATURES OF EPILEPTIC 
SEIZURES IN DEMENTIA AND MCI 
In chapter 3 I identified an increased prevalence of epileptic seizures (12.5% 
to 25.7%) when compared to a non-MCI or dementia control population 
(1.25%).  
The PrESIDe study was designed to investigate a number of unanswered 
questions about the prevalence and clinical features of epileptic seizures 
occurring in patients with dementia and MCI. 144 patients were recruited as part 
of this study, alongside a control group of 80 age- and gender- matched 
participants. The majority of participants (102/144) in the patient group were 
diagnosed with Alzheimer’s disease. Of the remainder, 20/144 were diagnosed 
with MCI, 16/144 with vascular dementia, 4/144 with Lewy Body dementia, 1/144 
with FTD and 1/144 with the posterior cortical atrophy (PCA) variant of AD. This 
patient group closely reflects the estimated prevalence of these conditions 
nationally (Onyike and Diehl-Schmid, 2013, Hugo and Ganguli, 2014, Rizzi et al., 
2014). Moreover, the design of the memory clinic from which they were recruited 
closely reflects the model for these services as outlined by the National Institute 
for Health and Care Excellence (Bayer et al., 1987, Jolley et al., 2006). I can 
therefore conclude that these figures are likely to be reflected in other memory 
clinics designed using this same framework across the UK. 
In our group I identified a clinical suspicion of epilepsy in 37/144 patients (25.7%). 
This figure comprises 18/144 (12.5%) in whom a diagnosis of epilepsy was felt to 
be probable (E-Pr), and 19/144 (13.2%) in whom it was felt to be possible (E-Po). 
In the remaining 107/144 (74.3%) there was no clinical evidence of epilepsy 
(NCEE). At the time of their initial PrESIDe assessment the patients in whom 
there was a clinical suspicion of epilepsy were not significantly different in terms 
of cognition, as measured using the Addenbrooke’s Cognitive Examination - 
Version III (ACE-III), from the NCEE group. However, a significant difference was 
identified on the informant completed questionnaires used for this study. On both 
the Cambridge Behavioural Inventory - Revised (CBI-R) and the Clinical 
Dementia Rating scale (CDR), patients in whom a clinical suspicion of epilepsy 
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was identified scored more highly, suggesting increased care requirements, 
reduced independence and greater overall cognitive change in these patients. 
A minority of patients with epilepsy (4/37, 10.8%) in our group described 
generalised tonic-clonic seizures. This is in keeping with other studies in this field 
which have shown this seizure semiology to be present in a minority only (Vossel 
et al., 2013). In PrESIDe, patients more commonly presented with focal seizure 
presentations: episodes of impaired awareness (28/37, 75.7%), periods of 
amnesia on waking (20/37, 54.1%), motor automatisms (11/37, 29.7%) and 
olfactory disturbance (1/37, 2.7%). These features suggest a combination of focal 
onset seizures with or without impaired awareness, and also some focal onset 
seizures with secondary generalisation. This is again in keeping with other 
research in this discipline which, using overnight or ambulatory EEG, have shown 
that patients with AD typically develop focal onset seizures, most commonly 
arising from the temporal lobes (Beagle et al., 2017, Horvath et al., 2017).  
 8.2.2 PROGNOSIS OF EPILEPTIC SEIZURES IN DEMENTIA AND MCI 
After a delay of 12 months, patients with MCI and dementia in whom a 
clinical suspicion of epilepsy is identified show a greater decline in 
cognition, across all domains, than patients in whom there is no evidence 
of seizures.  
In the second stage of PrESIDe, I followed-up patients from the original group 
and interviewed them once again, 12-months after their initial assessment. The 
aim of this phase of the study was to determine whether the presence of epileptic 
seizures had implications for the progression of cognitive impairment in these 
patients. Our goal was to identify what the prognostic value of identifying patients 
with epileptic seizures was and whether these changes would be apparent over 
a relatively short (12 month) interim period. I was able to interview 102/144 
(70.8%) of the original cohort. This follow-up cohort was not significantly different 
to the baseline group in terms of age, gender, dementia diagnosis, or cognitive 
performance. At this 12-month time point, patients in whom a diagnosis of 
epilepsy was suspected performed significantly worse on ACE-III cognitive 
testing, whilst maintaining a significant difference in both the CBI-R and the CDR 
informant questionnaires. This difference persisted, and in fact increased in size, 
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when the group was limited only to patients with AD. The findings of this study 
provide a significant contribution to our understanding of the role played by 
epileptic seizures in dementia, and suggest that identifying patients who have 
suffered from, or who are at risk of, epileptic seizures may be an important task 
for clinicians in the memory clinic setting. 6/37 patients in our seizure group 
(16.2%) experienced their first epileptic seizure after their first memory clinic 
appointment (and before their initial PrESIDe assessment). At present the 
memory clinic service in our region runs on a single appointment basis. Having 
received a diagnosis, patients are not routinely reviewed by the memory service. 
The emergence of epileptic seizures in these patients and their concomitant 
accelerated cognitive decline indicates that further follow-up in these patients 
might be of benefit, especially if it could be shown that treatment with anti-
epileptic medications could have a beneficial effect in this group. 
 8.2.3 EXPANDING THE CLINICAL SYNDROME OF TEA 
TEA is a condition with a mean age of onset of 61.7 years (26-77). In the 
TIME study, men were more commonly diagnosed than women (M:F = 
85:30).  
It is now almost 30 years since the term TEA was first developed (Kapur, 1993), 
over 21 years since the diagnostic criteria were developed (Zeman et al., 1998), 
and 12 years since the first TIME cohort of 50 patients was described (Butler et 
al., 2007). In this thesis I have outlined a further cohort of 65 patients and 
combined these two phases of the TIME study to present a cohort of 115 patients. 
This is the largest group of TEA patients that has been described and enables us 
to more fully enumerate the clinical features of this syndrome.  
Seizures in TEA typically last from 15 to 30 minutes and a seizure frequency 
of one per month is the most common presentation. 85% of patients 
experience attacks on waking and in 23.5% of cases amnesia is the sole 
seizure feature. A complete cessation of seizures following treatment with 
anti-epileptic medications is seen in 93% of patients.  
The ictal characteristics described by participants of both phases of the TIME 
study were highly consistent. This included olfactory hallucinations (42% in 
TIME1 and 45% in TIME2) and motor automatisms (36% in TIME1 and 45% in 
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TIME2). Generalised tonic-clonic seizures were seen in a minority of both cohorts 
(4% in TIME1 and 10.7% in TIME2). However, brief periods of unresponsiveness 
were more common in the TIME2 cohort (24% in TIME1, 50% in TIME2). 
Persistent interictal memory symptoms (autobiographical amnesia (AbA), 
ALF and topographical amnesia (TopA)) are common. MRI scanning is 
abnormal in only 4.6%; diagnostic epileptiform EEG abnormalities are 
identified in 30.6%.  
Since the first descriptions of TEA, it has been clear that in addition to the seizures 
themselves, patients commonly experience persistent interictal memory 
impairments. The reported rates of AbA, ALF and TopA were all significantly 
higher in TIME2 than they had been in TIME1. There was also an increase in the 
number of participants who had reported increased emotionality - noting they had 
been easily moved to tears since the onset of their seizures. 
I have also identified several consistent features between these two groups and 
the developing, international literature on this condition. There is a clear need for 
consistency in the identification of TEA cases, as well as a standard for the 
neuropsychological examination of these patients. In our review of the TEA 
literature I found that it was often difficult, if not impossible to directly compare 
different case studies and case series. However, from our review of the literature 
I have shown that TEA is a condition that most commonly presents in patients in 
the 6th and 7th decades (Lapenta et al., 2014, Mosbah et al., 2014, Lanzone et 
al., 2018). Whilst the case series of TEA have shown an increased prevalence in 
men, overall the literature indicates that there is no significant difference in 
prevalence between male and female patients. Patients with TEA typically have 
normal MRI scans, with no evidence of focal abnormalities (Mosbah et al., 2014, 
Ramanan et al., 2018), and EEG abnormalities were identified in >50% of 
patients in the literature (Lanzone et al., 2018, Ramanan et al., 2018).  
8.2.4 A COMPARISON OF TEA VS EPILEPSY IN DEMENTIA AND 
MCI 
Patients with TEA are younger than those who experience epileptic 
seizures as a feature of MCI or dementia. They perform significantly better 
on cognitive testing, and imaging investigations are more likely to be 
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normal. In TEA, transient amnesia is more likely to be the sole manifestation 
of a seizure; olfactory hallucination is also more commonly reported in this 
group. Patients who develop epileptic seizures as a feature of MCI or 
dementia are more likely to experience seizures where altered 
responsiveness / behavioural arrest is a feature. Patients with dementia 
demonstrate a clear progression of their cognitive decline, whereas those 
with TEA, exhibit stable cognitive performance, with decline in keeping with 
age related changes. 
TEA is an epilepsy syndrome in which patients describe both ictal and inter-ictal 
memory disturbances, suggesting temporal lobe involvement. Alzheimer’s 
disease is a dementia, the pathological features of which appear in the temporal 
lobes in their earliest stages, and during which, in some patients, epileptic 
seizures develop. It is clear that these two conditions overlap in several ways, 
and in this thesis I have been able to compare these two groups in order to better 
understand these intersections, as well as points in which they diverge, in order 
to expedite the diagnostic process in the clinical setting. This is important as a 
diagnosis of TEA is often delayed for several years from the onset of seizures 
(Butler et al., 2007), with many patients mistakenly being diagnosed with 
dementia, and many others fearing that this may be the cause of their memory 
impairment. Moreover, the under-recognition of epileptic seizures in dementia 
misses the opportunity to identify patients who are at a greater risk of a more 
accelerated cognitive decline and the chance to initiate antiepileptic treatment.  
I have also compared the neuropsychological performance of patients with TEA 
against those with MCI and a further group of patients with AD. In this comparison 
there were clear differences between all three groups. The performance of 
patients with AD was clearly worse than those with MCI and TEA on tests of 
verbal memory (RAVLT), visual memory (RCF) and on tests of executive function 
and attention (TMT and digit span). Patients with MCI and TEA performed 
similarly on digit span and TMT version B. However, on tests of memory, over a 
relatively short interval (RAVLT and RCF - both after a 30 minute delay), clear 





8.3 OUTSTANDING QUESTIONS AND SUGGESTIONS FOR FUTURE WORK 
 8.3.1 EPILEPTIC SEIZURES IN DEMENTIA AND MCI 
I have shown an increased prevalence of epileptic seizures in a population with 
MCI and dementia, when compared to an age-matched cognitively normal control 
population. However, there remain unanswered questions. What is the aetiology 
of seizures in this population? Do seizures occur as a result of a more rapidly 
progressive form of disease in which epilepsy is a feature, or are they a driver for 
an accelerated decline? These questions are not easily answered. There are 
several potential fields that could shed light on them. 
 8.3.1.1 GENETIC ANALYSIS 
If seizures occurring in these patients are a consequence of, rather than a cause 
of, a more rapidly progressive form of AD, it is possible that the causes of this 
more rapid decline are genetic. Looking, for example, at the proportion of patients 
with epilepsy who are APOE4 carriers might be one way of investigating this. A 
recent study has identified links between the prevalence of epilepsy and APOE 
status, indicating an increased risk with the APOE4 genotype (Liang et al., 2019). 
It would also be possible to look at the rate of other genetic and epigenetic factors, 
associated with a more rapid rate of decline in AD, and whether these have an 
increased prevalence in patients who demonstrate epileptic seizures. Over the 
last decade several large scale studies have increased our understanding of the 
polygenic nature of AD, and the variable effects and degrees of penetrance of 
these changes (Lambert et al., 2013, Chouraki and Seshadri, 2014, Karch and 
Goate, 2015). An understanding of how these relate to epilepsy in these 
populations may help to explain why some patients experience seizures and 
others do not. 
 8.3.1.2 NEUROIMAGING AND CEREBROSPINAL FLUID 
Developments in neuroimaging technologies have provided valuable insights in 
to the progression of cognitive impairment in dementia, and in particular in AD 
(Gordon et al., 2019, Krell-Roesch et al., 2016, Jack et al., 2018). These 
technologies could be used to better understand the phenomenon of epileptic 
seizures in dementia. A prospective study of patients with AD, both before and 
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following the onset of epileptic seizures could help to determine whether those 
who experience epileptic seizures are experiencing a form of disease which is 
more rapidly progressive from the outset, or whether the rate of decline only 
accelerates following the onset of seizures. A study of this nature could use both 
neuropsychological markers, as well as neuroradiology and CSF markers in order 
to measure these changes. In a recent study, it has been found that patients with 
AD who experience seizures have higher levels of CSF tau than those that do 
not (Tabuas-Pereira et al., 2019). An increase in this biomarker supports the idea 
that these patients are progressing more rapidly, that their disease is more 
destructive and associated with a more rapid accumulation of the pathological 
features of AD. However, from these data it remains unclear whether the seizures 
in these patients are a cause, or a result, of this more aggressive disease 
phenotype.  
 8.3.1.3 NEUROPHYSIOLOGY 
In order to answer these questions a better understanding of the causes and 
consequences of seizures in these populations is needed. This will require 
increases in our knowledge of these problems on a cellular level. Important work 
in the field of cellular electrophysiology is beginning to unpick the effects of 
seizures - both in terms of the spread of tau, and other mechanisms - such as 
microglial activation (Yang et al., 2010, Hiragi et al., 2018), in a way which may 
build the case for epileptic seizures as a key driver of cognitive decline in these 
patients. To a large extent, our understanding of epilepsy occurring in dementia 
is derived from mouse models of AD (Palop et al., 2007, Palop and Mucke, 2009). 
It is possible that these same models may help to provide further information 
regarding the pathophysiology of seizures. The J20 mouse model over-
expresses amyloid precursor protein (APP), leading to large increases in Aβ 
deposition (Mucke et al., 2000, Yang et al., 2010). Whilst we know that some 
mice with the J20 mutation experience seizures, we know that some don’t, and 
improvements in our understanding of the reasons for this are likely to impact on 
our understanding of disease in humans also. Studies in neurophysiology have 
also helped to increase our understanding of how pathology spreads in AD. 
Whilst some studies have suggested that the spread is primarily trans-neuronal, 
using a prion-like paradigm (Su et al., 1997, Lewis and Dickson, 2016, Cope et 
al., 2018), others have pointed towards trans-synaptic spread (Liu et al., 2012, 
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Pooler et al., 2013, Dujardin et al., 2014, Wang et al., 2017). In both models it 
has been shown that the spread of tau leads to increased neuronal excitability, 
potentially decreasing the seizure threshold (Brown et al., 2011, Booth et al., 
2016, Das et al., 2018).  
 8.3.1.4 EPIDEMIOLOGY 
Previous studies have shown that epileptic seizures are more common in younger 
AD patients, even when those with the most common genetic / familial causes of 
AD are excluded (Amatniek et al., 2006, Sherzai et al., 2014, Cook et al., 2015, 
Beagle et al., 2017). The reasons for this are unclear, although it is typically 
thought that patients with earlier onset of AD symptoms often do have a more 
rapidly progressive form of disease (Wattmo and Wallin, 2017, Tellechea et al., 
2018). It has also been shown that the incidence of a first seizure is higher in 
more advanced disease (Romanelli et al., 1990, Mendez et al., 1994). However, 
in the PrESIDe study I did not find a significant difference in the age of patients 
with seizures compared to those in whom there was no suspicion of epilepsy. It 
is possible that the reasons for this lie in the method of recruitment to our study. 
It could be that younger patients, especially those experiencing epileptic seizures 
are diagnosed with AD in a setting other than the memory clinic. It also possible 
that the brains of younger patients make them especially at risk of experiencing 
a more aggressive form of AD, and developing seizures. Studies have shown that 
the functional connectivity of neurons decreases with age (Cope et al., 2018, 
Franzmeier et al., 2019). Further studies have suggested that the 3 and 4 repeat 
helical tau fragments which are seen in AD have a particular affinity for the most 
connected ‘hub’ neurons, and the most metabolically active networks (Schultz et 
al., 2017, Cope et al., 2018, Maass et al., 2019). This suggests that it is this 
connectedness of younger brains that makes them most at risk of aggressive 
disease, and, as a result, of developing epileptic seizures. However, the role that 
seizures play in these patients is not clear: it is possible that they could be a result 
of rapid decline, or a driver of it. 
 8.3.1.5 ELECTROENCEPHALOGRAPHY 
In the PrESIDe study, a suspicion of epilepsy was based on the clinical history 
obtained from the participant and their informant. However, subclinical 
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epileptiform activity has been identified in several studies of dementia (Vossel et 
al., 2016, Horvath et al., 2017).  As a consequence EEG recording in our patients 
could further increase estimates of the prevalence of seizures in this population. 
Moreover, EEG recording could also help to support an epilepsy diagnosis where 
there remains clinical doubt (i.e. the E-Po population). However, several studies 
have shown that routine clinical EEG may fail detect epileptiform activity in these 
patients (Vossel et al., 2016, Horvath et al., 2017). It has been shown that 
prolonged EEG recording, recording during sleep and the addition of 
magnetencephalography increases the sensitivity of this investigation (Vossel et 
al., 2013, Horvath et al., 2016, Horvath et al., 2018). Ideally, therefore, the most 
useful study in this area would be one that combined 72 hour EEG recording, with 
MEG recording and that these data were analysed in a systematic way by 
someone blinded to the presence or absence of a clinical suspicion of epilepsy in 
these patients. Moreover, the clinical significance of subclinical epileptiform 
activity, particularly in patients with MCI and dementia remains unclear (So, 2010, 
Lv et al., 2013, Vossel et al., 2016). Further investigation is needed to determine 
how far we should go to look for these abnormalities and how aggressively they 
should be treated.   
 8.3.1.6 ROLE OF ANTI-EPILEPTIC MEDICATION 
I have not directly studied the important question of whether the use of anti-
epileptic medications in these patients has an effect on prognosis in patients who 
develop epileptic seizures as a feature of MCI or dementia. If epileptic seizures 
are a cause of a more accelerated decline in these patients it is possible that the 
use of anti-epileptic medications could have an impact on their rate of decline 
over time. Whilst many of our participants had not previously been identified as 
having had epileptic seizure, I also encountered patients in whom a suspicion of 
epilepsy was identified, but for whom no treatment was given. This was felt to 
relate to both an uncertain efficacy for this treatment in terms of the progression 
of their disease, but also, more commonly, a reluctance to prescribe these 
medications due to concerns regarding their possible cognitive side effects. 
Whilst there is extensive evidence that older anti-epileptic treatments (Phenytoin, 
Carbamazepine, Sodium Valproate, Phenobarbital) commonly have a negative 
impact on cognition (Vermeulen and Aldenkamp, 1995, Park and Kwon, 2008), 
the same is not true of newer treatments (Lamotrigine, Levetiracetam). There is 
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no robust evidence to support withholding treatment for epilepsy in these patients 
based on concerns about the potential for cognitive impairment. However, a 
recent study has identified an increased risk of pneumonia in patients with AD 
treated with anti-epileptic medications (Taipale et al., 2019), suggesting that 
these treatments are not risk free in this population. 
A recent Cochrane review on this topic found both Lamotrigine and Levetiracetam 
to be effective treatments for epileptic seizures in these patients (Liu et al., 2016). 
However, these findings were based on only one randomised controlled trial 
(Cumbo and Ligori, 2010). It concluded that, of these two, Levetiracetam was less 
likely to be associated with cognitive impairment, but more likely to be associated 
with a negative impact on mood, when compared to Lamotrigine. However, it is 
less clear whether either of these medications may reduce the progression of 
cognitive decline in these patients. There is experimental evidence, again largely 
from mouse models of AD, that Levetiracetam reduces the neuronal 
hyperexcitability seen in these patients (Sanchez et al., 2012, Musaeus et al., 
2017). Studies which have investigated the potential neuroprotective effects of 
Levetiracetam, and related drugs, have failed to find significant evidence for its 
use for this indication across all patients with MCI or dementia (Devi and Ohno, 
2013, Nygaard et al., 2015, Inaba et al., 2019), although further investigations are 
ongoing (Vossel, 2019). A randomised double-blind study, comparing the use of 
anti-epileptic medication, with placebo, in these patients could help to determine 
whether their use may be associated with a slower decline which would 
encourage their use in a clinical setting.  
 8.3.1.7 PROGNOSIS 
In the PrESIDe study, I have been able to conclude that patients who experience 
epileptic seizures as a feature of MCI or dementia, exhibit an accelerated rate of 
cognitive decline when compared to patients in whom there is no suspicion of 
epilepsy. However, the duration of follow-up in this study was limited to 12-
months after their baseline study assessment. It would be useful to have a study 
with a more prolonged period of follow-up that would enable us to assess whether 
this more rapid rate of decline was sustained. This is particularly true in terms of 
other markers of cognitive decline (increasing requirements for care support at 
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home, admission to nursing or residential homes and mortality) which may also 
be increased in these patients.   
8.3.2 TEA 
 8.3.2.1 ONGOING PROJECTS: PROGNOSIS &TREATMENT STUDIES 
It is over 12 years since the initial publication of the first TIME series of 50 patients 
with TEA (Butler et al., 2007). There is now extensive longitudinal follow-up 
information for this group of patients. Furthermore, 10/50 patients in this original 
cohort were initially seen as part of an earlier study, and for many patients more 
than 20 years of follow-up data are available (Savage et al., 2016). As a result of 
this there is a great opportunity to investigate and to describe the long term 
features of TEA; including the evolution of the interictal memory impairments 
described in this condition, the long term control of seizures, as well as other 
features - such as emotional lability, and olfactory dysfunction - which the TIME 
participants have described. Several studies have examined the long-term 
cognitive sequelae of temporal lobe epilepsy, and identified similar features in 
both neuropsychological and pathologic terms, with Alzheimer’s disease 
(Helmstaedter and Elger, 2009, Thom et al., 2011, Tai et al., 2016, Caciagli et al., 
2017). Investigating the long term effects of TEA, a form of temporal lobe epilepsy 
in which the main ictal feature is memory impairment, is particularly pertinent.  
I have shown that commonly prescribed anti-epileptic medications (including 
Levetiracetam, Lamotrigine, Sodium Valproate and Carbamazepine) effectively 
control seizures in patients with TEA. However, it is less clear whether these 
treatments also lead to an improvement of the interictal memory symptoms 
described by these patients. Such information is of great interest as, for many 
patients with TEA, these interictal features have a great impact on their day-to-
day lives. The TIME team has recently concluded a study investigating the effects 
of treatment on these features. Through neuropsychological testing of patients 
prior to starting treatment, and again 6 months later, once seizure control has 
been established, we are able to better understand the effects of anti-epileptic 
treatment. From meeting with TEA patients, as part of a TIME research day in 
2018, one of the key questions study participants and their families wanted to 
know about was which medication is best for them - in terms of seizure control, 
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side-effects and also for the interictal memory symptoms, and a study which best 
answers these questions is therefore very much desired by the TEA community. 
Whilst several studies have compared anti-epileptic treatments in this way 
(Ramsay et al., 2008, Brigo et al., 2016, Meador et al., 2016, Meschede et al., 
2018), none have focussed on the particular cognitive symptoms experienced by 
patients with TEA. Given that TEA is a relatively uncommon condition, such a 
study is unlikely to be possible. However the TIME treatment study will provide 
useful information and will enable us to advise our patients, as well as other 
clinicians, on the potential benefits of prompt anti-epileptic treatment. 
 8.3.2.2 TOPOGRAPHICAL MEMORY 
During the first phase of the TIME project it became clear that patients with TEA 
frequently experienced difficulties with navigation, this phenomenon was 
described in 36% of these patients. On further questioning, it became clear that 
this topographical memory impairment related to navigation of familiar routes and 
journeys and the recognition of landmarks. Patients frequently have a sense of 
unfamiliarity whilst on a journey that they have taken several times before. The 
role of the hippocampus in navigational tasks and spatial memory is well 
established (Maguire et al., 2000, Maguire et al., 2006, Hartley et al., 2007, 
Maguire et al., 2016). However, the precise nature and degree of impairment 
observed in patients with TEA has been difficult to evaluate on standard 
neuropsychological testing. More recently we have been incorporating the four 
mountains test to interrogate spatial memory (Chan et al., 2016). This test has 
been shown to identify patients with pre-Alzheimer’s disease, a group in whom 
topographical difficulties are common (Uc et al., 2004, Moodley et al., 2015, 
Wood et al., 2016), with high sensitivity. Several recent studies have utilised 
virtual reality technology to probe navigational impairments (Salgado-Pineda et 
al., 2016, Cogne et al., 2017, Sato et al., 2017), in the future it would be interesting 
to further examine the interictal topographical memory impairment seen in TEA 
using these strategies.  
 8.3.2.3 EMOTIONAL LABILITY 
26/65 (40%) patients with TEA in TIME2 reported that they had been aware of a 
change in their emotional responses since the onset of their epileptic seizures. In 
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most cases (24/65, 37%) this change took the form of being more easily moved 
to tears, in the setting of films, books or television programmes, but also to real 
life events. The physiology underlying this symptom is unclear, although it is 
thought to relate to changes to medial temporal lobe connections. A similar 
phenomenon has been described in the setting of autoimmune encephalitides, 
which also affect the mesial temporal lobes (Al-Diwani et al., 2019). However, in 
these patients a far broader range of neuropsychiatric presentations has been 
reported (Kayser et al., 2013, Gibson et al., 2019). In TIME, whilst this feature 
was often described by patients, it has not yet been investigated. Moreover, it has 
not consistently been reported by other case series or case reports of TEA. A 
systematic study of these altered emotional responses, involving both patient and 
informants, and relating these to underlying neurobiological mechanisms, would 
be of interest. Several tools have been designed to ask about mood (Bjelland et 
al., 2002, Smarr and Keefer, 2011). However, whilst depression is common in 
temporal lobe epilepsy (Orjuela-Rojas et al., 2015, Vrinda et al., 2017), patients 
with TEA do not consistently report changes in their mood - as evidenced by our 
own findings on HADS questionnaires.  
 8.3.2.4 ELECTROENCEPHALOGRAPHY IN TEA 
Several studies have shown that increased periods of EEG recording increase 
the detection rate for interictal epileptiform abnormalities (Werhahn et al., 2015, 
Burkholder et al., 2016), particularly when this recording is performed during 
sleep (Malow et al., 1999, Malow et al., 1998, Liu et al., 2018). In order to more 
thoroughly and systematically report on the EEG findings in these patients it 
would be useful to have prolonged EEG recordings, with periods of sleep and 
wakefulness, in all patients, and for these to be analysed in a consistent way (i.e. 
by a specific rater or raters), using validated criteria and more sophisticated 
techniques of network analysis. Moreover given that EEG analysis of deep medial 
temporal structures is often limited, other modalities may be useful - such as 
magnetoencephalography (MEG) (Baumgartner et al., 2000, Pizzo et al., 2019). 
Although even when this technology is available, the medial temporal lobe often 
still appears to be resistant to interrogation (Wennberg et al., 2011, Tamilia et al., 
2017). In addition, a more recent development, optically-pumped magnetometers 
(OPMs), have shown promise in facilitating mobile MEG equipment to be used 
whilst patients undergo tasks in a virtual reality environment (Boto et al., 2019, 
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Roberts et al., 2019). The use of new technologies, such as OPM-MEG, 
particularly in topographical and autobiographical memory tasks would be 
particularly useful in these patients. 
 8.3.2.5 GENETICS OF TEA 
Recent years have seen a rapid expansion in our understanding of the genetic 
basis of epilepsy. Several studies have identified genes which increase the risk 
of seizures and others which decrease it (Hildebrand et al., 2013, Moller et al., 
2015, Magalhaes et al., 2019). These studies have shown that there will be a 
genetic contribution to most epilepsies. An understanding of the genetics of what 
were previously thought of as ‘idiopathic’ epilepsies also has implications for the 
treatment of these conditions (Scheffer, 2014, Balestrini and Sisodiya, 2018).  At 
present no studies have looked at the genetic make-up of patients with TEA. 
However, the TIME team is increasingly collecting these data from participants in 
order to better understanding the pathophysiology of this condition and large 
scale, multi-centre studies of TEA will be required in order to establish a large 
enough cohort of patients to adequately power this research, and to reach 
definitive conclusions. 
 8.3.2.6 POST-MORTEM EXAMINATION OF TEA PATIENTS 
EEG and MRI have identified focal structural abnormalities in only a minority of 
patients with TEA (Mosbah et al., 2014, Lapenta et al., 2014, Lanzone et al., 
2018). However, to date there have been no post-mortem studies of patients with 
TEA.  Many participants of the TIME study have been kind enough to volunteer 
to donate their brains to science and research such as this will likely help us to 
better understand the underlying pathology of this condition and the long term 
effects of seizures in this population. Several post-mortem studies have shown 
an increased deposition of the pathological features of AD, Aβ and tau, in patients 
with epilepsy (Tai et al., 2016, Tai et al., 2018, Machado et al., 2019). A similar 
examination of the brains of patients with TEA would prove useful, in order to 
determine whether TIME project participants may also show these changes, and 
whether they correlate with the degree of memory impairment seen in these 
patients. Advances in tau-PET imaging, which have shown how well the 
deposition of tau correlates with cognitive decline in more classical tauopathies 
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(Ossenkoppele et al., 2016, Jack et al., 2018, Gordon et al., 2019), may lead to 
this also proving a useful tool in TEA.   
8.4 CONCLUSIONS 
As the global population ages there has been a commensurate increase in the 
prevalence of MCI and dementia. Whilst our understanding of these conditions 
increases, multiple drug trials have failed to identify disease modifying treatments 
for AD, or other forms of dementia (De Strooper, 2014, Cummings et al., 2019). 
Increasing evidence implicates early and mid-life modifiable risk factors in the 
development of AD, including diet, exercise and blood pressure (Lane et al., 
Lourida et al., 2019). Whilst the end product of all forms of dementia, regardless 
of risk factors, is progressive cognitive impairment, it is clear that the trajectory 
these patients take as their impairments accrue can vary significantly. For some 
patients the reasons for this will be genetic, for others lifestyle and environmental 
factors will play a significant role. For others the development of epileptic 
seizures, perhaps as a result of a dementia which was already more rapidly 
progressive, accelerates the decline further still. The utilisation of new and 
emerging technologies to better understand why this happens, and to further 
investigate the impact of anti-epileptic treatments in these patients may identify 
potential avenues for new treatments in these patients.  
In this thesis I have shown an increased prevalence of epilepsy in patients with 
MCI and dementia. I have shown that these patients are no different than those 
in whom there is no evidence of epilepsy in terms of age or cognitive function at 
the time of their diagnosis. I have gone on to show that cognitive decline occurs 
more rapidly in patients with epilepsy and that their level of disability is greater, 
as evidenced by CDR and CBI-R. Whilst the problem of epileptic seizures 
occurring in dementia is not a new one, it is attracting increasing interest. 
Research in this field is providing valuable insights into the pathophysiology of 
dementia. However, whether seizures are a cause of this accelerated decline, or 
a marker of it, requires further study.  
Patients with TEA report transient periods of impaired memory, but also 
persistent interictal memory difficulties. In these patients seizures frequently 
occur on waking, and on a monthly basis. Whilst amnesia is often the sole feature 
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of a seizure, in around 40% of patients, olfactory hallucinations are seen. Patients 
with TEA commonly report interictal memory features including AbA, ALF and 
TopA. In TIME2 these features were all present in >70% of cases. I have reported 
on the largest cohort of TEA patients to date, and in doing so have further 
consolidated the phenotype of this epilepsy syndrome.  
Finally, I have shown how patients with TEA are different from those who 
experience epileptic seizures as a feature of MCI or dementia. Patients with TEA 
are typically younger and demonstrate less impairment on neuropsychological 
testing. Patients who experience epileptic seizures as a feature of MCI or 
dementia are more likely to report episodes of loss of consciousness and less 
likely to experience seizures on waking or olfactory hallucinations. These patients 
show an accelerated rate of cognitive decline, and their increased impairments 
place an increased demand for care from those closest to them. The prompt 




















APPENDIX 1: PrESIDe DATA COLLECTION FORM 
Epileptic seizures in Dementia and MCI 
      
Interviewer    Interview_date    
Place_of_interview    Interview_time    
      
First_name    DOB    
Last_name    Age_when_seen    
Study_ID       
      
            
dementia details      
ACE-III       
date_seen_in_mem_clinic    Mem_clinic_Diagnosis    
Duration_of_symptoms    age_at_onset    
      
   Describe an example  
memory_difficulties        
 
YES/ NO 
      




     




     




     




     




     




     




     




   
      
example of memory problems 
         
       
        
        
        
          
      
Assessment_of_fluctuation       
One_day_fluctuation       
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    Study ID: 
    
Participant 
Initials: 
fluctuation  YES/ NO    
fluctuation_example          
         
        
          
Loss_of_consciousness  YES/NO    
LOC_example          
        
          
      
      
Seizure features.  Please indicate Y or N    
      
Generalised seizures  YES/ NO       
 
     
Partial seizures      
Automatisms  YES/ NO 
      
     
Olfactory / gustatory hallucinations  YES/ NO 
     
      
Dejavu  YES/ NO 
     
      
Period of altered responsiveness  YES/ NO 
     
      
amnesic episodes (on waking)  YES/ NO 
     
      
amnesic episodes (at other times)  YES/ NO 
     
      





   
Triggers  YES/ NO 
      
      
Aura  YES/ NO 
  
      
example seizure          
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Family history    Study ID: 
Fam_Hx_dementia  YES/ NO  
participant 
Initials: 
Fam_Hx-Epilepsy  YES/ NO    
Fam_Hx_other          
        
        
Current_medications          
         
         
Past-medical_Hx          
         
           
      
Birth_trauma / Anoxia  YES/ NO    
birth_trauma / anoxia_details 
         
         
      
Febrile_seizures  YES/ NO    
Febrile_seizures_details          
          
      
Significant_head_injury  YES/ NO    
Head_injury_details          
          
      
Intracranial_infection  YES/ NO    
Intracranial infection details          
          
      
Stroke   YES/NO       
Stroke_details           
            
      
EEG  YES/ NO    
EEG_result          
          
MRI  YES/ NO    
MRI _result          
        
CT  YES/NO       
CT_Results          





































































APPENDIX 4: CLINICAL DEMENTIA RATING SCALE 
Please tick the ONE statement from each of the six following categories that you feel best applies 
to the patient: 
1. Memory 
a. No memory loss or slight inconsistent forgetfulness 
b. Mild consistent forgetfulness; has partial recollection of recent events 
c. Moderate memory loss more marked for recent events; interferes with everyday 
activities 
d. Severe memory loss; only highly learned material retained, new memories rapidly lost 
e. Severe memory loss; only fragments of memory for past remain 
 
2. Orientation 
a. Fully orientated. Aware of time, day, month and place 
b. Some difficulty with time or day; oriented for familiar places and people, but not those 
which are unfamiliar 
c. Usually disorientated in time, often for place 
d. Severe disorientation except for own name 
 
3. Judgement, problem solving and decision making 
a. Solves everyday problems well; judgement good in relation to past performance 
b. Only doubtful impairment in solving problems 
c. Moderate difficulty in handling complex problems 
d. Severely impaired in handling problems 
e. Unable to make judgements or solve problems 
 
4. Job, shopping, handling money, paying bills 
a. Independent function at usual level in job, shopping, business and financial affairs, 
volunteer and social groups 
b. Only doubtful or mild impairment in these activities 
c. Unable to function independently at these activities though may still be engaged in 
some 
d. Unable to function independently outside the home 
 
5. Home (cooking, housework), hobbies, interests 
a. Normal 
b. Only slightly impaired 
c. Mild but definite impairment. Difficult chores and more complicated hobbies 
abandoned 
d. Simples chores preserved; very restricted interests 
e. No significant function in home 
 
6. Personal care (shaving, grooming, bathing) 
a. Fully capable of self-care 
b. Needs occasional prompting 
c. Requires assistance in dressing, washing, keeping personal effects 





APPENDIX 5: ILLUSTRATIVE CASES FROM THE PrESIDe STUDY 
 
Case 1 (EX125) Alzheimer’s Disease (NCEE) 
TF is an 86-year old retired telephonist and secretary. She was seen in the 
memory clinic in March 2017 with a history of progressive memory impairment 
which she described as ‘not very bad’. However, her husband reported that he 
had become increasingly concerned about her, and that he could no longer rely 
on her short term memory. He described that if she were to answer the phone 
and to take a message, by the time the conversation was over, the message 
would have been forgotten. He felt that it was now up to him to keep track of 
appointments, household finances and much of the cooking at home. TF herself 
reported some intermittent word-finding difficulties, and in particular recognised 
that she would have trouble remembering the names of other couples who they 
would see each week at their square-dancing classes.  
There had been no change in behaviour, no history of hallucinations, and both 
TF and her husband felt that her memory impairment was relatively consistent 
from one day to the next. TF denied any change in her mood although her 
husband felt that she could be a bit low sometimes and on other occasions might 
be a bit short tempered, particularly when she felt that he doubted her memory. 
At her memory clinic appointment in February 2017 her ACE-III score was 77/100 
(attention 17/18, memory 12/26, fluency 8/14, language 25/26, visuospatial 
15/16).  A CT head scan performed at that time showed evidence of mild small 
vessel disease and a degree of atrophic change a little in excess of what would 
be expected for her age. 
At the time of her first PrESIDe visit (August 2017) her ACE-III score had 
decreased to 68/100 (attention 13/18. Memory 13/26, fluency 6/14, language 
21/26, visuospatial 15/16). Her CDR-SOB score was 4.0 and her CBI-R score 37, 
both of which pointed in particular to problems with memory, and in the case of 
the CDR to definite impairments in home, hobbies and interests. 
At her second visit (August 2018) there had been some further deterioration, 
although TF herself was not convinced - ‘my husband thinks I have got worse’. 
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The ACE-III had decreased to 66/100 (attention 12/18, memory 12/26, fluency 
6/14, language 22/26, visuospatial 14/16). 
TF was diagnosed with Alzheimer’s disease at her memory clinic appointment 
and this was confirmed using diagnostic criteria at her initial PrESIDe 
assessment. 
 
Case 2 (EX132) Vascular Dementia (NCEE) 
MP is a 79-year old farmer’s wife, who was seen in the memory clinic in April 
2017 alongside her son. He described a 12-month history of a step-wise decline 
in cognitive function, which had become significantly worse around the time of a 
fall during the previous November. At that time she was admitted to hospital and 
found to have atrial fibrillation. MP admitted to a ‘bad memory’ but felt that she 
was coping OK at home by herself. Her son however, had numerous concerns: 
she could get lost when out of the house, she struggled to learn new technology, 
such as the television, and could misplace things around the house. She had 
become increasingly reliant on her family to support her in her activities of daily 
living - such as preparing meals and cleaning the house. 
Whilst she denied any change in behaviour, MP’s son had felt that she was less 
motivated and had become a bit apathetic about many things. There was no 
history of psychosis / hallucinations and no concerns about low mood.  
At her memory clinic appointment her ACE-III score was 69/100 (attention 14/18, 
memory 15/26, fluency 2/14, language 23/26, visuospatial 15/16). Of particular 
note, both category and letter fluency were slow she found it difficult to sustain 
attention on these tasks. Free recall was poor, but improved significantly with 
prompting. A CT head scan was performed and showed diffuse small vessel 
disease, which was more prominent in the posterior frontal lobe. An established 
lacunar infarct was seen in the right basal ganglia. 
At the time of her first PrESIDe (September 2017) assessment her ACE-III score 
had dropped to 57/100 (attention 13/18, memory 12/26, fluency 1/14, language 
21/26, visuospatial 10/16). This dropped further to 55/100 at her 12-month follow-
up visit in September 2018 (attention 12/18, memory 12/26, fluency 0/14, 
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language 21/26, visuospatial 10/16). On the informant completed questionnaires 
there was evidence of multi-domain impairment affecting scores for memory, 
orientation, judgement, and home hobbies and interests on the CDR. 
At her initial memory clinic appointment MP was diagnosed with vascular 
dementia, although it was recognised that Alzheimer’s disease could not be 
excluded. The vascular dementia diagnosis was confirmed using diagnostic 
criteria at the time of her initial PrESIDe assessment. 
 
Case 3 (EX100) Dementia with Lewy Bodies (NCEE) 
BW is an 80-year old retired farmer. He was seen in the memory clinic in 
December 2016 alongside his wife and daughter-in-law. They reported a 3-year 
history of increasing concern about his memory. More recently they had also 
been aware of worsening slowness of his movements and a right upper-limb 
tremor which was present at rest. It was felt that his memory symptoms could 
fluctuate from one day to the next.  
BW himself had good insight into his memory problems. He recognised that he 
would forget recent conversations and have trouble remembering appointments 
or when medications were due. He could misplace items around the house and 
needed more help with keeping track of household finances. He did have some 
problems with word-finding and remembering the names of people and things. 
There was no history of becoming lost in unfamiliar surroundings, his mood was 
good and he was completely independent with personal care. 
At his memory clinic appointment (December 2016) his ACE-III score was 58/100 
(attention 11/18, memory 15/26, fluency 3/14, language 21/26, visuospatial 8/16). 
A CT head scan performed at that appointment showed some very mild 
periventricular and basal ganglia low attenuation in keeping with minimal small 
vessel disease, and some generalised involutional changes which were felt to be 
consistent with the patient’s age. 
At his initial PrESIDe visit (June 2017) the ACE-III score was 63 (attention 13/18, 
memory 17/26, fluency 4/14, language 19/26, visuospatial 10/16). The CDR-SOB 
score was 5.0 and the CBI-R total score was 56. These informant completed 
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questionnaires pointed especially to difficulties with memory and orientation, 
everyday skills, sleep and motivation. At the time of this assessment BW’s wife 
also reported two episodes of visual hallucination which had occurred in the 
preceding months. 
The ACE-III score at the 2nd PrESIDe (June 2018) visit was 61 (attention 13/18, 
memory 10/26, fluency 5/14. Language 23/26, visuospatial 10/16). Whilst BW felt 
that his memory had been fairly stable, his wife was clear that she had had to 
take over more and more of the household jobs, and was now completely in 
charge of household finances. She was no longer comfortable with him being out 
of the house by himself and some further episodes of hallucination had occurred. 
At the time of his memory clinic appointment a diagnosis of dementia with Lewy 
Bodies was suspected and this was confirmed using formal criteria at the time of 
his initial PrESIDe assessment. 
 
Case 4 (EX023) Frontotemporal Dementia (NCEE) 
IG is a 68-year old retired IT project manager. He was seen in the memory clinic 
in June 2016 alongside his wife. They reported that a three to four year history of 
increasing concerns about language, memory and in particular behavioural 
change. He was becoming increasingly frustrated by his difficulties in expressing 
himself and his needs. Having always been calm and mild-mannered, his family 
had become concerned that he was now short-tempered and verbally aggressive. 
He never previously used to swear, but now did so often. He was aware of 
difficulties with short term memory, and struggled with tasks that involved 
planning and sequencing - a significant change for someone whose career had 
demanded great proficiency on this front.  
His ACE-III score at that time was 79/100 (attention 18/18, memory 16/26, fluency 
7/14, language 23/26. Visuospatial 15/16). A CT head scan reported on marked 
atrophy of the left temporal lobe, although the right was relatively normal, and 
notable thinning of the gyri in both frontal lobes particularly on the left.  
At his initial PrESIDe assessment (December 2016) he reported worsening 
language difficulties - getting ‘me’ and ‘you’ mixed-up and using increasingly short 
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sentences with frequent grammatical errors. On that occasion his ACE-III score 
was 75/100 (attention 18/18, language 18/26, fluency 4/14, language 20/26, 
visuospatial 15/16). The CBI-R total score of 51 and a CDR-SOB of 3.5. These 
questionnaires highlighted problems with judgement, changes in behaviour and 
difficulties with naming objects and things.   
By the time of his 12-month follow-up assessment (January 2018) this score had 
dropped further to 55/100 (attention 14/18, memory 11/26, fluency 1/14, language 
16/26, visuospatial 13/16). The questionnaires completed by IG’s wife reflected 
this decline (CDR-SOB 7.5, CBI-R 73), in particular highlighting significant 
problems with judgement, writing letters, using the telephone and electrical 
appliances and an increased predilection for sweet foods. 
At his initial memory clinic appointment a diagnosis of frontotemporal dementia 
was made. In particular, the clinical features reported by IG and described by his 
wife are in keeping with the behavioural variant of this condition. 
 
Case 5 (EX041) Posterior Cortical Atrophy Variant of Alzheimer’s Disease 
(NCEE) 
JB is 64-year old retired accountant. She initially presented to the memory clinic 
in July 2015 but no diagnosis was made at that time. She was seen again in 
February 2016, on which occasion a diagnosis of mild Alzheimer’s disease was 
made. In August 2016 she was seen for a third time. At that appointment a 
diagnosis of the posterior cortical atrophy variant of Alzheimer’s disease was 
made.  
In 2015 she described a 2-year history of gradual cognitive decline. She reported 
struggling with complex tasks, to a degree that had prompted her early retirement. 
However, she recognised that her problems were often not noticeable to others. 
Her ACE-III score at that appointment was 74/100 and a CT head scan showed 
only mild involutional changes. The findings on a subsequent MRI scan were in 
keeping with a diagnosis of PCA. 
At the time of her initial PrESIDe assessment in February 2017 (4 years after the 
reported onset of symptoms) she reported a range of cognitive impairments. By 
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her own admission, her memory was bad and getting worse. She struggled with 
complex sequences of tasks such as cooking or navigating routes. She had been 
attending French lessons and although she had always been academically very 
successful she now found herself unable to keep up with the rest of the class. 
Despite this she felt that she was still good with names and had good verbal 
communication. She reported that she had trouble telling the time from a clock, 
might struggle to see what was right in front of her and could fail to notice objects. 
Climbing stairs had become difficult, because she struggled to walk on uneven 
surfaces. On a recent holiday on a river cruise she had great difficulty in 
navigating the boat and on several occasions got lost finding her way back to the 
cabin. 
At that time her ACE-III score was 72 (attention 13/18, memory 17/26, fluency 
10/14, language 26/26, visuospatial 6/16). On the informant questionnaires the 
CDR-SOB was 4.0 and the total CBI-R score was 44. These questionnaires 
highlighted problems completing everyday tasks such as writing letters and using 
a telephone and a moderate difficulty in handling complex problems. 
The ACE-III score had fallen further to 65/100 after 12-months (February 2018) 
(attention 13/18, memory 20/26, fluency 5/14, language 26/26, visuospatial 1/16). 
The informant questionnaires drew attention to the same problems but also 
reflected JB’s own frustrations at her difficulties in self-care (including grooming 
and dressing) some mild problems in feeding herself, and worsening of her 
previously reported low mood. At that appointment the CDR-SOB had increased 
to 7.5 and the CBI-R to 51. 
The pattern of cognitive impairments seen in JB - relatively preserved memory in 
the face of dramatic decline in visuospatial skills - alerted clinicians to the 
diagnosis of posterior cortical atrophy which was confirmed using established 
diagnostic criteria.  
 
Case 6 (EX067) Mild Cognitive Impairment (NCEE) 
DM is an 82-year old retired tax inspector. He presented to the memory clinic in 
June 2016 with a 2 year history of memory problems. He reported that he could 
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lose things now and again and his wife had noticed difficulty with remembering 
the names of people, and an occasional wrong turn when driving. There was 
however, no concern regarding the safety of his driving. DM felt that he was 
slower at processing information than he was before although he was still able to 
manage household finances without any assistance. 
There were no concerns about behavioural or mood change, no problems with 
sleep and no evidence of psychosis or hallucinations of any form. At this 
appointment the ACE-III score was 92/100 (attention 18/18, memory 23/26, 
fluency 9/14, language 26/26, visuospatial 16/16). A CT head scan showed some 
age-related involutional changes but no significant abnormalities.  
At his first PrESIDe assessment (March 2017), DM reported that his memory was 
working at ‘about 50%’ and ‘getting gradually worse’.  He denied ever getting lost, 
but was becoming increasingly reliant on writing down plans and appointments 
on a calendar in order to avoid forgetting them. His past medical history included 
atrial fibrillation, for which he takes warfarin. He reported a family history of 
dementia (Alzheimer’s disease in his eldest sister). On that occasion his ACE-III 
score was 88/100 (attention 17/18, memory 22/26, fluency 8/14, language 25/26, 
visuospatial 16/16). The CDR-SOB was 2.0 and the CBI-R total score was 31. 
These questionnaires pointed towards difficulties in remembering names of 
people and objects and occasional problems with losing or misplacing things.  
As he had been diagnosed with MCI at his memory clinic appointment, DM 
underwent further neuropsychological testing. On the Rey Auditory Verbal 
Learning Task (RAVLT) he reached the 80% criteria (12/15 words) after 9 trials, 
recalled 5 after interference and only 3 after 30 minutes. The Rey Complex Figure 
copy score was 32/36 but fell to 10/36 after 30 minutes. The time on the Trail 
Making Test A was 68 seconds, TMT B 189 seconds. These tests identified a 
degree of impairment in keeping with the MCI diagnosis, being greater than 1 
standard deviation below age and education standardised normative data. 
At his 12-month follow-up assessment (March 2018), the ACE-III score was 
75/100 (attention 14/18, memory 14/26, fluency 7/14, language 26/26, 
visuospatial 14/16). This decline was also echoed by the CDR-SOB (6.5) and 
CBI-R (56) where difficulties in remembering what day it is, repetition, poor day-
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to-day memory and concentration had all increased. DM himself denied 
significant decline in his memory function but his wife was aware that his memory 
problems had begun to affect what he could do and what he could not do. She 
had taken over management of the household finances and was no longer happy 
to let him go to the shops by himself, as when he did he would invariably forget 
certain items.  
Given the decline in his cognitive and everyday functioning between the time of 
his initial memory clinic appointment and his 2nd PrESIDe assessment it was 
clear, based on diagnostic criteria, that DM had converted from MCI to AD over 
the course of the preceding 2 years.  
 
Case 7 (EX001) Epilepsy Probable 1 (AD) 
NM is a 88-year old who was seen alongside her daughter in the memory clinic 
in April 2016 with a 2-3 year history of progressive memory impairment. Whilst 
NM herself did not feel she had a significant problem, her daughter described a 
number of short term memory difficulties which had been becoming increasingly 
hard to miss. She was forgetting conversations and had trouble remembering 
recent events. She was now completely reliant on her daughter to remember 
appointments. There were reports of some word finding difficulties and 
navigational difficulties.  
NM’s daughter also reported occasional episodes of poor memory which is much 
worse than at other times. These often occur alongside brief periods of 
unresponsiveness where she appears to ‘disappear off somewhere’ and on some 
occasions makes repetitive movements in the arms and hands. Both her son and 
daughter had witnessed her making repeat picking movements with her right 
hand over the blanket on her lap in an almost trance-like state. These episodes 
were followed by a period of fatigue and increased confusion. Given this clear 
story of repeated, witnessed episodes which were suggestive non-convulsive 
seizures NM was characterised in to the epilepsy probable group. Her cognitive 
impairment met diagnostic criteria for Alzheimer’s disease. 
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At her memory clinic appointment NM scored 78/100 on the ACE-III examination 
(attention 18/18, memory 18/26, fluency 6/14, language 20/26, visuospatial 
16/16). By the time of her initial PrESIDe appointment (November 2016) this had 
decreased to 71/100 (attention 16/18, memory 15/26, fluency 8/14. Language 
17/26, visuospatial 15/16). NM’s daughter reported ongoing episodes of being 
vacant, but these had decreased in frequency following the initiation of 
Levetiracetam treatment (current dose 500mg twice daily). The CDR-SOB was 
8.0 and the CBI-R 34. The questionnaires highlighted problems with poor day-to-
day memory and becoming confused in unfamiliar surroundings.  
At the 12-month follow-up assessment (December 2017) the ACE-III score had 
further declined to 63/100 (attention 16/18, memory 15/26, fluency 6/14, 
language 11/26, visuospatial 15/16). This was associated with relative stability in 
the CDR-SOB (7.5) and CBI-R (39). The CDR highlighted that NM was unable to 
make judgements or solve problems, and needed occasional prompting with 
personal care. NM now rarely left the house, except to go to bingo, and showed 
little interest in doing anything outside of her usual routine. 
 
Case 8 (EX084) Epilepsy Probable 2 (MCI-AD) 
KK is 75-year old retired naval officer who was seen in the memory clinic in July 
2016 with a 1-2 year history of memory concerns. He was aware that he was 
forgetting details of conversations and could forget the names of people. He was 
increasingly reliant on writing things down to help him keep track of what was 
going on, and on a couple of occasions he failed to remember places he had 
visited before. 
In March 2016 he had a single, witnessed, generalised tonic-clonic seizure. 
Following that seizure an MRI had been performed, which did not show any 
significant abnormalities. At the time of his memory clinic appointment his ACE-
III score was 84/100 (attention 17/18, memory 17/26, fluency 8/14, language 
26/26, visuospatial 16/16). Whilst the cognitive testing highlighted memory 
impairments, it was not felt that these had progressed to a degree that was 
limiting KK’s ability to perform his day-to-day activities and consequently a 
diagnosis of MCI was made.  
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At the time of his initial PrESIDe appointment (April 2017) KK felt that there had 
been further cognitive decline. The ACE-III score was now 83/100 (attention 
17/18, memory 18/26, fluency 9/16, language 24/26, visuospatial 15/16). The 
CDR-SOB score was 4.0 and the CBI-R score 51.  The CDR highlighted 
moderate memory loss which interferes with everyday activities. Given the 
memory clinic diagnosis of MCI, further neuropsychological testing was 
performed. On RAVLT he reached the 80% criteria after 10 trials, recalled 4 after 
interference and only 3 after 30 minutes. The RCF copy score was 34/36, and fell 
to 18.5 after 30 minutes. TMT A was 62 seconds, TMT B 108 seconds. These 
memory tests highlight a cognitive impairment greater than 1.5 SD below age-
matched normative data and alongside the memory impairment which was felt to 
be limiting daily activities KK met diagnostic criteria for a diagnosis of AD. 
Between his memory clinic appointment and his baseline PrESIDe assessment 
KK had experienced no further tonic-clonic seizures but did report episodes of 
having a ‘muzzy’ head. He could seem vacant, and on occasion confused, take 
a long time to answer simple questions and struggling more than normal to 
remember information he was told. He would often sleep for several hours after 
these events. Given these episodes and the previous generalised seizure, KK 
was diagnosed with epilepsy and started on Levetiracetam (current dose 750mg 
twice daily). 
By the time of his 12-month follow-up assessment (April 2018), the ACE-III score 
had further decreased to 72/100 (attention 13/18, memory 16/26, fluency 4/15, 
language 23/26, visuospatial 16/16). The CDR-SOB was 4.0 and the CBI-R 54, 
pointing towards moderate difficulty in handling complex problems, poor day-to-
day memory constantly and frequently misplacing things around the house. 
Whilst there had been no further tonic-clonic seizures there had been further 
‘strange’ episodes of acutely increased confusion, where KK could seem 
‘puzzled’. On one occasion he went to let the dog out in to the garden, having 
completely forgotten that the dog had died almost 12-months ago, which was a 
mistake that he had not made before, or since.  
Given these witnessed, recurrent episodes of abnormal behaviour and a previous 




Case 9 (EX005) Epilepsy Possible 1 (MCI-AD) 
FM is an 84-year old retired builder. He was seen in the memory clinic, alongside 
his wife in August 2016. They had previously been seen there 2 years previously, 
at which point a diagnosis of MCI had been made. In 2016 FM reported that he 
had problems with forgetting less familiar names and faces, and short-term 
memory loss. It was felt that, despite these problems, FM remained independent 
and had no significant loss in efficiency or ability when completing everyday 
tasks.  At that time he was still driving. His ACE-III score from the 2016 
appointment was 79/100 (attention 18/18, memory 22/26, fluency 7/14, language 
17/26, visuospatial 15/16). A CT head scan showed mild small vessel disease, 
as it had done in 2014. Overall there had been no significant functional decline 
since 2014 and the diagnosis of MCI was maintained.  
In January 2017, FM underwent his initial PrESIDe assessment. He again 
reported that his short-term memory was ‘not so good’ and that he might forget 
the names of people he didn’t know so well. He denied any problems with route-
finding or navigation, and there was no history of mood or behaviour change, 
hallucination or psychosis. On further questioning FM’s wife reported a single 
episode of unresponsiveness 6 months previously (between the memory clinic 
appointment and PrESIDe assessment). This episode lasted less than a minute, 
and was not convincingly followed by a period of confusion. There was no tongue-
biting or urinary incontinence. On one further occasion FM’s son had found him 
at home and reported that he was ‘dazed’ and ‘a bit out of sorts’ but no further 
information was available. At the time of his PrESIDe assessment FM’s ACE-III 
score was 83/100 (attention 18/18, memory 24/26, fluency 6/14, language 20/26, 
visuospatial 15/16). The CDR-SOB score was 0.5 and the CBI-R 27. As a 
diagnosis of MCI was made at the memory clinic, further neuropsychological 
testing was performed.  On RAVLT he reached the 80% criteria after 9 trials, 
recalled 5 after interference and only 2 after 30 minutes. The RCF copy score 
was 33/36, and fell to 10/36 after 30 minutes. TMT A was 51.67 seconds, TMT B 
136 seconds. Although the ACE-III score had not deteriorated, the performance 
on these tests, alongside evidence of functional impairment on the history, meant 
that the diagnostic criteria for dementia were met at this time, changing the 
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diagnosis from MCI to AD. Given the single episode of witnessed 
unresponsiveness, and a further unclear episode of out-of-character confusion 
FM was classified into the epilepsy possible group. 
At the time of the 12-month follow-up appointment (January 2018) there had been 
a decline in the ACE-III score to 70 (attention 17/18, memory 14/26, fluency 6/14, 
language 17/26, visuospatial 16/16). This change was accompanied by some 
increased concerns reported by FM’s wife, of worsening short-term memory, poor 
recall of recent conversations, and some navigational problems. FM had now 
stopped driving. At this time the CDR-SOB was 2.5 and the CBI-R score was 38. 
These questionnaires identified an increased frequency in forgetting the names 
of familiar people, and poor concentration when reading or watching television. 
However, no further episodes of unresponsiveness were reported.  
 
Case 10 (EX117) Epilepsy Possible 2 (AD) 
SR, an 81-year old retired manager of an engineering company was seen 
alongside his wife in the memory clinic in February 2017. She reported a 1-year 
history of progressive memory problems affecting conversations, names, and 
misplacing items. His ACE-III score at that time was 70/100 (attention 16/18, 
memory 17/26, fluency 3/14, language 23/26, visuospatial 11/16). A CT head 
scan was performed and this reported age-related involutional changes and 
minimal small vessel ischaemic changes. Given the degree of memory 
impairment which was reported and the effect of this on SR’s daily function, a 
diagnosis of AD was made and Donepezil was initiated. 
By the time of the initial PrESIDe assessment (August 2017), there had been 
clear deterioration in his cognitive function, such that the ACE-III score had 
decreased to 60/100 (attention 15/18, memory 12/26, fluency 2/14, language 
21/26, visuospatial 10/16). He met diagnostic criteria for AD. The CDR-SOB was 
2.0 and the CBI-R score 27, describing mild consistent forgetfulness, moderate 
difficulty handling complex problems and losing or misplacing things on a roughly 
daily basis. SR’s wife reported a few occasions where SR may appear briefly ‘out 
of it’. At these times his head might drop and then afterwards he picks it up and 
carries on as he was before. These episodes remained unexplained and 
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investigations were ongoing to elucidate a possible cause. Unfortunately SR did 
not tolerate his Donepezil medication and this had therefore been stopped.  
When he was reviewed in August 2018 for his 12-month follow-up PrESIDe 
assessment, the ACE-III score had decreased to 50/100 (attention 7/18, memory 
10/26, fluency 2/14, language 19/26, visuospatial 12/16). The CDR-SOB was 7.0 
and the CBI-R score was 68. These questionnaires now reported that SR was 
usually disorientated in time, often for place, was severely impaired in handling 
problems and had moderate memory loss. He was now reliant on his wife for his 
medication, appointments and all meals. Whilst a year ago she had been happy 
to let him walk in to the village by himself to buy a paper each day, she now made 
sure this was delivered to the house due to her concerns about his memory. 
SR had had further brief vacant episodes, and his wife was concerned that on a 
couple of occasions he had seemed more confused than others, although the 
cause of these episodes remained incompletely understood. Whilst these 
episodes were repeated and stereotyped, it was not clear that they represented 















APPENDIX 6: TIME DATA COLLECTION FORM 
TIME Background History 
Interviewer    Interview_date    
Place_of_interview       
      
First_name    DOB    
Last_name    Age_first_seen    
      
Witness    First_attack_date    
Initial_diagnosis    Last_attack_date    
Initial_diagnosis_date    Age_onset    
TEA_Diagnosis_date    First_to_last_attack    
Duration_epilepsy_months    (months)   
      
Total_number_attacks    Duration 1st attack    
Yearly_frequency_attacks       
Duration_of_attacks       
      
Seizure features.  Please indicate Y or N    
Attacks_on_waking  YES/ NO Description of other seizure types 
Triggers  YES/ NO       
Aura  YES/ NO      
Pure_amnesic_attacks  YES/ NO      
Automatisms  YES/ NO      
Olfactory_gustatory_hallucinations  YES/ NO      
Decreased_sense_smell  YES/ NO      
Dejavu  YES/ NO      
Period_of_unresponsiveness  YES/ NO      
Other_seizure_types  YES/ NO      
Repetitive_questioning  YES/ NO      
RNBATR  YES/ NO       
       
Seizure description      
Degree_of_Ictal_AA          
Degree_of_Ictal_RA          
Postictal_state          
        
          
Subjective_during_attack          
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Witness_during_attack          
        
          
      
Seizure details      
Attack_example1          
        
        
        
        
          
      
Attack_example2          
        
        
        
        
        
          
      
Attack_example3          
        
        
        
        
        
          
      
Response_to_treatment  YES/ NO    
Current_AEDs          
        
          
Previous_AEDs          
        
          
Current_other_medication          
        
          
      
EEG  YES/ NO    
EEG_result          
          
MRI  YES/ NO    
MRI _result          
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Antibodies_test  YES/ NO    
Antibodies_result          







Memory Disturbances      
Accelerated_forgetting  YES/ NO    
ALF_details          
        
        
          
Autobiographical_RA  YES/ NO Extent_autobiog_RA    
RA_details          
        
        
          
Public_event_amnesia_recent  YES/ NO    
Public_event_amnesia_remote  YES/ NO    
Topographical_amnesia  YES/ NO    
Names_faces_amnesia  YES/ NO    
      
Other changes      
Pathological_emotionalism  YES/ NO    
Current depression  YES/ NO    
Current anxiety  YES/ NO    
      
Medical History      
Birth_history  YES/ NO   
Birth_history_details          
          
Childhood_milestones  YES/ NO    
Childhood_milestones_details          
          
Febrile_seizures  YES/ NO    
Febrile_seizures_details          
          
      
Significant_head_injury  YES/ NO    
Head_injury_details          
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Intracranial_infection  YES/ NO    
Intracranial_infection_details          
          
      
Migraine  YES/ NO    
Migraine_details          
          
      
Stroke  YES/ NO    
Stroke_details          
          
TIA  YES/ NO    
TIA_details          
          
Hypertension  YES/ NO    
Hypertension_details          
          
Ischaemic_HD  YES/ NO    
Ischaemic_HD_details          
          
Other_cardiac  YES/ NO    
Other_cardiac_details          
          
Peripheral_Vascular_Disease  YES/ NO    
PVD_details          
          
Diabetes_mellitus  YES/ NO    
Diabetes_mellitus_details          
          
Hyperlipidaemia  YES/ NO    
Hyperlipidaemia_details          
          
Current_smoker  YES/ NO    
Current_smoker_details          
          
Ex_smoker  YES/ NO    
Ex_smoker_details          
          
      
Other_epilepsy_risk_factors  YES/ NO    
Other_epilepsy_risk_factors_details          
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Past_psychiatric_hx  YES/ NO    
Past_psychiatric_hx_details          
          
      
Hx_of_Medically_Unexplained_Sx  YES/ NO    
MUS_details          
          
      
Alcohol_excess  YES/ NO    
Alcohol_details          
          
Recreational_drugs  YES/ NO    
Recreational_drugs_details          
          
      
Past_medical_history          
        
        
        
          
Family medical history      
Family_history_epilepsy  YES/ NO    
First_degree_family_history  YES/ NO    
Details_of_Family_History          
        
          
      
Vascular_family_history  YES/ NO    
Vascular_family_history_details          
        
        
          
      
Other_information          
        
Age left school        
Years of education        
Marriage status        
Employment status          
      
      

























APPENDIX 8: REY AUDITORY VERBAL LEARNING TEST (RAVLT) 
 
Trial 1 - I am going to read a list of words.  Listen carefully, for when I stop, you are to repeat 
back as many words as you can remember.  It doesn’t matter in what order you repeat them.  
Just try to remember as many as you can.  Read list 1, with a 1 sec interval between each word.  
Give no feedback.   
Trial 2 – 10 - Now I am going to read the same words again, and once again when I stop, I 
want you to tell me as many words as you can remember, including words you said the first 
time.  It doesn’t matter in what order you say them.  Just say as many words as you can 
remember, whether or not you said them before.   
After reached criterion: 12/15 or after 10 trials: Please count backwards from 100 (stop after 
40”). Now what were those words I asked you to remember? 
After 30 mins  A short while ago I read a list of words to you several times, and 
you were trying to learn these words.  Tell me the words from that list again 
(that is, the list that we went through several times).  
Start time:_____________   End time: _______________ Trials to criterion:  
 
 Training   Recall Trials 




Drum           Drum    
Curtain           Curtain    
Bell           Bell    
Coffee           Coffee    
School           School    
Parent           Parent    
Moon           Moon    
Garden           Garden    
Hat           Hat    
Farmer           Farmer    
Nose           Nose    
Turkey           Turkey    
Colour           Colour    
House           House    
River           River    
SCORE               
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APPENDIX 9: HOSPITAL ANXIETY AND DEPRESSION SCALE 
 
For each of the following 14 statements, please circle the number (0,1,2,3) that most 
accurately corresponds to how you currently feel.   
 
1 I feel tense or ‘wound up’:  A 
 Most of the time…………………………………………………………………………………………… 3  
 A lot of the time …………………………………………………………………………………………… 2  
 From time to time, occasionally …………………………………………………………………… 1  
 Not at all ………………………………………………………………………………………………………. 0  
    
2 I still enjoy the things I used to enjoy:  D 
 Definitely as much ……………………………………………………………………………………….. 0  
 Not quite so much ……………………………………………………………………………………….. 1  
 Only a little ………………………………………………………………………………………………….. 2  
 Hardly at all …………………………………………………………………………………………………. 3  
    
3 I get a sort of frightened feeling as if something awful is about to happen:  A 
 Very definitely and quite badly ……………………………………………………………………. 3  
 Yes, but not too badly ………………………………………………………………………………….. 2  
 A little, but it doesn’t worry me …………………………………………………………………… 1  
 Not at all ………………………………………………………………………………………………………. 0  
    
4 I can laugh and see the funny side of things:  D 
 As much as I always could ……………………………………………………………………………. 0  
 Not quite so much now ……………………………………………………………………………….. 1  
 Definitely not so much now …………………………………………………………………………. 2  
 Not at all ……………………………………………………………………………………………………… 3  
    
5 Worrying thoughts go through my mind:  A 
 A great deal of the time ……………………………………………………………………………….. 3  
 A lot of the time …………………………………………………………………………………………… 2  
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 From time to time, but not too often …………………………………………………………… 1  
 Only occasionally …………………………………………………………………………………………. 0  
    
6 I feel cheerful:  D 
 Not at all ………………………………………………………………………………………………………. 3  
 Not often ……………………………………………………………………………………………………… 2  
 Sometimes …………………………………………………………………………………………………… 1  
 Most of the time ………………………………………………………………………………………….. 0  
    
7 I can sit at ease and feel relaxed:  A 
 Definitely ……………………………………………………………………………………………………… 0  
 Usually …………………………………………………………………………………………………………. 1  
 Not often ……………………………………………………………………………………………………… 2  
 Not at all ………………………………………………………………………………………………………. 3  
8 I feel as if I am slowed down:  D 
 Nearly all the time ……………………………………………………………………………………………. 3  
 Very often ………………………………………………………………………………………………………… 2  
 Sometimes ……………………………………………………………………………………………………….. 1  
 Not at all …………………………………………………………………………………………………………… 0  
    
9 I get a sort of frightened feeling like ‘butterflies’ in the stomach:  A 
 Not at all …………………………………………………………………………………………………………… 0  
 Occasionally ……………………………………………………………………………………………………… 1  
 Quite often ………………………………………………………………………………………………………. 2  
 Very often ………………………………………………………………………………………………………… 3  
    
10 I have lost interest in my appearance  D 
 Definitely ………………………………………………………………………………………………………….. 3  
 I don’t take as much care as I should…………………………………………………………………. 2  
 I may not take quite as much care ……………………………………………………………………. 1  
 I take just as much care as ever ………………………………………………………………………… 0  
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11 I feel restless as I have to be on the move:  A 
 Very much indeed …………………………………………………………………………………………….. 3  
 Quite a lot ………………………………………………………………………………………………………… 2  
 Not very much ………………………………………………………………………………………………….. 1  
 Not at all …………………………………………………………………………………………………………… 0  
    
12 I look forward with enjoyment to things:  D 
 As much as I ever did ………………………………………………………………………………………… 0  
 Rather less than I used to …………………………………………………………………………………. 1  
 Definitely less than I used to …………………………………………………………………………….. 2  
 Hardly at all ………………………………………………………………………………………………………. 3  
    
13 I get sudden feelings of panic:  A 
 Very often indeed …………………………………………………………………………………………….. 3  
 Quite often ………………………………………………………………………………………………………. 2  
 Not very often ………………………………………………………………………………………………….. 1  
 Not at all …………………………………………………………………………………………………………… 0  
    
14 I can enjoy a good book or radio or TV program:  D 
 Often ………………………………………………………………………………………………………………… 0  
 Sometimes ……………………………………………………………………………………………………….. 1  
 Not often ………………………………………………………………………………………………………….. 2  
 Very seldom ……………………………………………………………………………………………………… 3  
    
 Total A:    
 Total D:    
 
0-7 N 







APPENDIX 10: AN ILLUSTRATIVE CASE FROM THE TIME STUDY 
 
Case VA (case ID 195) 
In 2013, a 59yr right handed aircraft engineer, VA, was referred to the cognitive 
neurology clinic. He described a two-year history of transient episodes of memory 
impairment. 
The first of these occurred whilst on a motorcycle holiday with his wife. One 
morning, he woke up, unsure of where he was or what he had been doing on the 
previous day. He did not ask repetitive questions and within a few minutes he had 
returned to normal. As they were in the middle of their holiday his wife attributed 
his disorientation to their travels and thought nothing more of it. VA himself does 
not recall this episode. 
Approximately one month later, VA awoke unsure of where he was. He was 
unable to recollect his son’s wedding which had taken place 4 days previously. 
Once again, this lasted for only a few minutes before resolving. His amnesia for 
this episode was incomplete: he is able to remember not being able to remember. 
One month after that, a further episode occurred whilst visiting his daughter in 
her new house. VA’s wife reports that she saw him walking to the bedroom 
window and asking ‘where are we?’ He could not recall the previous day, or that 
they were staying with their daughter. 
At around this time VA’s wife noticed that these early morning amnesic episodes 
would be preceded by ‘mouthing movements’. VA himself would notice a strange 
taste or smell, which was sometimes pleasant and sometimes unpleasant, at the 
time of these episodes. 
In addition to these transient episodes of memory impairment, VA reported some 
interictal memory disturbances.  He described ‘blanks’ for salient events over the 
last 5 years. These included holidays, weddings and other events which he felt 
that he should have been able to remember. He felt that memories ‘faded’ more 
rapidly than he would have expected. For example, if he was to read a book, he 
could pick it up again a week later, with no recollection that he had read it before. 
Although he reported that his memory for routes had never been particularly 
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good, he was also aware that this had deteriorated over the same period. In 
particular he found it difficult to visualise familiar routes. 
He described being more emotional than he was previously; he could be moved 
more easily by something on radio or television. Furthermore, he reported that he 
was more irritable than he had been prior to the start of these episodes. 
His past medical history is notable only for previous sinus surgery which had 
affected his sense of smell, and two episodes of what he referred to as ‘burn-out’ 
in 1989 and 1999. Although, he has never satisfied the criteria for major 
depression, he met criteria for current and past generalised anxiety disorder. He 
is a non-smoker, with no history of excess alcohol consumption. 
His neurological examination was entirely normal as was an MRI brain scan. An 
EEG showed occasional bursts of low voltage discrete spike and slow wave 
activity maximal over the right centro-temporal region. An example of this 
abnormality is shown below (fig.1). Given the clinical history, and evidence 
provided by the EEG, it was felt that VA’s amnesic events were epileptic seizures. 
VA was started on lamotrigine which was increased up to 100mg. He has had no 
further episodes since commencing treatment in December 2013. 
Following his initial interview VA was recruited to the TIME (The Impairment of 
Memory in Epilepsy) study, and underwent a formal neuropsychological 
evaluation. The battery comprised standard tasks to estimate premorbid and 
current general cognitive ability, visual and verbal anterograde memory tests, a 
semantic memory test, and tests of executive function. Episodic autobiographical 
memory across the life span was assessed via the Modified Autobiographical 
Memory Interview. Finally, to assess forgetting over time, VA completed a 
modified version of a word learning task, the Rey Auditory Verbal Learning Test 
(RAVLT). Here he was required to repeat learning trials until he could recall at 
least 80% (12 words) of the list, with delayed recall assessed at 30 minutes and 




















































































































































Overall, VA’s general cognitive abilities were rated within the high average range 
for his age. There was no evidence of impairment in his visuo-constructional 
abilities, executive function or semantic memory (although his approach to 
drawing the Rey Complex Figure task was somewhat unusual and fragmented).  
He performed variably on tests of anterograde memory.  He showed good verbal 
recognition memory (words), and his learning over the standard 5 trials of the 
RAVLT was within the average range for his age. He was, however, less efficient 
in reaching the 80% learning criterion when compared with IQ-matched healthy 
controls, but did well to maintain his learning after a 30-minute delay.  VA’s 
immediate recall of a story was low average, while his 30 minute recall was poor.  
Visual memory was generally weaker. He showed disproportionally poorer visual 
recognition (for faces versus words) to a level observed in only 5-10% of his peer 
group. His recall of the complex figure was distorted and below the 1st percentile 
for his age. 
When retention of information was assessed over a longer period (1 week), clear 
difficulties emerged.  VA was unable to freely recall any of the words correctly 
from the list (recalling he had done the task, but confabulating 4 incorrect 
responses).  Although he correctly recognised 13 of the 15 words when cued, he 
also endorsed having learned 5 words that were not on the list.  
Assessment of his autobiographic memory revealed that while VA could recall 
specific events from each of the decades of his life, these often lacked rich 
episodic detail.  In one instance, he could recall facts regarding his son’s wedding 
























































APPENDIX 12: DIGIT SPAN TEST 
Digit Span (WMS-III) 
“I am going to say some numbers. Listen carefully, and when I am through, I want you to say them 
right after me.  Just say what I say.”   Discontinue after two consecutive errors on the 
same item number. 
Forwards  
Item Trial Response Score 
 0 or 1 
1 1-7   
 6-3   
2 5-8-2   
 6-9-4   
3 6-4-3-9   
 7-2-8-6   
4 4-2-7-3-1   
 7-5-8-3-6   
5 6-1-9-4-7-3   
 3-9-2-4-8-7   
6 5-9-1-7-4-2-8   
 4-1-7-9-3-8-6   
7 5-8-1-9-2-6-4-7   
 3-8-2-9-5-1-7-4   
8 2-7-5-8-6-2-5-8-4   
 7-1-3-9-4-2-5-6-8   
Raw: __________     Max Digits Forwards:  
        
“Now I am going to say some more numbers. But this time when I stop, I want you to say them 
backward.  For example, if I say 7-1-9, what would you say?” 
If correct: “That’s right”. 
If incorrect: “No you would say 9-1-7.  I said 7-1-9, so to say it backward you would say 9-1-7. Now try 
these numbers.  Remember, you are to say them backward: 3-4-8.” 
Backwards 
Item Trial Correct Response Participant Response Score 
 0 or 1 
1 2-4 4-2   
 5-7 7-5   
2 6-2-9 9-2-6   
 4-1-5 5-1-4   
3 3-2-7-9 9-7-2-3   
 4-9-6-8 8-6-9-4   
4 1-5-2-8-6 6-8-2-5-1   
 6-1-8-4-3 3-4-8-1-6   
5 5-3-9-4-1-8 8-1-4-9-3-5   
 7-2-4-8-5-6 6-5-8-4-2-7   
6 8-1-2-9-3-6-5 5-6-3-9-2-1-8   
 4-7-3-9-1-2-8 8-2-1-9-3-7-4   
7 9-4-3-7-6-2-5-8 8-5-2-6-7-3-4-9   
 7-2-8-1-9-6-5-3 3-4-6-9-1-8-2-7   
Raw:    __________   Max Digits Backwards: 
 _____ 
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